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A few years into the project, a disturbing message appeared on my computer 
(Figure 0A). Luckily, this was far from the truth. On the contrary, several people 
deserve my thanks for their participation in the project, and even more for their 
general importance in my life. 
 
Figure 0A. Screenshot of a disturbing message from my computer: “You are no longer 
part of a common context” (Bergen, July 8th 2016). 
 
Family, (an alien cat,) and good friends 
First and foremost, I want to express gratitude to my dear wife Kristine and our kids 
Vegard and Emile, who have shown such patience and support throughout the 
project (despite my complete lack of interest in The Cat). You provide me with love 
and a meaning in life that endless hours in the lab and in front of a computer cannot 
replace. It may therefore seem contradictory that I have spent so much time working 
on the project. However, since I am also cursed (/blessed) with a personality that 
tends to put me in situations where deeply focused work over time is perceived as 
required, such dualities in life have become a normality. I thank my parents Solrun 
and Reidar, my sister Ranveig and my brothers Dagfinn and Øystein, for allowing 
me the honour of sharing excellent genes, and for your continuous/distant support 
throughout the years. Thanks also to Eli1 and Geir and the rest of Kristine’s family 
for all your friendliness and hospitality. 
I also want to thank my friends for all the good times we share together, and for 
staying around as an extended safety-net in life. 
 
Wisdom, and a self-citation 
In many aspects, the project has been an ambivalent journey balancing on edges 
between frustration and excitement, 
demotivation and motivation, 
pessimism and optimism, solitude 
(Figure 0B) and fellowship.  
I have continuously tried to 
convince (or fool?) myself that a 
huge pile of work is nothing else 
than a collection of numerous tiny 
tasks. By solving them one-by-one, the work will eventually be done.  
 
 
My colleagues are also my friends 
I want to thank my friends and colleagues at Haukeland University hospital and the 
University of Bergen for contributing to a vibrant professional and social 
environment. You have all contributed to this thesis, either directly or indirectly, by 
being around, asking questions, eating lunch together, or simply by avoiding to 
disturb me. I also acknowledge that my lack of participation in the routine work has 
put extra workloads on many of you. Thanks to each and every one of you at 
Section of Clinical Pharmacology and RELIS Vest! Special thanks to Charlotte for 
 
1 Although I cannot promise that I will comply with all your hairdressing advices 
“A huge pile of work is nothing else than a collection of numerous tiny tasks” 
Bjånes, T. Journal of Self-deception and Cognitive Diversions 2019; 1(1):1. 
Figure 0B. Floor map adding to the 
loneliness that can be experienced while 
passing through the basement level of the 
laboratory building at Haukeland  
collaboration in drug-committee-related topics, to Trond for being so inspirational, 
to Jon for staying in the game despite my discontinuity, and Silje for joining the 
team. I also want to thank Tina Kamceva for invaluable efforts in LC-MS/MS 
method development, collaboration in writing papers and for input to this thesis.  
 
Bettina and Jan, and a second self-citation 
My main supervisor Bettina Riedel and co-supervisor Jan Schjøtt have been 
indispensable throughout the project. I thank you for all the practical and financial 
arrangements that you have helped establish. I thank you for supporting me, 
pushing me (and yourselves) and for believing in me. Your ability of diving into 
details (Bettina  / Jan ) and of zooming out from them (Bettina  / Jan ), have 
sometimes been frustrating, but most of all educational. Throughout the project you 
have been exposed to my wordiness in writing, my interpositions and parentheses 
(among other things) that may have challenged the fluency in reading (despite the 
opposite being my intention2), but you have continuously provided specific advice 
and support and, as a consequence, have helped me overcome my wordiness in 
writing and the use of interpositions (and, to some extent, parentheses). In addition, 
you have advised me to avoid unnecessary repetitions that would otherwise have 
been repeated, unless you have repeatedly advised me not to do so (over and over 
again). 
   
 
Emmet and his group 
I want to thank my co-supervisor Emmet McCormack for opening your lab and 
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“In addition, you have advised me to avoid unnecessary repetitions” 
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Last, but not least, as well as first and foremost4.  
 
3 Andreas Westin’s Doctoral thesis 2018, page 5 (http://hdl.handle.net/11250/2571266) 
4 If you are indifferent to the remaining contents of this thesis, I suggest reading the Acknowledgements over 
and over again. Further reading also in: Bjånes, T. Journal of Perpetual Motion Machines 2019;1(2):3-. 
Scientific environment 
• Section of Clinical Pharmacology, Department of Medical Biochemistry and 
Pharmacology, Haukeland University hospital. 
https://helse-bergen.no/avdelinger/laboratorieklinikken/medisinsk-biokjemi-
og-farmakologi. 
• The Bergen Pharmacy and Pharmacology Research Group, Department of 
Clinical Science, University of Bergen. https://www.uib.no/en/rg/pharm  
• SonoCURE, University of Bergen and Haukeland University Hospital. 
https://sonocure.w.uib.no/aboutsonocure/  
 
Section of Clinical Pharmacology at the Department of Medical Biochemistry and 
Pharmacology at Haukeland University hospital provides an extensive laboratory 
service within therapeutic drug monitoring (TDM) and drugs-of-abuse testing, in 
addition to providing decision support in complex drug-regimes, drug interactions 
and adverse reactions. Associate Professor / Head senior consultant Bettina Riedel 
is the section leader. 
The Bergen Pharmacy and Pharmacology Research Group consists of personnel 
from Section of Clinical Pharmacology who are also employed at the University of 
Bergen or otherwise engaged in collaborative activities within research related to 
drugs. Professor Svein Haavik is the group leader.  
SonoCURE is a research group umbrella connecting researchers with different 
projects within sonoporation and pancreatic cancer in in vitro and preclinical 
models. Professor Emmet McCormack and Associate Professor Spiros Kotopoulis 
are the group leaders. 
  
A brief story about the project 
The project started early in 2011, when we became engaged in the planning of a 
phase 1 clinical trial in pancreatic cancer (PDAC) patients. An interdisciplinary 
team of gastroenterologists, oncologists and ultrasound physicists at Haukeland 
University hospital and the University of Bergen wanted to explore the potential of 
ultrasound and microbubbles (sonoporation5) to improve the efficacy of 
gemcitabine treatment in PDAC, based on an assumption that chemotherapeutic 
drug delivery to the tumours could be increased.  
Section of Clinical Pharmacology was contacted to provide advice in 
pharmacokinetic assessments of gemcitabine. This included the study protocol and 
the application to the Norwegian Medical Agency, in addition to development of 
analytical methods to quantify gemcitabine and its main metabolites in patients and 
subsequently in in vitro experimental PDAC-models.  
Via funding and in collaboration with Professor Asbjørn Svardal at the University 
of Bergen (UiB), we were able to initiate method development on a UiB-based LC-
MS/MS-platform. We developed two analytical methods: one for extracellular 
gemcitabine and inactive metabolite, and one for the main intracellular active 
metabolite, and both were published in 2015 [1, 2] (Paper I and II).  
In 2016, the final results from the phase 1 clinical trial were published [3], and we 
turned our focus to in vitro PDAC models in order to study basal aspects of 
gemcitabine uptake and metabolism, with (Paper V) or without (Paper IV) 
sonoporation.  
From January 2017, I became a PhD-candidate with grant from Helse Vest for a 50 
% position over three years.  I worked with an in vitro PDAC model system in 
which a wide range of ultrasound intensities, microbubble brands and microbubble 
concentrations were applied in order to optimize membrane permeabilization 
without destroying the cells. This comprehensive optimization process6 led to the 
 
5 A method to increase the permeability of biological barriers. See more details in section 1.3 
6 To be published separately, not included as part of the current PhD-project 
selection of a subset of sonoporation parameters that were combined with 
gemcitabine in further in vitro experiments (Paper V).  
Early in the project period, there were concerns about the relevance of spending 
more research efforts on gemcitabine, since new and more effective drug regimens 
emerged. However, the work was justified for several reasons that continued 
throughout the period, such as: 1) Gemcitabine monotherapy is still being used in 
many countries, and not only in patients experiencing toxicity of the combined 
drug-regimens, and 2) Combined treatment with gemcitabine and nab-paclitaxel 
became one of two first-choice regimens.  
 
The focus within this thesis is on drug delivery in PDAC, with special emphasis on 
quantification of gemcitabine uptake and metabolism, with or without sonoporation 
using ultrasound at diagnostic intensities. 
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Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis due to late stage 
diagnosis and unresponsiveness to chemotherapies. A dense desmoplastic tumour 
stroma is considered to represent a barrier against drug delivery. Gemcitabine, until 
recently the first choice chemotherapeutic in metastatic PDAC, improves median 
overall survival by only 1 – 2 months. Poor drug delivery to PDAC cells may 
contribute to the limited efficacy. Recently, ultrasound combined with microbubbles 
has been introduced as a method to increase the permeability of biological barriers, 
through a process called sonoporation. 
 
Overall objective 
The overall objective of the project was to evaluate quantitative aspects of 
gemcitabine delivery and metabolism combined with sonoporation in PDAC 
patients and in in vitro models. 
 
Methods 
In paper I, we described the development of a liquid chromatography tandem mass 
spectrometric (LC-MS/MS) method for quantification of extracellular gemcitabine 
and inactive metabolite (dFdU), and we studied the stability of the analytes in blood 
samples. In paper II, a LC-MS/MS method for intracellular active gemcitabine 
metabolite (dFdCTP) was developed. Paper III was a clinical phase 1 trial in ten 
PDAC patients who were treated with gemcitabine combined with ultrasound and 
microbubbles. In this study, safety was a primary and survival a secondary outcome 
measure. Systemic pharmacokinetics (PK) of gemcitabine was also assessed. Papers 
IV and V were in vitro studies in PDAC cell line models, in which gemcitabine 
uptake was quantified following exposure to therapeutically relevant gemcitabine 
concentrations, with and without sonoporation and pharmacological modulation of 
drug transport and metabolism. 
 
Results 
The validated concentration ranges of gemcitabine, dFdU (Paper I) and dFdCTP 
(Paper II) were 0.125 – 40 µg/mL, 1.25 – 80 µg/mL and 0.05 – 28.1 µM, 
respectively, with coefficients of variation (CV) of 11.5, 5.2 and 11.4 % at their 
lower limits of quantification. Stabilities of gemcitabine and dFdU (Paper I) were 
demonstrated for at least four hours in whole blood samples kept on ice, when the 
cytidine deaminase (CDA) inhibitor tetrahydrouridine (THU) was added. In the 
clinical trial (Paper III), no additional toxicity of sonoporation to that of 
gemcitabine was noted, and gemcitabine PK was not different from patients treated 
with gemcitabine alone. The study patients tended to survive longer and received a 
higher number of treatment cycles, compared to a historical control group. In paper 
IV, we showed that intracellular CDA could inactivate gemcitabine extensively and 
hereby regulate intracellular dFdCTP accumulation. In paper V, we demonstrated 
that sonoporation contributed to only a minor extent of gemcitabine uptake 
compared to physiological membrane transporters. 
 
Conclusions 
Quantitative assessments of gemcitabine and its main extra- and intracellular 
metabolites in different matrices enabled elucidation of drug distribution, uptake 
and metabolism in PDAC. Our data support further clinical studies of sonoporation 
combined with chemotherapies, but underscores the importance of taking 
physiological mechanisms of drug transport and metabolism into account.  
Future studies in more complex PDAC models are required to investigate tumour 
tissue drug distribution and cellular uptake, and to elucidate other mechanisms 




The following three main sections cover background topics related to the 
current research field, focused on pancreatic cancer and chemotherapeutic drug-
delivery by sonoporation, with special emphasis on the nucleoside analogue 
gemcitabine and quantitative aspects of cellular uptake and metabolism. 
1.1. PANCREATIC CANCER 
1.1.1. Burden of disease 
Pancreatic ductal adenocarcinoma (PDAC) is the seventh most common 
form of all cancers worldwide [4]. In Norway, more than 800 new patients 
were diagnosed in 2017 [5, 6]. PDAC was the fourth leading cause of 
cancer deaths in Europe in 2018, with approximately 95.000 cases [4]. The 
mortality-to-incidence ratio is above 0.9 [6, 7], and the overall five-year 
survival rate is as low as 5-8 % [5, 6, 8]. This poor prognosis is highly 
attributable to the fact that a majority of patients develop symptoms at late 
stage, with incurable disease at the time of diagnosis [8, 9]. Incidences of 
PDAC is increasing in conjunction with increasing age of the population in 
developed countries. Within 2040, the number of PDAC patients is 
projected to increase by 30 % in the European Union and 40 % in the 
United States of America [4, 7]. 
 
The severity of this disease and its increasing incidence represent a highly 
unmet medical need that challenges the healthcare providers and research 




1.1.2.1. Clinical signs and radiological examinations 
Typical symptoms preceding a diagnosis of PDAC include jaundice, 
poor appetite, loss of weight, and pain [5]. The purpose of diagnostic 
evaluations is to reveal whether a tumour is present, determine the stage 
of disease according to the TNM-classification of malignant tumours [5, 
10], and whether it can be treated surgically. The main radiologic 
modalities applied include computed tomography (CT), ultrasound (US), 
magnetic resonance imaging (MRI) and positron-emission tomography 
(PET) [11, 12].  
 
Recent studies suggest that endoscopic ultrasound (EUS) and contrast 
enhanced ultrasound (CEUS), in the hands of skilled clinicians, equal the 
diagnostic accuracy of CT imaging [13], and may even be superior 
modalities for detection of small lesions [14].  Furthermore, researchers 
at our institution have recently proposed funding [15] of a development 
project in which EUS and CEUS will also be employed in the early 
response-evaluations of PDAC patients undergoing treatment.  
 
1.1.2.2. Histology and molecular biology 
In inoperable patients, ultrasound-guided fine-needle aspirations from 
tumours are performed prior to commencement of palliative 
chemotherapy [5]. In resected tumour specimen, the whole tumour and 
its excised surroundings are examined. Histological examinations are 
needed in order to verify the PDAC diagnosis, the tumour resection 
margins and lymph node invasion, and to rule out differential diagnoses 
such as neuroendocrine tumours [16]. 
There are no unique diagnostic molecular markers for PDAC, but several 
mutations are prevalent (e.g. activation of Kirsten rat sarcoma (KRAS) 
and inactivation of Tumour protein 53 (TP53), Cyclin dependent kinase 
inhibitor 2A (CDKN2A) and Suppressor of mothers against 
decapentaplegic 4 (SMAD4)) and provide prognostic information [9, 
16]. As they do not convincingly provide guidance into selection of 
patients for specific personalized treatment strategies, the application of 
such markers is limited. However, several promising markers are being 
explored in a research setting, of which approaches encompassing 
multiple genes and proteins that delineate unique signatures [17, 18] of 
the cancer cells and their microenvironment, dominate. For example, 
tumours with a high mutational burden and infiltrated with lymphocytes, 
may be candidates for immunotherapeutic treatment [16]. Moreover, 
expression of the equilibrative nucleoside transporter 1 (hENT1), 
deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in tumour 
tissue may predict the outcome of treatment with gemcitabine (see details 
in section 1.2). It has also been suggested that the amount and 
characteristics of circulating tumour cells [19] and nucleic acids [20] in 
blood, and the pattern of mutations of KRAS and TP53 in pancreatic 
juice [21], may be useful prognostic biomarkers.  
 
1.1.2.3. Early detection to improve prognosis 
Lifestyle factors such as cigarette smoking, alcohol overuse, overweight 
and poor blood-glucose control represent potentially modifiable risk 
factors of developing PDAC [4, 22]. Heritable risk factors, such as 
mutations in Breast cancer gene 2 (BRCA2), Partner and localizer of 
BRCA2 (PALB2) and other genes, and/or multiple relatives diagnosed 
with PDAC [22], account for less than 10 % of new cases [4]. For 
patients with heritable risk, systematic screening strategies may be 
justified in order to detect the disease at an early stage where curative 
treatment may still be an option. However, up to date no firm evidence 
exists that such screening programs provide a positive benefit-cost-
balance [17, 22].  
 
Clinical symptoms and signs are often unspecific or lacking until the 
disease has progressed to an advanced stage, and early detection is still 
unrealistic in the vast majority of patients [9]. Therefore, there is a focus 
on research within the field of PDAC in order to develop new and 
improved treatment strategies7. 
 
1.1.3. Treatment strategies 
1.1.3.1. Surgery 
Only 15 % of newly diagnosed PDAC tumours are surgically resectable 
[5, 8]. For operable patients, the prognosis has improved somewhat over 
the last decades, of which a broader application of multimodal treatment, 
such as early post-operative mobilisation, optimized analgesia, 
 
7 https://clinicaltrials.gov and https://www.clinicaltrialsregister.eu (Search “pancreatic cancer”) 
thrombosis prophylaxis and nutrition, may have contributed [5]. 
However, even after potentially curative surgery, followed by adjuvant 
chemotherapy [5, 23], most patients eventually experience locoregional 
recurrences or metastatic disease. As a result, the median and five-year 




1.1.3.2.1. General considerations 
Eighty five percent of newly diagnosed PDAC tumours are 
considered unresectable due to locally advanced disease with 
encasement of large blood vessels or neighbouring organs, or the 
presence of metastases [8]. Chemotherapy produces moderate 
objective responses, but is not curative in this setting [5]. 
Chemotherapy is also used in the adjuvant setting in selected patients 
who are sufficiently fit after surgery, whereas conclusive evidence is 
still lacking on the role of neo-adjuvant chemotherapy [17]. Patients 
who do not tolerate chemotherapy due to poor performance status or 
severe weight loss, should nevertheless receive supportive care 
according to best practice guidelines [25].  
 
1.1.3.2.2. Poor compound delivery  
PDAC tumours are characterized by a dense fibrotic reaction 
consisting of, among others, fibroblast and an abundant extracellular 
matrix, often referred to as desmoplasia, with a high interstitial fluid 
pressure and poor blood supply that results in a nutrient-poor and 
hypoxic environment [26, 27]. These features may also hamper 
diffusion of therapeutic compounds into the tissue, and are thought to 
represent a general mechanism of treatment resistance [28-30].  
Efforts to overcome this potential barrier against effective drug 
delivery have been explored, for example by using inhibitors of sonic 
hedgehog signalling or focal adhesion kinase (FAK) aiming at 
reducing desmoplasia [30], so called stromal depletion therapies. 
While increased efficacy of chemotherapies were achieved in vitro, 
initial clinical studies were disappointing in terms of improving 
survival of patients. It has been demonstrated that bacteria [31, 32], 
fibroblasts [33] and macrophages [34, 35] in the tumour 
microenvironment might modulate intratumoural drug distribution 
and metabolism, and it has been suggested that such factors might be 
equally important mechanisms of treatment resistance as poor drug 
delivery [33]. Moreover, drug delivery from the vascular 
compartment into the tumour interstitium is only a part of the whole 
picture, since transport of chemotherapeutics across cellular 
membranes is also a prerequisite in order to inhibit growth and kill 
cancer cells.  
Drug transport between the blood plasma, tissues and organs is 
mainly mediated by diffusion and convection, with concentration and 
pressure gradients as their respective driving forces. The amount of 
drug transported per time unit depends on blood flow, perfusion and 
the expression of transmembrane influx and efflux transporter 
proteins in the region of interest, and the hydrophilic/lipophilic 
properties of the drug and their extent of binding to plasma- and 
tissue proteins [36, 37].  
  
1.1.3.2.3. Current chemotherapeutic drug regimens 
Three main chemotherapeutic drug regimens are the current basis of 
first and second line palliative treatment of PDAC patients: 1) 
Gemcitabine monotherapy, 2) gemcitabine combined with nab-
paclitaxel, and 3) a combined regimen of folinic acid, 5-fluorouracil 
(5-FU), irinotecan and oxaliplatin (FOLFIRINOX) [5, 38].  
 
Gemcitabine monotherapy was introduced as first line palliative 
chemotherapy in 1997, based on a study that showed median overall 
survival of 5.7 months, compared to 4.4 months with 5-FU [5, 38]. 
In addition, the clinical benefit in terms of symptom relief was better 
with gemcitabine compared to 5-FU, with 23.8 vs 4.8 % responders 
[38]. From 2011 and onwards, gemcitabine monotherapy was 
gradually replaced by more effective regimens, but also more toxic, 
in patients with sufficient performance status who would tolerate a 
greater toxicity.  
 
In a randomized phase 3 clinical trial where gemcitabine was 
compared to FOLFIRINOX [39], the authors reported median overall 
survival of 6.8 and 11.1 months, respectively. FOLFIRINOX was 
also significantly more toxic, and reduced doses in a modified 
regime, commonly referred to as “mFOLFIRINOX”, was later 
proposed as an option for some patients [38, 40].  
 
In 2013, a randomized phase 3 trial comparing gemcitabine 
monotherapy with gemcitabine and albumin-bound paclitaxel (nab-
paclitaxel) [41], median overall survival increased from 6.6 months 
with monotherapy to 8.7 months with the combined regime.  
 
No head-to-head study between gemcitabine/nab-paclitaxel and 
FOLFIRINOX has been conducted, but both regimens possess 
individual strengths. A greater survival benefit was reported in the 
FOLFIRINOX study [39]. In the gemcitabine/nab-paclitaxel study 
[41], the proportion of older patients was higher. Ultimately, the 
choice between no chemotherapy, gemcitabine monotherapy, 
gemcitabine/nab-paclitaxel or FOLFIRINOX comes down to the 
patient’s own preferences and individual risk factors such as age, co-
morbidities and performance status [25, 38].  
 
  
1.1.4. PDAC disease models 
In vitro and in vivo tumour models are fundamental in basal cancer research 
projects. In vitro cell line models are useful for several reasons, such as 
identification of the intracellular pathways driving disease development, for 
high-throughput screening of potential therapeutics, and characterization of 
cellular drug metabolism and mechanisms of action [42, 43]. Several 
immortalized PDAC cell lines are available for such research purposes. The 
cells display a wide range of genotypic and phenotypic traits [44] that might 
also mirror the variability between PDAC tumours in patients. Several 
different cell lines, such as BxPC-3, MIA PaCa-2 and PANC-1, have been 
included in in vitro studies of PDAC, and have contributed to an increased 
understanding of the disease [45]. Cell line models are usually based on 
two-dimensional (2D) monolayer or multilayer [46] growth on a sterile 
plastic surface, with direct access to nutrients and other components added 
to the culture media. Hence, the resulting cellular growth patterns and the 
microenvironment are quite unlike PDAC tumours in patients, in which an 
abundant desmoplastic extracellular matrix and multiple other cell types are 
dominant features [47, 48] . To address some of these shortcomings, three-
dimensional (3D) in vitro culture systems [49] based on for example 
collagen,  reconstituted basement membranes (Matrigel™) [47], or 
decellularized matrix scaffolds [50] have been developed. These systems 
are suitable to study cell-cell interactions and allow chemotherapeutic drug 
sensitivity testing in a more realistic in vivo-like microenvironment, but 
require more time and resources compared to 2D-cultures [50]. 
 
In vivo PDAC models have been established in immunodeficient mice by 
injecting cell lines or implanting solid tumour pieces from patients, either 
subcutaneously or orthotopically. Such models are generally referred to as 
cell-line derived or patient-derived xenografts (PDX) [49], and are superior 
to in vitro models, e.g. in their ability to mimic the systemic 
pathophysiology of the disease. However, PDAC PDXs have not been able 
to fully reproduce the desmoplastic reaction seen in patient tumours, and 
the clinical relevance of these models have been questioned [27]. In 
genetically engineered mouse models (GEMM) where PDAC tumours may 
arise spontaneously, desmoplasia is a more prominent feature. However, 
several positive results from preclinical GEMM models have also turned 
out negative in clinical studies [49]. Moreover, mouse studies are labour-
intensive, and many researchers therefore still make use of refined in vitro 




Gemcitabine, or 2’,2’-difluoro-2’-deoxycytidine (dFdC), is a fluorinated 
analogue of the endogenous pyrimidine nucleoside deoxycytidine (dC) 
(Figure 1), and as such its transport, metabolism and effects are related to 
the cellular nucleoside pathways [52, 53].  
 
 
Figure 1. Structure of deoxycytidine (left) and its analogue 
gemcitabine (right). The two fluor-atoms in 2’-position indicated in 
yellow. Positions of metabolic activation (phosphorylation) and 
inactivation (deamination) are indicated in red and green, respectively. 
 
1.2.2. Cellular uptake 
Gemcitabine enters the cells via transmembrane nucleoside transporter 
proteins, of which the human equilibrative transporter 1 (hENT1) plays the 
dominant role, and to a lesser extent, the human concentrative transporters 1 
(hCNT1) and 3 (hCNT3) [52, 54]. Equilibrative transporters allow 
bidirectional transport along the concentration gradient of the substrate, 
whereas concentrative transporters are active and utilize sodium co-
transport together with the substrate [55]. The particular importance of 
hENT1 on gemcitabine efficacy is underscored by its correlation with drug 
uptake and cytotoxicity in cancer cells in vitro [56], and on tumour 
regression and patient survival in vivo [54]. Koay and co-workers [29, 57] 
found that both cellular hENT1-activity and general mass transport 
properties of the connective tissue are important sources of variable 
gemcitabine uptake in PDAC tumours.  
It has been shown that hENT1 activity in cells [56] and expression in 
tumour tissues [58, 59] might be a suitable biomarker for prediction of 
gemcitabine efficacy. Greenhalf and co-workers [59] suggested that in 
tumours with low hENT1-expression, gemcitabine should be avoided due to 
a poor anticipated efficacy, and that alternative drug regimens should be 
considered. Due to the lack of prospective evaluations of hENT1 as a 
predictive biomarker [18], and suboptimal agreement between 
immunohistochemistry assessments performed with different antibodies 
[55, 60], it is not implemented as a routine pre-treatment procedure in most 
clinics. In 2010, Paproski and co-workers validated an imaging method for 
assessment of cellular hENT-activity, employing the PET-tracer 3’-deoxy-
3’-fluorothymidine (FLT) [56], but to our knowledge this approach has not 




1.2.3. Gemcitabine metabolism 
Gemcitabine is subject to extensive systemic and cellular metabolism, 
either to inactive or active metabolites, and the balance between these two 
opposing pathways may be a determinant of drug efficacy. Figure 2 
illustrates the complexity of this system. 
 
1.2.3.1. Active metabolites and drug targets 
The main activation pathway consists of a series of intracellular 
phosphorylation reactions via nucleoside kinases, of which deoxycytidine 
kinase (dCK), catalysing the initial phosphorylation to gemcitabine 
monophosphate (dFdCMP), is the rate-limiting step [52, 61]. Expression 
of dCK in tumour specimen has been suggested as a potential predictive 
biomarker of gemcitabine response [18]. dFdCMP is further 
phosphorylated to gemcitabine diphosphate (dFdCDP) and triphosphate 
(dFdCTP), both of which are pharmacologically active metabolites. A 
small fraction of dFdCMP is also deaminated by deoxycytidylate 
deaminase (DCTD) to dFdUMP. dFdUMP in turn inhibits thymidylate 
synthetase (TS) responsible for the synthesis of thymidine 
monophosphate (dTMP) [52], a precursor of thymidine triphosphate 
(dTTP) (Figure 2). dFdCDP inhibits ribonucleotide reductase (RR), an 
important enzyme regulating nucleotide pool homeostasis by catalysing 
the reduction of ribonucleotides to deoxyribonucleotides [52, 61]. 
Overexpression of RR in PDAC tumours has been found to correlate 
with poor outcome in patients treated with gemcitabine in the adjuvant 
setting, probably due to an increase in deoxynucleoside triphosphates 
(dNTPs) [62], including dCTP (Figure 2). 
dFdCTP competes directly with dCTP for incorporation into DNA, 
which results in inhibition of DNA-synthesis through masked chain-
termination [52]. The cytotoxic effect of dFdCTP is primarily exerted in 
the S-phase of the cell cycle [53]. Intracellular dFdCTP concentration in 
peripheral blood mononuclear cells (PBMC) has been used as a surrogate 
marker for drug exposure [63] and risk of hematotoxicity [64], and in 
cancer cells as a pharmacodynamic endpoint related to inhibition of 
DNA-synthesis [65] and cytotoxicity [66]. The use of dFdCTP 
concentrations in these settings is also supported by the fact that the 
intracellular concentrations of gemcitabine and the other intermediate 
metabolites are very low, which might preclude their quantification [67].  
 
1.2.3.2. Inactivation 
The main elimination pathway of gemcitabine to 2’,2’-difluoro-2’-
deoxyuridine (dFdU) is catalysed by cytidine deaminase (CDA) [68], 
which is widely expressed in blood, liver and several other tissues [61, 
69]. Deamination of dFdCMP to dFdUMP by intracellular 
deoxycytidylate deaminase (DCTD), followed by dephosphorylation, 
might also represent a minor source of dFdU [52, 68, 70] (Figure 2). 
Efflux of dFdU from the cells is mediated by multiple different ABC-
transporter proteins, and it has been postulated that their activities might 
indirectly influence cellular gemcitabine sensitivity. The proposed 
mechanism is that low efflux leads to intracellular accumulation of 
dFdU, which in turn may inhibit CDA activity. Theoretically, this would 
allow more gemcitabine to be activated [71]. dFdU itself is considered 
mainly inactive, and the relevance of suggested active intracellular 
dFdU-metabolites [72] has been questioned [61].  
Other intracellular enzymes may also to some extent promote 
gemcitabine inactivation. For example, cytosolic 5’-nucleotidase III (cN-
IIIA) [73], has been shown to dephosphorylate dFdCMP to dFdC and 
hereby oppose the intracellular accumulation of dFdCTP. 
  
 
Figure 2. Schematic overview of gemcitabine cellular uptake, metabolic 
pathways and mechanisms of action. Arrows indicate transport and enzymatic 
processes. Examples of the interplay between gemcitabine metabolites and 
endogenous nucleotides, and of intrinsic regulation and pharmacological 
inhibition: Red and green lines and corresponding symbols indicate inhibitory 
and stimulatory actions, respectively. 
ADP: adenosine diphosphate; dADP: deoxyADP; dATP: deoxyadenosine triphosphate; CDA: 
cytidine deaminase; CDP: cytidine diphosphate; dCDP: deoxyCDP; dCTP; deoxycytidine 
triphosphate; dCK: deoxycytidine kinase; dFdC; 2’,2’-difluoro-2’-deoxycytidine (gemcitabine); 
dFdCMP: gemcitabine 5’-monophosphate; dFdCDP: gemcitabine 5’-diphosphate; dFdCTP: 
gemcitabine 5’-triphosphate; dFdU; 2’,2’-difluoro-2’-deoxyuridine; dFdUMP; dFdU-5’-




1.2.4. Intrinsic regulation of gemcitabine transport and metabolism  
Regulatory mechanisms within the intracellular nucleotide pathways 
illustrate the interplay between endogenous nucleotides and gemcitabine 
metabolites. Selected examples are given below and in Figure 2. 
1) Inhibition of ribonucleotide reductase by dFdCDP results in reduced 
synthesis of dCTP and other dNTPs. This might increase 
gemcitabine cytotoxicity via two overlapping mechanisms, referred 
to as self-potentiation [52]: 
a. Reduced feedback-inhibition of dCK by dCTP favours the 
synthesis of dFdCMP and subsequently results in increased 
dFdCTP concentrations 
b. The combined effect of reduced dCTP and increased dFdCTP 
concentration favours incorporation of the latter compound 
into DNA 
2) dFdCTP exerts feedback inhibition on deoxycytidylate deaminase, 
hereby favouring its own activation pathway by limiting the 
deamination of dFdCMP [52] 
3) Several enzymes involved in nucleoside metabolism employ 
adenosine triphosphate (ATP), cytidine triphosphate (CTP) or 
uridine triphosphate (UTP) as phosphate donors [74]. In cell 
cultures, it has been shown that treatment with gemcitabine induces 
perturbations in the ribonucleotide pools, including ATP, CTP and 
UTP [75, 76]. Since gemcitabine, being a nucleoside analogue, is 
also metabolised via these enzymes, this could represent another 




1.2.5. Pharmacological modulation of gemcitabine transport and 
metabolism pathways 
Tetrahydrouridine (THU), a CDA-inhibitor [77], and dilazep, an inhibitor 
of hENT1 and hENT2 [78] (Figure 2), have both been applied as 
pharmacological modulators in experimental studies involving gemcitabine.  
THU has been used in vivo in mice [79] and in patients [80], and in vitro 
[81] to prolong the half-life of pyrimidine nucleoside analogues in an 
attempt to increase their efficacy. Moreover, it is routinely used as an 
additive in blood sample tubes to prevent ex vivo deamination of 
gemcitabine and other nucleoside analogues [82]. Although promising 
therapeutic results have been achieved by combining THU and nucleoside 
analogues in leukaemia patients [83, 84], the increase in toxicity may also 
limit their combined use. To our knowledge, no clinical trial combining 
gemcitabine with THU has been conducted in PDAC patients.  
Dilazep is one of several drugs [85] that has been used to inhibit nucleoside 
membrane transport in vitro, including in PDAC cells treated with 
gemcitabine [56, 78]. The purpose of employing transport inhibitors has 
mainly been to isolate individual mechanisms of drug transport. The 
relevance of such experimental approaches in PDAC is underscored by the 
importance of hENT1 in cellular gemcitabine uptake [56, 58, 59]. 
 
  
1.2.6. Concentration-time relations 
In the following, examples of gemcitabine studies in vivo and in vitro will 
be given, with emphasis on drug exposure over time, and on extra- and 
intracellular concentrations of gemcitabine and its main metabolites.  
 
1.2.6.1. Plasma concentrations 
 
Figure 3. Schematic plasma concentration profile after intravenous 
drug infusion. Drug concentrations increase rapidly during drug 
infusion (dark green), followed by a concentration plateau (light green) 
with a balance between the dose-rate and distribution/elimination rates. 
After the infusion is terminated, a rapid initial decline (red, -phase) is 
observed when distribution/elimination dominates, followed by a more 
gradual decline (orange, -phase) after distributional equilibrium has 
been reached and drug elimination dominates. The total drug exposure 
over time is calculated as area under the curve (AUC, shaded area).  
 
The clinically dominating dosing regimen of gemcitabine in PDAC 
consists of repeated courses of weekly 30-minutes infusions of 1000 
mg/m2, both when administered as monotherapy [5, 53] and when 
combined with nab-paclitaxel [86]. Plasma concentrations (mean±SD) 
reach a peak plateau of 82±21 µM (21.6±5.6 mg/L) towards the end of 
the infusion, followed by a rapid elimination with a half-life of 7–18 
minutes [69]. Systemic gemcitabine exposure, expressed as area under 
the curve (AUC) of plasma-concentrations (see schematic in Figure 3), is 
within 41±12 µM*h (10.8±3.2 mg/L*h) in the majority of patients [69]. 
Systemic CDA activity is the main route of gemcitabine elimination with 
dFdU as the sole plasma metabolite. Only 5–10 % of gemcitabine is 
excreted unchanged in urine [53, 69]. Towards the end of gemcitabine 
infusions or soon thereafter, dFdU reaches peak concentrations of 106–
197 µM (28–52 mg/L) is reached, and subsequently eliminated by renal 
excretion with a terminal half-life of 33–85 hours [53].   
 
1.2.6.2. Tissue and pericellular concentrations 
1.2.6.2.1. In vivo gemcitabine and dFdU concentrations 
According to in silico simulations by Battaglia and co-workers [87], 
peak gemcitabine concentration around 20 µM could be expected in 
tumour interstitial fluid in patients receiving gemcitabine 1000 
mg/m2 infusions, followed by a similar elimination rate as from the 
plasma compartment. As a result, a theoretical tissue-to-plasma AUC 
ratio of approximately 1/3 could be expected. 
To our knowledge, no researchers have directly measured 
gemcitabine concentrations in PDAC tumour tissue during 
intravenous drug infusions in human studies. Bapiro and co-workers 
[88] measured dFdC and dFdU concentrations in plasma and excised 
pancreatic tumour tissue specimen from mice, 60–75 minutes after 
intraperitoneal administration of 50 (n=3) or 100 mg/kg (n=3) 
gemcitabine. Mean dFdC concentrations were 27.0–132.2 µM (7.1–
34.8 mg/L) in plasma and 15.2–38.8 µM (4.0–10.2 ng/kg8) in tissue, 
and mean dFdU concentrations were 49.0–72.6 µM (12.9–19.1 
 
8 Unit conversions from ng/kg tissue based on an assumed tissue density of 1 g/mL (Bapiro et al 2011). 
mg/L) in plasma and 42.3–69.2 µM (11.2–18.2 ng/kg) in tissue. 
Tissue-to-plasma concentration ratios were 0.29–0.56 for dFdC and 
0.87–0.95 for dFdU. Neesse and co-workers [89] found comparable 
concentrations. In both studies [88, 89], gemcitabine concentrations 
in plasma were high compared to human studies [69], and cannot be 
directly compared due to different routes of administration. 
However, relative distribution of gemcitabine between plasma and 
tissue compartments seemed to fit reasonably well within the in 
silico estimates, as reported by Battaglia and co-workers [87]. 
 
1.2.6.2.2. In vitro gemcitabine concentrations 
Numerous studies of in vitro gemcitabine-exposures have been 
performed. As an illustration, Paproski and co-workers [56] applied 
three principally different durations of incubation with 0.1–100 µM 
3H-gemcitabine: 
1)  45 seconds in membrane uptake assays,  
2) 60 minutes when assessing uptake and activation / 
phosphorylation 
and 
3) up to 72 hours in gemcitabine toxicity assays 
 
Other authors have used conceptually similar gemcitabine exposures 
[33, 66, 71, 78], with a duration of 24 hours dominating in most 
studies. In most studies, the rationale for the chosen gemcitabine 
concentration is not elaborated, whereas in some studies the 
investigators aimed at concentrations in near proximity to the IC50-
limits [90, 91]. Others have chosen the highest drug concentrations 
possible that did not precipitate in the wells or expose the cells to 
toxic concentrations of the solvent dimethylsulphoxide (DMSO) 
[92]. 
 
Most researchers prepare spike-solutions based on a priori 
theoretical calculations, and direct quantification of gemcitabine and 
metabolite concentrations in cell culture media are, with a few 
exceptions [93], not reported. 
 
1.2.6.3. Intracellular active metabolite concentrations 
dFdCTP is the main intracellular metabolite, and its concentration after 
gemcitabine exposure is used as measure of cellular uptake and 
activation [56], and has also been related to drug efficacy [63-66]. Due to 
its high polarity with three phosphate groups, dFdCTP is trapped inside 
cells and is not found extracellularly [88].  
As exemplified by Derissen and co-workers [61], intracellular dFdCTP 
may be expressed as ng per mg protein, µmol per litre cell volume or 
pmol per 106 cells (hereafter abbreviated as pmol/106). In our experience, 
the latter unit, pmol/106, is preferred by most researchers. Moreover, it 
might be a complex task to compare intracellular dFdCTP-concentrations 
between studies due to exposure with different gemcitabine 
concentrations and cell lines used. Selected examples from the literature 
are given below. 
 
1.2.6.3.1. In vivo dFdCTP concentrations 
In patients, dFdCTP concentrations in mononuclear cells (PBMCs) 
are commonly used as surrogate marker of gemcitabine exposure and 
activation. In PBMCs isolated from a patient after a 30-minutes 300 
mg/m2 gemcitabine infusion, Veltkamp and co-workers [94] found a 
dFdCTP peak concentration of approximately 590 pmol/106 two 
hours after end of the infusion. Abbruzzese and co-workers [95] 
measured dFdCTP concentrations in PBMCs collected in a phase 1 
dose-escalation study with 30-minutes infusions of gemcitabine 22.5 
– 1000 mg/m2.  At 350 and 1000 mg/m2 they found peak dFdCTP 
concentrations of 284 ± 72 (mean ± SEM) and 224 ± 13 µM, 
respectively, 30 minutes after the end of infusions. The authors did 
not convert concentrations to pmol/106, but discussed that variable 
cell counts between samples may have been a weakness in their 
study [95]. PBMCs may not reflect the situation in solid tumour 
cells, in terms of drug exposure to the target and activities in 
intracellular metabolic pathways [61], but are often preferred as 
model due to their availability for repeated sampling at multiple time 
points during and after gemcitabine treatment. Moreover, tumour 
tissue heterogeneity further complicates the picture. As an example, 
Koay and co-workers [29] measured dFdCTP incorporation into 
DNA in tumour tissue specimen excised at the end of intraoperative 
gemcitabine infusions9 in 12 patients. They found highly variable 
concentrations between the different patients, which to some extent 
could be explained by variable hENT1-expression, vascular supply 
and different cell numbers in tumour specimens. Bapiro and co-
workers [88] also measured dFdCTP concentrations (ng/mg tissue) 
in tumour tissue from mice one hour after i.p. administration of 100 
mg/kg gemcitabine. A considerable variation between the mice was 
noted, with concentrations of dFdCTP ranging from below the lower 
limit of quantification (LLOQ) to 30 ng/mg.  
 
1.2.6.3.2. In vitro dFdCTP concentrations 
Following 24 hours in vitro incubation of 19 different cancer cell 
lines with 1 or 10 µM gemcitabine, van Moorsel and co-workers [66] 
reported median intracellular dFdCTP concentrations of 450, 614, 
816 and 925 pmol/106 in ovarian, head-and-neck, lung and colon 
cancer cell lines, respectively. Nishi and co-workers [96] incubated 
the leukaemia cell line HL60 for 1.5 hours with 2.0 µM gemcitabine, 
and primary leukemic cells collected from a patient with chronic 
lymphocytic leukaemia (CML) for 2.0 hours with 2.0 µM 
 
9 To our knowledge this trial is the only reported human study in which gemcitabine has been administered 
intraoperatively and with samples collected from tumours directly after treatment  
gemcitabine. Intracellular dFdCTP concentrations were 75 and 20 
pmol/106 in HL60 and CML cells, respectively. 
 
The time course (kinetics) of dFdCTP accumulation and elimination 
has also been investigated in a few studies. In general, accumulation 
of dFdCTP increases when gemcitabine incubation time is increased. 
Ohmine and co-workers incubated the PDAC cell line PK9 with 1 
µM dFdC for 10 min, and 1, 6, 12 and 24 hours. Intracellular 
dFdCTP increased up to approximately 35 pmol/mg protein at 6 
hours (Tmax), after which a plateau or a small decrease up to 24 hours 
was noted. A comparable Tmax was also found in a study of Chinese 
hamster ovary (CHO) cells by Heinemann and co-workers [97]. Van 
Haperen and co-workers [75] incubated the ovarian cell line A2780, 
and the murine and human colon cell lines C26-10 and WiDr with 1, 
10 or 100 µM gemcitabine for 4 hours and 24 hours. In all cell lines, 
higher dFdCTP concentrations were seen with increasing 
gemcitabine concentrations up to 10 µM, and with 24 hours 
incubation compared to 4 hours. Moreover, they noted variations in 
peak dFdCTP concentration from approximately 600 pmol/106 in 
WiDr to 1700 pmol/106 in C26-10 at 24 hours, which also reflected 
different gemcitabine sensitivities between the cell lines. In the same 
study [75], cellular elimination of dFdCTP was studied after 24 
hours incubation with 1 or 10 µM gemcitabine. In all cell lines, peak 
dFdCTP was seen within 1 hours after terminating drug incubation, 
followed by a decrease to 0-50 % of the peak concentration after 
another 24 hours incubation in drug-free medium. In CHO cells, 
incubated up to 4 hours with 10 µM gemcitabine, Heinemann and 
co-workers [97] found that dFdCTP was highest immediately after 
termination of the incubation, and decreased gradually thereafter. 
 
  
1.2.7. Concluding remarks 
Gemcitabine undergoes extensive extra- and intracellular metabolism, and 
exerts its cytotoxic effects by modulating intracellular nucleotide 
metabolism and inhibiting DNA synthesis. The relationship between drug 
exposure and active metabolite accumulation and toxicities has been 
explored both in vivo and in vitro, and has exhibited great variability. 
Whether gemcitabine delivery into PDAC tumour cells represents a liming 
factor for its efficacy at clinically relevant concentrations, remains to be 
elucidated.  
1.3. SONOPORATION: Ultrasound- and microbubble-assisted drug 
delivery 
Poor chemotherapeutic drug delivery into PDAC tumours may be a general 
mechanism of treatment resistance, mediated by the dense tissue stroma acting 
as a barrier against compound diffusion [28-30]. 
Ultrasound (US) and ultrasound contrast agents, i.e. microbubbles (MB), have 
increasingly been used in order to enhance permeability of biological barriers 
[98-102]. By exposing gas-filled MB to US pressure waves, they volumetrically 
oscillate due to increasing and decreasing internal gas-pressures10, while the 
surrounding lipid shell stretches and contracts. MBs oscillating close to cell 
membranes may create transient pores, stimulate endocytosis or, at higher 
ultrasound intensities, induce microbubble implosions that can destroy 
membranes [102]. It has also been seen by electron microscopy that MB may 
directly enter the interior of the cells (Figure 4), or pass through them. These 
phenomena are commonly referred to as sonoporation. The resulting increase in 
permeability of biological barriers, such as in blood vessels and tumour cell 
membranes, may facilitate increased extravasation and cellular uptake of drugs 
[102]. The main mechanisms of such transport are thought to be either passive 
diffusion through hydrophilic pores along concentration gradients, by direct 
ultrasound-mediated propulsion or via endocytosis, or a combination [101]. 
Moreover, it has been shown that different cell types respond differently to 
sonoporation [103, 104], and that the dominant mechanism of compound uptake 
depends on the US acoustic pressures [105]. High acoustic pressures may also 
result in cell membrane disintegration [105] and induce changes in signalling 
pathways related to cellular growth and viability, in particular when combined 
with higher MB concentrations [104].  
 
 
10 This phenomenon is also called cavitation, which may be either stable or inertial. Stable cavitation is 
observed at low US acoustic intensities where the MB retain their integrity over time, whereas inertial 
cavitation at higher intensities involves complete disruption of the MBs 
 
Figure 4. Electron microscopy image displaying the interaction between 
microbubbles (dark spheres) and pancreatic cancer cells, under the 
influence of low energy, clinically safe ultrasound intensities. The 
bubbles can be seen to merge with, drill into and pass through cells. 
(Original photo by: Spiros Kotopoulis, University of Bergen / Phoenix 
Solutions AS) 
 
Uptake of poorly membrane-permeable fluorescent dyes such as fluorescein 
isothiocyanate (FITC)-labelled dextrans [103] and calcein [104] have served as 
“model drugs” in many in vitro sonoporation-studies. Routine flow-cytometry 
methods allow distinction between positive and negative cells11 and give 
semiquantitative estimates of amounts of intracellular dye12 [105]. Despite their 
widespread application in basal studies of sonoporation, cell-impermeable dyes 
cannot be regarded as valid model compounds representing all properties of 
chemotherapeutic drugs. Lammertink and co-workers [101] gave an overview 
of several in vitro cell line13 and in vivo animal studies performed with a 

11 The efficacy of in vitro sonoporation is expressed as % positive cells in many studies 
12 The signal intensity in positive cells may be expressed as MFI = mean fluorescence intensity (De Cock 
2015) 
13 Cell lines derived from brain, head-and-neck, breast, liver, kidney and colon cancers 
combination of chemotherapeutics and sonoporation. In the majority of in vitro 
studies cell viability, cell death or apoptosis were used as outcome measures, 
whereas in in vivo animal studies the most frequently reported outcomes were 
tumour volume and survival [106]. Intratumoural drug accumulation has been 
assessed in only a few studies [101], but none in which gemcitabine was used. 
 
Taken together, it has been demonstrated that sonoporation can increase the 
permeability of cell membranes, but the underlying mechanisms by which this 
may improve the outcome of treatment with chemotherapeutics remains 
incompletely understood. Specifically, the concept of sonoporation as a 
potential method to increase the delivery of gemcitabine and other drugs to 
PDAC cells needs further exploration. Additionally, in order to bring this 
concept into clinical use, there is a need to study the efficacy and safety of 







The overall objective of the project was to evaluate quantitative aspects of 
gemcitabine delivery and metabolism combined with sonoporation in PDAC 
patients and in in vitro models. 
 
Figure 5 illustrates the overall project and its individual parts. 
 
Specific aims 
- To develop and validate liquid chromatography tandem mass spectrometric 
methods (LC-MS/MS) for quantification of gemcitabine and its main extra- 
and intracellular metabolites (Paper I & II) and related endogenous 
nucleotides (Paper II) 
 
- To establish a protocol for collecting and handling blood samples from 
gemcitabine-treated patients that ensures preanalytical stability of the 
analytes (Paper I) 
 
- To assess the safety and feasibility of treating PDAC patients with 
gemcitabine combined with microbubbles and ultrasound, and to evaluate 
systemic pharmacokinetics of the drug in this setting (Paper III) 
 
- To study the role of intracellular cytidine deaminase activity on gemcitabine 
metabolism in PDAC cell lines (Paper IV) 
 
- To study uptake and metabolism of gemcitabine in PDAC cell lines exposed 
to clinically applicable ultrasound intensities and microbubbles 




Figure 5. Overview of the project “Drug delivery in pancreatic cancer” 
* Data briefly mentioned in Paper V.   
3. Methods 
Table 1 gives an overview of study designs, main objectives and methods used in 
the project. In the following, each approach will be briefly explained. 
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3.1. Study designs and main objectives 
3.1.1. Paper I and II – method development and validation 
Paper I describes a liquid chromatography tandem mass spectrometry (LC-
MS/MS) method for quantification of extracellular gemcitabine and dFdU, 
and preanalytical stability of the compounds in blood samples from PDAC 
patients [1]. Paper II describes a LC-MS/MS method for quantification of 
intracellular dFdCTP and endogenous nucleotide triphosphates (NTPs and 
dNTPs), including challenges and solutions in sample preparation 
procedures [2]. The main purpose of both methods (Paper I and II) were to 
enable quantitative measurements of gemcitabine and its metabolites in 
subsequent clinical and in vitro PDAC model studies. In Paper II, the 
inclusion of NTPs and dNTPs together with dFdCTP, was based on the idea 
that their concentrations could be used as an integrated pharmacokinetic-
pharmacodynamic measure of gemcitabine efficacy. 
 
3.1.2. Paper III – clinical phase 1 trial 
Ten incurable PDAC patients (3 males, 7 females; mean age 59 years) were 
included in this open-label clinical phase 1 trial [3]. Safety and survival 
were primary and secondary outcome measures. Patients received 
intravenous infusions of gemcitabine, followed by intravenous SonoVue® 
microbubble injections and transabdominal low intensity ultrasound 
focused at their tumours. Blood samples for pharmacokinetic (PK) 
evaluations of gemcitabine were collected at the first day of treatment. 
Radiological response evaluations and assessment of performance status 
and blood biochemistry were performed regularly. A historical group of 63 
PDAC patients treated with gemcitabine alone were used as clinical 
controls, and data from the literature were used as comparator for 
gemcitabine PK. 
 
3.1.3. Paper IV and V – in vitro cell line studies 
Three different PDAC cell lines were used in in vitro studies of gemcitabine 
uptake and metabolism. The purpose of paper IV was to study intracellular 
metabolism of gemcitabine with emphasis on CDA-activity with or without 
tetrahydrouridine (THU), a CDA-inhibitor, in cells with different 
expression of the enzyme. In paper V we assessed whether in vitro 
sonoporation could facilitate increased cellular uptake and retention of 
gemcitabine, in cells with operational and inhibited membrane transporters.  
 
3.2. Laboratory methods 
3.2.1. Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
3.2.1.1. Instrumentation and facilities 
LC-MS/MS methods were developed on Agilent 1200 series separation 
module and Agilent 6410 triple-quad mass spectrometer with electron 
spray ionization (ESI) at the University of Bergen. The LC-system 
consisted of a binary pump, a degasser and a thermostated autosampler 
with a variable volume injector. Chromatographic separation was 
conducted on a BDS Hypersil C18 column (Paper I) and a Hypercarb 
column (Paper II). During the project, both methods were transferred to a 
similar instrument at the Department of Medical Biochemistry and 
Pharmacology.  
 
3.2.1.2. LC-MS/MS method development and validation 
Development and validation of the LC-MS/MS methods were based on 
protocols within our laboratory that complied with consensual 
accreditation standards14. The general principles of LC-MS/MS method 
validation, including linearity, within- and between run precision and 
accuracy, recovery, lower limit of quantification (LLOQ) and stability, 
have been covered in a recent review by van Nuland and co-workers 
[107]. The intracellular method validation [2] was particularly 
challenging, mainly for three reasons: 
 
14 Internal quality document at https://handbok.helse-bergen.no/eknet/docs/pub/dok21930.htm (last update 
July 2018) 
1) The endogenous nucleotides are structurally very similar, and 
their intracellular concentrations differed widely 
2) All analytes are highly polar with poor retention on 
conventional reverse phase chromatographic columns. This 
required introduction of ion-pair agents in the mobile phase in 
combination with less robust porous graphitic carbon (PGC) 
columns 
3) Preparation of calibration and quality control (QC) standards in 
cell lysates that already (naturally) contained all the analytes of 
interest. In order to “strip” the matrix, incubation of the cell 
lysates with activated charcoal was undertaken prior to addition 
on the analytes 
 
3.2.2. Preanalytical sample quality 
3.2.2.1. Sample collection and preparation 
In paper III, IV and V, four main steps in the sample collection process 
were undertaken in order to optimize the sample quality: 
1) CDA activity: Tubes had been spiked with 200 µM THU prior 
to sample collection, in order to inhibit deamination of 
gemcitabine 
2) Temperature: All samples from in vivo and in vitro 
experiments were collected in pre-chilled (4 °C) tubes and 
immediately placed on ice. The purpose was to inhibit cellular 
membrane transport and enzyme activities in general 
throughout the sample preparation process 
 
3) Time: Cells, mononuclear blood cells (PBMCs) in paper III and 
PDAC cells in paper IV and V, were isolated and processed as 
soon as possible after harvest in order to limit post-experimental 
changes in analyte concentrations. From in vitro experiments, 
adherent PDAC cells 
were trypsinized at 37 
°C for 5 - 8 min, 
followed by addition 
of ice-cold (0 - 4 °C) 
culture media and 
centrifugation for 5 
minutes before 
isolation.  Isolation of 
PBMCs from patient 
blood were performed 
with density gradient centrifugation in Lymphoprep™ Tubes 
(Figure 6) at 4 °C, which required centrifugation for 25 minutes 
before careful pipetting of the cell layer 
4) Inactivation and lysis: Isolated cells were forcefully dissolved 
in ice-cold (-20 - 0°C) 60 % methanol (MeOH), snap-frozen in 
liquid nitrogen, and then transferred to a -80 °C freezer 
 
3.2.2.2. Preanalytical stability of gemcitabine in blood samples 
In paper I, we assessed whether the time spent from blood sampling to 
centrifugation and separation of plasma from blood cells, influenced 
stability of gemcitabine and dFdU. Figure 7 shows the principal 
workflow. The purpose was to establish a protocol that allowed 
collection of multiple samples in succession, followed by centrifugation 
in a batch rather than one-by-one. 

Figure 6. Isolation of PBMC from 
whole blood using Lymphoprep™ 




Figure 7. Workflow of sample collection and –processing in the 
preanalytical study. Blood was collected from PDAC patients at 
gemcitabine Tmax in heparin and ethylene-diamine tetra acetic acid 
(EDTA) tubes collected in rapid succession. Tubes were centrifuged and 
plasma separated sequentially at eight time points up to 24 hours. 
(Illustration: from poster presented by TK Bjånes at The European 




3.2.3. Cell culture 
Three PDAC cell lines; BxPC-3, MIA PaCa-2 and PANC-1, were used in 
studies of in vitro gemcitabine metabolism and in sonoporation experiments 
in paper IV and V, respectively. All three cell lines were of human origin, 
and are commonly used in in vitro studies of PDAC. When cultured, they 
have been shown to display capabilities that resemble the behaviour of 
tumour cells in vivo, including adhesion to extracellular matrix components, 
migration, invasion and the ability to form tumours [44]. Moreover, 
mutations in KRAS, TP53, CDKN2A and SMAD4 characteristic for PDAC 
tumours, have also been found to variable degrees in BxPC-3, MIA PaCa-2 
and PANC-1. As such, they may also be considered representative of the 
diversity seen in pancreatic cancers in vivo [44]. Cells were cultured at two 
different conditions: 1) at normoxia in a) standard culture flasks for 
expanding cell populations prior to experiments, and b) six-well plates 
(Figure 8A) for gemcitabine incubation experiments in Paper IV, or 2) in 
PetakaG3™ LOT15 hypoxic bioreactors (Figure 8B) for experiments with 
sonoporation in Paper V.  
 
Figure 8. Culture conditions in paper IV (A) and paper V (B), and the 
estimated oxygen tensions compared to tumours (C). 
 
3.2.4. Gene and protein expression 
In paper IV, we assessed the influence of intracellular CDA activity on 
gemcitabine metabolism in PDAC cells, with or without pharmacological 
CDA inhibition with 200 µM THU. Expression levels of CDA and other 
proteins involved in transport, metabolism and mechanism of action of 
gemcitabine in untreated cells were assessed by a collaborator at the Centre 
de Recherche en Cancérologie de Lyon, Lyon, France. Gene expression was 
performed with real-time polymerase chain reaction (RT-PCR). For each 
gene, expression in one individual cell line was calculated as relative to the 
mean of all three cell lines by the delta-delta cycle threshold (CT)-
method [108], using 28S mRNA as a housekeeping gene. Protein 

15 LOT = Low Oxygen Transfer. Read more on supplier webpage: http://celartia.com/petaka-options/#LOT-
Hypoxia-chamber 
expression was assessed by Western blot [109], with beta-actin as loading 
control in each sample.  
 
3.2.5. In vitro sonoporation 
Prior to the experiments in paper V, comprehensive 
exploration of multiple different sonoporation parameters 
was performed; four ultrasound intensities, four microbubble 
brands and six microbubble concentrations (Figure 9). The 
membrane-impermeable 
fluorescent dye calcein was used 
as an indicator substance, and cells 
were analysed with flow-
cytometry. Calcein positive cells 
were separated from negative cells, and the percentage (%) of positive cells 
within each sample was used as a measure of the amount of cells 
permeabilized by sonoporation (Figure 9). The ultrasound intensities and 
microbubble concentrations used in paper V had been shown to result in 30 
– 80 % calcein positive cells. In paper V, we assessed gemcitabine and 
metabolite concentrations in cells with operational and inhibited hENTs, 
and in cells with inhibited CDA. hENT inhibition was achieved by 
incubating the cell lines with 100 µM dilazep 20 minutes prior to 
gemcitabine incubation, whereas CDA inhibition was achieved by co-
incubating gemcitabine with 200 µM THU. 
 
3.2.6. Cell viability 
In Paper V, cells that had been exposed to gemcitabine, sonoporation or 
both, were reseeded in wells with drug-free media, and their growth was 
compared to untreated cells for up to ten days post-exposure. Daily 
snapshots were captured using a Zeiss Vert.A1 microscope with an 
Axiocam 105 camera and a computer with Zeiss ZEN Pro software. Surface 
area coverage of cells within each image were calculated with the MIPAR® 
image analysis software [110].  
Figure 9. QR-code with link to 
poster of in vitro optimization of 
sonoporation conditions (presented 
at the 51st meeting of the European 
Pancreatic Club, Bergen, June 2019) 
3.3. Data processing and Statistics 
Processing of quantitative data was performed with Agilent MassHunter 
software (LC-MS/MS), SPSS Statistics 21.0 - 24.0 (IBM Inc., Armon, NY, 
USA) and GraphPad Prism 7 - 8 (San Diego, CA, USA) for Windows. 
 
In papers I and II, calibration curves in LC-MS/MS methods were constructed 
by linear regression from triplicate values at each data point. Goodness of fit 
was indicated by R2. Method performance were expressed as mean and standard 
deviations (SD) of ten replicates from three (paper II) or five (paper I) different 
QC concentrations. Coefficients of variation (CV), calculated as SD divided by 
means, were used as comparator across concentrations.  
 
In the stability experiment in paper I, changes over time from the initial 
concentrations were related to the LC-MS/MS method performance. This was 
done in order to discriminate between systematic and random deviation, using 
an adaptation of the Bland-Altman method [111]. 
 
Concentrations of gemcitabine and metabolites in paper I, IV and V were 
expressed as mean±SD, range (low–high), or as absolute difference or percent 
(%) compared to baseline. Continuous data in paper III – V were analysed using 
unpaired two-sided student’s t-tests. For comparisons between more than two 
groups in paper IV, we used analysis of variance (ANOVA) with Bonferroni 
adjusted post hoc tests. In paper III, patient survival data was analysed with the 
log-rank test. P-values of less than 0.05 were considered statistically significant. 
 
In paper V, one tailed Pearson’s correlation was used to determine trends of 
gemcitabine and metabolite concentrations with changing ultrasound intensities.  
 
  
3.4. Ethical considerations 
The clinical trial (ClinicalTrials.gov number: NCT01674556) was conducted 
according to the Helsinki Declaration16 and national regulations, with approval 
from the Regional Ethics Committee (2011/1601/REK Vest) and the Norwegian 
Medicines Agency. All patients participating in the clinical trial (Paper III) and 






4. Summary of Results 
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III Combined treatment of PDACe 
patients with gemcitabine and 
sonoporation was safe and 
feasible 
 
Improved survival compared to 
historical controls. 
Similar systemic gemcitabine 
pharmacokinetics as in literature 
IV Intracellular CDAf activity in 
PDAC cell lines regulated the 
amount of gemcitabine into the 
activation pathway 
 
Phenotypical assessment of CDA 
activity was superior to expression 
analyses 
 
V Sonoporation induced increases in 
gemcitabine uptake in PDAC 
cells, but pre-existing activities in 
membrane transporters and 
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4.1. Paper I 
Bjånes T, Kameva T, Eide T, Riedel B, Schjøtt J, Svardal A. J Pharm Sci 2015; 
104(12): 4427-32. 
 
We presented a LC-MS/MS method for gemcitabine and dFdU, and stability 
assessment of both analytes in blood samples from seven PDAC patients. 
Linear ranges were 0.125–40.0 and 1.25–80.0 µg/mL for gemcitabine and 
dFdU, respectively. The method displayed a between run precision CV of 6.5 % 
or better for gemcitabine QC samples above the LLOQ.  
Four hours after blood collection from patients, gemcitabine concentrations 
were within the 95 % confidence interval (CI) of LC-MS/MS precision. After 
24 hours, concentrations showed a greater deviation and tended to drop below 
the lower boundary of 95 % CI, which indicated analyte instability (Figure 10). 
 
Figure 10. Stability of gemcitabine in blood from PDAC patients. dFdC 
(X-axis) represent the difference from the initial separation. Grey lines 
represent the upper and lower boundaries of 95 % CI of method performance, 
based on a between run precision (CV) of 6.5 %. (Illustration from: Poster 
presented at The European Therapeutic Drug Monitoring Conference, Prague, 
Czech Republic, August 2014)  
4.2. Paper II 
Kameva T, Bjånes T, Svardal A, Riedel B, Schjøtt J, Eide T. J Chromatogr B 
Analyt Technol Biomed Life Sci 2015; 1001: 212-20. 
 
We described development and validation of a LC-MS/MS method for 
quantitative analysis of four ribonucleotide triphosphates (NTPs): ATP, CTP, 
GTP and UTP; four deoxyribonucleotide triphosphates (dNTPs): dATP, dCTP, 
dGTP and TTP; and gemcitabine triphosphate (dFdCTP). The linear range for 
dFdCTP was 0.02–31.3 µM, with a between-run precision from 11.4 % at the 
lowest to 3.87 % at the highest QC standard. Method validation included 
charcoal incubation to strip the off nucleotides from the cell matrix before 
spiking with reference substances when preparing calibration and QC samples. 
Sample preparation with solid 
phase extraction (SPE) and 
protein precipitation without 
SPE was also assessed. The 
absolute recoveries were 20–
30 % lower without SPE. 
However, this was 
compensated by the presence 
of 13C,15N-isotope labelled 
internal standards that were 
equally affected as their 
respective analytes. 
The method was applied for 
analyses of dFdCTP concentrations in blood mononuclear cells from PDAC 
patients treated with gemcitabine. We observed a gradual increase up to 380 
pmol/106 cells 240 minutes after initiating a 30-minutes gemcitabine infusion 
(Figure 11). We also measured NTPs and dNTPs 240 minutes after gemcitabine 
infusions, and observed that all analytes were three to seven times higher than 
before infusions.  

Figure 11. Concentration course of 
intracellular dFdCTP in blood mononuclear 
cells collected from a PDAC patient up to 240 
minutes after initiating a 30-minutes infusion 
of 1000 mg/m2 gemcitabine. (Illustration 
from: Paper II) 
4.3. Paper III 
Dimcevski G, Kotopoulis S, Bjånes TK, Hoem D, Schjøtt J, Gjertsen BT, 
Biermann M, Molven A, Sørbye H, McCormack E, Postema M, Gilja OH. J 
Control Release 2016; 243; 172-181. 
 
The main results of this phase I clinical trial in ten PDAC patients were that 
combined treatment with ultrasound, microbubbles and gemcitabine 
o was feasible and safe, and with no additional toxicity noted 
o seemed to increase the median survival from 8.9 (historical controls, 
n=63) to 17.6 months (n=10, p=0.011). The patients were also able to 
receive an increased number of treatment cycles; from 8.3±6.0 
(historical controls, n=63) to 13.8±5.6 (n=10, p=0.008) (Figure 12) 
o resulted in similar systemic gemcitabine pharmacokinetic data as 
described in literature (without sonoporation) 
 
Figure 12. A: Whisker plot comparing the number of treatment cycles in the 
two treatment groups (sonoporation + gemcitabine (n=10) and gemcitabine 
alone (n=63; historical controls)) and B: Survival plot of the two treatment 
groups. (Illustration from: Paper III) 
 
  
4.4. Paper IV 
Bjånes TK, Jordheim LP, Schjøtt J, Kamceva T, Cros-Perrial E, Langer A, de 
Garibay GR, Kotopoulis S, McCormack E and Riedel B. Submitted to Drug 
Metabolism and Disposition September 13th 2019 (Manuscript ID: 
DMD/2019/089334, ongoing minor revision). 
 
We examined gemcitabine metabolism in vitro in three PDAC cell lines, BxPC-
3, MIA PaCa-2 and PANC-1, with emphasis on the regulatory role of CDA on 
intracellular gemcitabine activation. All three cell lines were incubated with 10 
or 100 µM gemcitabine for 60 minutes or 24 hours, with or without 200 µM THU. 
CDA activity and expression varied widely between the three cell lines studied, 
with low activities in MIA PaCa-2 and PANC-1 compared to BxPC-3.  
Our main finding was that intracellular CDA in BxPC-3 mediated an extensive 
deamination of gemcitabine that seemed to limit the amount gemcitabine 
available for activation to dFdCTP (Figure 13).  
 
Figure 13. Extracellular dFdU (A) and intracellular dFdCTP (B) after 24 hours 
incubation with 10 or 100 µM gemcitabine in BxPC-3 (orange), MIA PaCa-2 
(purple) and PANC-1 (green) with (solid lines) or without (dashed lines) THU. 
(Illustration from: Paper IV). 
 
  
4.5. Paper V 
Bjånes TK, Kotopoulis S, Murvold ET, Kamceva T, Bjørn Tore Gjertsen, Schjøtt 
J, Riedel B and McCormack E. Manuscript in preparation. 
 
We observed that sonoporation induced moderate increases in gemcitabine 
uptake in PDAC cells, but that activities in membrane transporters (hENTs) and 
intracellular CDA were more important determinants of metabolite 
accumulation. Increasing ultrasound intensities resulted in reduced extracellular 
gemcitabine concentrations in cell lines with inhibited hENTs (Figure 14). 
Intracellular dFdCTP concentrations did 
not change in any of the cell lines with 
operational hENTs, either with or 
without inhibited CDA. In cells with 
inhibited hENTs, but without 
sonoporation, dFdCTP concentrations 
were low, 10–30% of baseline. 
Sonoporation partially restored uptake 
in these cells, as indicated by moderate 
increases in dFdCTP in MIA PaCA-2 
and PANC-1 (Figure 14, top right). In 
BxPC-3, gemcitabine was inactivated to 
dFdU (Figure 14, middle left), and no 
increase in dFdCTP was seen. 
 
Figure 14. Effect of sonoporation (“Control”, “Medium”, “High”) on 
extracellular gemcitabine (bottom line) and dFdU (middle line), and 
intracellular dFdCTP (top line) concentrations, in cells with inhibited hENTs. 
*p<0.05, **p<0.01. (Illustration from: poster presented at the 51st meeting of the 
European Pancreatic Club, Bergen, June 2019).  
5. Discussion  
Improved treatment of PDAC represents a highly unmet medical need [4, 6, 7] 
and poor drug delivery is considered to be a major limitation for effective 
chemotherapeutic treatment [28-30]. Hence, the aims within the current project, 
combining quantitative assessments of gemcitabine and its main metabolites 
with in vivo and in vitro drug-delivery studies in PDAC, may be considered 
highly relevant.  
 
In accordance with the specific aims within the project, we 
I. Developed and validated a LC-MS/MS-method for gemcitabine and 
dFdU, and demonstrated that the analytes were stable for at least four 
hours in anticoagulated THU-spiked blood kept on ice. This allows batch 
centrifugation of samples acquired during this time interval, and is an 
important prerequisite for quantification of gemcitabine in 
pharmacokinetic studies in which consecutive blood sampling is 
performed 
II. Developed and validated LC-MS/MS-method for quantitation of 
intracellular gemcitabine triphosphate and 8 endogenous nucleotide 
triphosphates, using a porous graphitic column. Moreover, we 
demonstrated that the treatment of cell supernatants with activated 
charcoal was an effective method of creating a nucleotide-free matrix 
that could be used for preparation of internal standards 
III. Demonstrated that treatment of PDAC patients with gemcitabine 
combined with ultrasound and microbubbles was safe and feasible, and 
potentially clinically beneficial. We found that the systemic 
pharmacokinetics of gemcitabine was not influenced by intravascular 
microbubble injections and transabdominal ultrasound. No conclusions 
could be drawn about local drug delivery to the tumours, since such 
measures were not part of the study protocol 
IV. Demonstrated the role of intracellular cytidine deaminase (CDA) activity 
in regulating the accumulation of dFdCTP. Our data support the notion 
that gemcitabine inactivation by intracellular CDA may represent a 
protective mechanism against gemcitabine cytotoxicity 
V. We demonstrated that increased cellular uptake of gemcitabine did not 
necessarily result in an increased intracellular accumulation of the active 
metabolite. In vitro sonoporation allowed increased transmembrane 
transport of gemcitabine in PDAC cell lines, but the effect was negligible 
in terms of dFdCTP accumulation due to pre-existing nucleoside 
transporters and intracellular cytidine deaminase activities 
 
There are several limitations within the current project. No PDAC model with a 
representative tumour microenvironment, such as multiple cell types or 
abundant desmoplastic stroma [26, 27], was included. Although our findings 
from the in vitro PDAC cell line studies may fit well into existing knowledge of 
cellular gemcitabine uptake and metabolism, they cannot be generalized to an in 
vivo situation where blood flow and tissue perfusion are also important 
determinants of drug delivery [36, 37]. Another limitation is that the clinical 
study was small and based on a historical control group. As a consequence, no 
general conclusions could be drawn about treatment efficacy. Moreover, the 
current first-line chemotherapeutic drug regimens used for PDAC, such as nab-
paclitaxel [5, 41] or FOLFIRINOX [5, 39], were not included.  
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5.1. Methodological considerations 
5.1.1. LC-MS/MS 
We established two LC-MS/MS methods (Paper I and II) [1, 2] that enabled 
quantification of gemcitabine and its main inactive and active metabolites 
in blood cells and in cultured PDAC cell lines. LC-MS/MS is considered 
the gold standard in pharmacokinetic studies, due to a superior analyte 
specificity and its ability to quantitate analytes over a broad range of 
concentrations [107]. The LC-MS/MS methods were used for the 
generation of data for all papers included in this thesis.  
 
5.1.2. Analyte stability 
Gemcitabine is rapidly metabolized to dFdU in blood, and addition of the 
CDA-inhibitor THU into collection tubes is required to retain gemcitabine 
until quantification [82]. We added 200 µM (50 µg/mL) THU in blood 
collection tubes when sampling from PDAC-patients in paper I [1] and III 
[3] and in the culture media used for collecting cells at the end of in vitro 
experiments in paper IV and V. A concentration of 200 µM THU was 
primarily based on an ex vivo study in human blood by Bowen and co-
workers [112]. In paper IV, we demonstrated that the proposed 
concentration of 200 µM THU effectively blocked in vitro deamination of 
up to 100 µM gemcitabine.  
In addition to pharmacological inhibition of CDA, we routinely kept 
collected samples on ice in order to slow down active transport and 
intracellular enzyme reactions in cell samples [67]. Most authors emphasize 
that complete inactivation of transporters and enzyme activities should be 
performed immediately when analysing cellular nucleotide concentrations 
[113].  Potassium hydroxide [56, 78], sodium hydroxide [90], perchloric 
acid (PCA) [76, 93], commercial cell lysis reagents [71] or 60-70 % MeOH 
[72, 114] have been used to dissolve cell pellets, followed by immediate 
freezing of the samples. In our experience, forceful dissolution of cell 
pellets in cold 60 % MeOH followed by snap-freezing in liquid nitrogen, 
resulted in complete disruption of the cellular integrity and hence represent 
a final inactivation of transport and enzyme activities. Cohen and co-
workers [115] exemplified the importance of such inactivation on the 
stability of dFdCTP; in intact PBMCs kept on ice its half-life was only 100 
minutes, but with immediate dissolution in PCA and storage of the extracts 
at -80°C, stability was demonstrated for at least 7 months. 
 
5.1.3. Cell line studies 
Several well-known shortcomings of in vitro cell lines studies, as described 
in section 0, also apply to paper IV and V. Specifically, the lack of a more 
complete dynamic tumour model with other cell types and tissue 
components that may influence local drug distribution and metabolism [31-
35], represent major limitations for the in vivo relevance of our results.  
Nevertheless, we have explored basal mechanisms of gemcitabine transport 
and metabolism in three different PDAC cell lines, BxPC-3, MIA PaCa-2 
and PANC-1 [45], that may also mirror a diversity between tumours [42, 
43]. We have highlighted that intracellular drug metabolism should be taken 
into account in drug delivery studies [116]. This view is further 
strengthened by the fact that other cell types in PDAC tumours might also 
influence intratumoural gemcitabine metabolism and distribution, as 
demonstrated by Hessmann and co-workers [33]. 
 
5.1.4. Drug exposure 
In the majority of in vitro drug incubation studies, the concentration-time 
profile differs from its profile in vivo (Figure 15), unless specialized 
dynamic bioreactor systems that mimic in vivo drug delivery and 
elimination are used [117].  
 
Figure 15. Illustration of typical 1) in vivo and 2) in vitro drug 
administrations. 1) Displays an increase in concentrations during 
intravenous drug infusion and a gradual decline after termination. 2) 
Displays a rectangular concentration-time profile during in vitro drug 
incubation. 
 
In paper IV and V, gemcitabine concentrations and duration of in vitro 
incubations were chosen based on two main assumptions. 
1. The interstitial/pericellular AUC derived from in silico simulations [87] 
is representative for the in vivo tissue exposure during and after 
intravenous gemcitabine infusions 
2. An in vitro gemcitabine AUC which is comparable to an in vivo 
interstitial/pericellular AUC would represent the clinically most relevant 
exposure 
 
Gemcitabine AUC of 41±12 µM*h in plasma from patients [69] would on 
average result in AUC of 13–14 µM*h in tumour interstitial fluid (i.e. 1/3 
of plasma), according to in silico simulations [87]. As an example, the in 
vitro exposure used in paper V, 10 µM gemcitabine over 60 minutes (i.e. 
AUC 10 µM*h), was comparable to the data obtained by the simulations. 
However, the lack of an in vivo PDAC tumour tissue model in which actual 
interstitial gemcitabine exposures could be quantified, represents a 
limitation to the clinical relevance of the in vitro results. In particular, the 
unrestricted compound diffusion within culture media may differ widely 
from the in vivo situation in tumours [26, 27]. 
 
5.1.5. Methodological considerations specific to the individual papers 
5.1.5.1. Paper I 
We demonstrated that gemcitabine and dFdU were stable in blood from 
PDAC patients for at least four hours when kept on ice, provided that 
200 µM THU was added. In a more recent study by Kozo and co-
workers [82] gemcitabine (concentrations not stated) and 500 µM THU 
were spiked into freshly drawn blood, and kept at room temperature (RT) 
or at 2 – 8 °C. The authors showed that gemcitabine was stable for at 
least 8 hours at RT. This may indicate that our limit of 4 hours on ice 
was too strict. However, the studies differed in at least two aspects.  
1. The definitions of analyte stability were different: In our study, the 
analytes were considered stable when the difference from the control 
sample was not greater than the theoretical deviation seen with the 
poorest precision of the LC-MS/MS method in samples above LLOQ. 
Kozo and co-workers made use of an in-house definition of <10% 
loss as cut-off for analyte stability 
2. Our study was performed in blood samples acquired directly from 
patients at the end of gemcitabine infusions, while Kozo and co-
workers used blood spiked with gemcitabine. It has been argued that 
an inaccurate spike procedure may represent an additional source of 




5.1.5.2. Paper II 
5.1.5.2.1. Endogenous nucleotides and modification of the LC-
MS/MS method 
An initial purpose of paper II [2] was to quantify intracellular NTPs 
and dNTPs (“endogenous nucleotides”) together with dFdCTP as an 
integrated pharmacokinetic/pharmacodynamic measure, based on the 
potential regulatory action of endogenous nucleotides on 
gemcitabine cytotoxicity [52, 66]. In paper II, we observed that 
concentrations of dFdCTP as well as endogenous nucleotides in 
PBMCs increased up to 240 minutes after initiating gemcitabine 
infusions [2]. We speculated that the increase in endogenous 
nucleotides might be explained by a transient upstream accumulation 
secondary to dFdCTP-induced DNA synthesis inhibition (LP 
Jordheim, personal communication, August 1st 2014), but had no 
additional data to support this view. In a few initial in vitro 24 hours 
gemcitabine incubation experiments in MIA PaCa-2, we observed a 
decrease in most endogenous nucleotides. As an example, a decrease 
of dATP, dCTP and dGTP with increasing gemcitabine 
concentrations (Figure 16) was considered to reflect the inhibition of 
ribonucleotide reductase by dFdCDP [52, 61], as illustrated in Figure 
2. However, the sensitivity of the LC-MS/MS-method for dNTPs 
was challenged, and we also experienced repeated problems with the 
LC-MS/MS instrument, a >10 years old Agilent 641017. For this 
reason, we had to abandon further exploration of the nucleotide pools 
within this project. The LC-MS/MS method was simplified and 
restricted to quantification of dFdCTP only (Paper IV and V), which 
allowed shorter run-time and hence, increased sample throughput. 
 
Development of a LC-MS/MS method for analysis of gemcitabine, 
dFdU and dFdCTP in a single run would have been more rational if 
 
17 https://www.agilent.com/cs/library/support/documents/f391141304.pdf (Last updated in 2006) 
the original plan had not included endogenous nucleotides. Indeed, 
several LC-MS/MS methods have been published for the 
simultaneous analysis of all three analytes in plasma18, blood cells 
and tissues, with run-times of only 15 minutes [67, 88].  
 
 
Figure 16. Intracellular concentrations of three endogenous nucleotide 
triphosphates following 24 hours in vitro incubation of MIA PaCa-2 
cells with 0 – 100 µM gemcitabine.  
dATP: deoxyadenosine triphosphate, dCTP: deoxycytidine triphosphate, dFdCDP: gemcitabine 





18 Exception: dFdCTP not detectable in plasma samples 
5.1.5.2.2. Porous graphitic carbon (PGC) columns  
Porous graphitic carbon (PGC) columns enable separation of 
structurally very similar analytes, including polar compounds, and 
have been applied in several nucleotide assays due to this unique 
property. Challenges with unpredictable analyte retention over time 
have been described [119]. As a result, the majority of LC-MS/MS 
methods with PGC have included thorough reconstitution procedures 
to retain the quality of columns. As a result, the run times have 
usually been long (up to 2 hours). Bapiro and co-workers [119] 
recently described a simple solution to these challenges by 
optimizing the composition of the mobile phases. They found that a 
2-minutes maintenance step with 95 % methanol towards the end of 
each analytical run effectively prevented a gradual loss of retention 
properties.  
With our method [2], each analytical run (total runtime of 68–69 
minutes) included a reconditioning phase of 14 minutes. Despite this, 
we experienced repeated problems with loss of analyte retention. 
Hence, the study by Bapiro and co-workers [119] may be of great 
value in future method developments using these columns. 
 
5.1.5.3. Paper III 
This small clinical trial (n=10) was the first to explore in vivo 
sonoporation in PDAC patients. An important experience was that the 
treatment was feasible with commercially available ultrasound 
equipment, and with ultrasound intensities and microbubbles that were 
already approved for clinical applications [3, 120]. Due to the 
encouraging results, the study also paved the way for increased research 
efforts into drug delivery in PDAC both in vitro [90], in pre-clinical 
studies [106] and into developing larger clinical trials [120]. A limitation 
in the study design was the use of a historical control group, and as a 
consequence no firm conclusions could be drawn about survival benefits. 
Larger randomized trials are needed in order to explore the clinical 
outcome of chemotherapy combined with sonoporation. 
 
5.1.5.3.1. Gemcitabine concentrations 
We demonstrated that gemcitabine systemic PK in the study patients 
did not differ from values in the literature. However, we did not 
measure gemcitabine and –metabolite concentrations in the tumours. 
Therefore, our data did not prove that sonoporation using low-
intensity ultrasound facilitates increased in vivo gemcitabine delivery 
to PDAC tumours in patients. However, since tumour biopsies 
during (intraoperative) drug administration would be resource 
demanding, methodically complicated [29, 88] and also ethically 
challenging, such questions must primarily be addressed in suitable 
model systems. Indeed, there are currently several ongoing projects 
at the University of Bergen, briefly mentioned in Section 6.  
 
5.1.5.4. Paper IV  
In vivo inactivation through CDA in blood is a well-recognized 
determinant of gemcitabine elimination kinetics and toxicity [112, 121]. 
We undertook this in vitro study to explore the importance of 
intracellular CDA on the metabolic fate of gemcitabine in PDAC cell 
lines. The main finding was that an extensive CDA-mediated inactivation 
of gemcitabine in BxPC-3 cells limited the intracellular dFdCTP 
accumulation. We also hypothesized that saturation of dCK was likely to 
explain a lack of increase in dFdCTP with increasing gemcitabine 
concentrations in cells with low CDA activities. Although we initially19 
did not perform cytotoxicity experiments following gemcitabine 
exposure in cells with inhibited CDA, our results supported the notion 
[122-125] that intracellular conversion to dFdU may represent a 
mechanism of gemcitabine resistance. Furthermore, the relative mRNA 
 
19 In a currently ongoing revision of the paper, cell viability experiments are being performed as required by 
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expression of CDA and other proteins involved in gemcitabine transport 
and metabolism in BxPC-3, MIA PaCa-2 and PANC-1, was in 
agreement with previous findings by Funamizu and co-workers [126]. 
Our observation that protein expression (Western blot) was inferior to 
phenotypic assessment of CDA activity (i.e. direct measurement of 
gemcitabine and dFdU), was in agreement with a recently presented 
expert opinion concerning in vivo CDA activity assessments [121].  
 
 
5.1.5.5. Paper V 
5.1.5.5.1. Cell culture in hypoxic bioreactors 
The choice of hypoxic bioreactors (Petakas) in sonoporation 
experiments were done for three main reasons;  
1. The bioreactors could be immersed into a water bath that allowed 
access to the whole surface area for ultrasound exposure 
2. The closed system minimized the risk of bacterial contamination 
during experiments (which included transport across a non-sterile 
environment) 
3. Restricted access to oxygen was considered to resemble the in 
vivo microenvironment in PDAC tumours (Figure 8C) 
It has been demonstrated that hypoxia induces a reduction in the 
expression of ribonucleotide reductase (RR) and intracellular dNTP 
concentrations in PANC-1 [127]. Since intracellular gemcitabine 
metabolism and efficacy are also related to the activity of RR and the 
nucleotide pools [52, 61], hypoxic culture of the PDAC cell lines 
may represent the most relevant experimental condition for the study 
of this drug. 
 
  
5.1.5.5.2. dFdCTP as a measure of cellular gemcitabine uptake 
We aimed to assess whether gemcitabine uptake could be facilitated 
by sonoporation. We initially explored whether direct intracellular 
quantification of unmetabolized gemcitabine was feasible, but found 
that the concentrations were less than 1 % of dFdCTP and often 
below LLOQ of our method (Paper I), even after 24 hours incubation 
with gemcitabine. Indeed, Heinemann and co-workers [76] also 
found that after four hours gemcitabine incubation, intracellular 
concentrations of dFdC, dFdCMP, dFdCDP and dFdCTP accounted 
for 0.2, 2.4, 5.6 and 89 %, respectively, of the total amount of all 
metabolites. In compliance with the approach of other researchers 
[66, 94, 96], we used intracellular dFdCTP as a measure of 
gemcitabine uptake and intracellular retention, since this metabolite 
is also related to drug efficacy [63-66]. 
In sonoporation experiments, the Tmax of dFdCTP following 
gemcitabine incubations was perceived as the optimal time point of 
sampling in order to demonstrate whether gemcitabine uptake was 
successfully increased. In order to establish Tmax, we collected cells 
incubated in drug free medium up to 24 hours after termination of 60 
minutes gemcitabine exposure in six well plates. We found that Tmax 
of intracellular dFdCTP was achieved immediately after terminating 
60 minutes incubation with 10 µM gemcitabine (example in Figure 
17), which was in line with previous studies in other cell lines [97]. 
These data supported our choice of sampling the cells immediately 
after 60 minutes incubation also from Petakas.  
 
Figure 17. Elimination of intracellular dFdCTP from MIA PaCa-2 
following termination of 60 minutes incubation with 10 µM gemcitabine. 
A similar concentration course was also demonstrated in BxPC-3. 
(Illustration from: Unpublished pilot experiments prior to sonoporation 
experiments in Paper V)  
 
  
6. Main conclusions and future perspectives 
Overall, our studies contribute to an increased understanding of drug delivery in 
PDAC. As such, they may provide help for further research to improve the 
treatment outcome of this disease.  
Quantitative assessment of gemcitabine and its main extra- and intracellular 
metabolites in different matrices enabled elucidation of drug distribution, uptake 
and metabolism in PDAC. In particular, we showed that gemcitabine delivery 
through in vitro sonoporation depends on the cellular phenotype in terms of 
membrane transporter and intracellular enzyme activities. The findings are of 
relevance to improve efficacy of PDAC treatment with gemcitabine, but also to 
develop sonoporation as a clinical method for delivery of other chemotherapeutics 
to cancer cells. Furthermore, the in vitro findings might question the quantitative 
importance of sonoporation on cellular drug delivery.  
 
Our studies have addressed several issues that deserve further exploration. In 
particular, they underpin the need to take mechanisms of drug uptake and 
metabolism into account. Studies in relevant PDAC models are required. At 
Haukeland University Hospital and the University of Bergen, the following projects 
are within our current scope of further advancements within the field: 
 
Evaluation of drug uptake in PDAC tissue models 
We suggest that gemcitabine uptake combined with sonoporation should be studied 
in a PDAC 3D organoid model with multiple cell types and connective tissue 
components20. Using in-house developed scaffold models [50] both in vitro and in 
vivo drug delivery studies should be feasible. Furthermore, in vitro bioreactors that 
mimic vascular dynamics is currently under development, and the plan is to culture 
PDAC organoids within these. An advantage over static in vitro systems would be 
 
20 By using cell lines (PDAC, fibroblasts, endothelial cells etc.) or tumour specimen from PDAC patients 
that the transport of chemotherapeutics and microbubbles resemble the in vivo 
situation more closely.  
 
LC-MS/MS development 
A LC-MS/MS method comprising gemcitabine, dFdU and dFdCTP in a single run 
allows a more streamlined process of sample preparation and analysis. Other 
chemotherapeutics used against PDAC, should also be considered in a new or 
improved method. Furthermore, validation of the methods for use in tissue 
samples/homogenates is a prerequisite in order to address questions related to drug 
distribution and uptake in tumour tissues. 
 
Clinical trial 
Larger randomized clinical trials are needed in order to further explore the 
therapeutic potential of combining sonoporation with gemcitabine or other 
chemotherapeutics in the treatment of PDAC. Indeed, a protocol of a four-arm 
randomized clinical trial with FOLFIRINOX or gemcitabine+nab-paclitaxel, with 
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ABSTRACT: Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC) and metabolite (2′,2′-difluoro-2′-deoxyuridine, dFdU) quantification is
warranted for individualized treatment strategies. Analyte stability is crucial for the validity of such quantification. We therefore studied the
impact of the time interval from blood sampling to separation of plasma on gemcitabine stability. Blood from gemcitabine-treated patients
was drawn into tetrahydrouridine (THU)-spiked heparin and ethylenediaminetetraacetic acid tubes and kept on ice until separation.
Plasma was separated sequentially up to 24 h after sampling and dFdC and dFdU were quantified by liquid chromatography tandem mass
spectrometry (LC–MS/MS). The change in plasma concentrations over time was compared with the highest imprecision for concentrations
above the lower limit of quantification of the LC–MS/MS method. Analyte concentrations decreased slightly over time, but for samples
stored for 4 h on ice, the decline was smaller than the expected analytical imprecision. After 24 h, the maximum decline was 14.0%,
which exceeded the expected analytical imprecision. dFdC and dFdU stabilities were acceptable for at least 4 h when THU-spiked whole
blood samples were kept on ice. This is within the scope of routine sampling procedures. Further, variations in separation time intervals
within this time frame are negligible when interpreting drug concentrations. C© 2015 Wiley Periodicals, Inc. and the American Pharmacists
Association J Pharm Sci
Keywords: analysis; cancer chemotherapy; clinical pharmacokinetics; HPLC; stability
INTRODUCTION
Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC) is a nucle-
oside analog used in chemotherapeutic drug regimens against
several human cancers, including pancreatic ductal adenocar-
cinoma (PDAC).1 Intra- and interindividual variations in gem-
citabine pharmacokinetics are hypothesized to have an im-
pact on drug efficacy.2–4 Hence, quantification of dFdC and
its main metabolite (2′,2′-difluoro-2′-deoxyuridine, dFdU) in
plasma is warranted in the development of individualized treat-
ment strategies.5 The validity of quantitative analyses of dFdC
and dFdU relies on both the quality of the analytical method,
and on the preanalytical stability of the analytes in blood collec-
tion tubes. Several preanalytical aspects have to be taken in to
account for dFdC and dFdU plasma concentrations to mirror in
vivo conditions (Supplementary Fig. S1). In vitro deamination
of dFdC to dFdU by cytidine deaminase (CDA) is a major issue
and can be inhibited by tetrahydrouridine (THU).11 Assessment
of both analytes and of their ratio contributes as a control of the
sample quality in this setting. Moreover, both dFdC and dFdU
Abbreviations used: CDA, cytidine deaminase; CI, confidence interval; CV,
coefficient of variation; dFdC, 2′,2′-difluoro-2′-deoxycytidine; dFdC*, dFdC stable
13C, 15N2-isotope; dFdU, 2
′,2′-difluoro-2′-deoxyuridine; dFdU*, dFdU stable 13C,
15N2-isotope; Cmax, maximum concentration; EDTA, ethylenediaminetetraacetic
acid; EPP, erythrocyte/plasma partition; IS, internal standard; LC–MS/MS,
liquid chromatography tandem mass spectrometry; QC, quality control; PDAC,
pancreatic ductal adenocarcinoma; THU, tetrahydrouridine.
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are bidirectionally transported across cellular membranes by
nucleoside transporter proteins,6,7 and distributional changes
may occur ex vivo before plasma separation is performed. How-
ever, data on the magnitude of potential distributional changes
in dFdC and dFdU concentrations over time are sparse. In ve-
nous blood from eight healthy volunteers, the in vitro erythro-
cyte/plasma partition (EPP) ratio for dFdC was 1–5 in sam-
ples incubated with 0.500–100 :g/mL dFdC for 1 h at 37°C.12
Whether this corresponds to the in vivo EPP ratio in patients
treated with 30-min gemcitabine infusions is not known.1,13 The
time interval from blood sampling until separation of plasma
varied from “without delay”14 to 1 h15 in studies reporting dFdC
and dFdU plasma concentrations from treated patients, but
was not given in most other studies.16–19 Hence, because of a
potential transmembranous transport ex vivo (Supplementary
Fig. S1), lack of standardization of time to separation could be
a source of error when interpreting plasma concentrations of
dFdC and dFdU within and across studies. In most studies,
blood was kept on ice until centrifugation at 4°C in order to
minimize instability of analytes. In one study of [3H]uridine (a
human equilibrative nucleoside transporter 1 substrate) trans-
port across isolated red blood cell membranes, the maximum
transport velocity (Vmax) at 0.5°C–0.7°C was found to be 23%
of Vmax at 23°C.
20 In another study, in washed human ery-
throcytes, Vmax of [
3H]uridine transport at 5°C was only 2%
of Vmax at 25°C.
21 These studies indicate that time, tempera-
ture, and enzyme activities are essential factors in transmem-
brane nucleoside transport and stability ex vivo that has to be
controlled for.
Therefore, the authors studied the preanalytical stability
of dFdC and dFdU in freshly drawn blood samples from
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gemcitabine treated patients in a routine clinical setting at the
Oncology Department of the Haukeland University Hospital,
using a newly established and validated liquid chromatogra-
phy tandem mass spectrometric (LC–MS/MS) method.
METHODS
Chemicals and Reagents
Gemcitabine hydrochloride was purchased from Sigma–Aldrich





purchased from Toronto Research Chemicals (Toronto, ON,
Canada). THU was purchased from AH diagnostics AS (Oslo,
Norway). HPLC grade methanol (CH3OH) and acetonitrile
(CH3CN) were obtained from Fisher Scientific (Loughborough,
UK). Formic acid (CHOOH) was purchased from Sigma–
Aldrich. All solutions were made using ultra-pure water
from Milli-Q Advantage A10 Ultrapure Water Purification
System. Vacutainer Hemoguard EDTA and heparin tubes were
purchased for Medinor AS (Oslo, Norway). HPLC-columns and
precolumns were purchased from Matriks AS (Oslo, Norway).
Study Population and Sample Collection
Seven PDAC patients treated with 30-min infusions of gemc-
itabine 1000 mg/m2 at the Oncology Department of the Hauke-
land University Hospital were included. Written informed con-
sent was obtained from all. The protocol was approved by the
Regional Committee for Medical and Health Research Ethics.
All blood-handling procedures were performed at ice-cold
temperatures (1°C–4°C). Blood was collected into three 6.00 mL
heparin and three 6.00 mL ethylenediaminetetraacetic acid
(EDTA) vacuum tubes approximately 3 min before gemcitabine
infusions were terminated. All tubes had been prefilled with
30.0 :L (300 :g) of a 10.0 mg/mL aquatic solution of the
CDA enzyme inhibitor THU. The six tubes were collected
in rapid succession, alternating between heparin and EDTA
tubes. Blood was pooled to final volumes of 18.0 mL heparin
and 18.0 mL EDTA blood. From each sample pool, 1.50 mL
aliquots were drawn and centrifuged according to the following
time-schedule (time after sampling): “as soon as possible,” 15,
30, 45, 60, 120 and 240 min, and 24 h. Thus, eight samples with
EDTA plasma and eight with heparin plasma were generated
from each patient. Samples centrifuged “as soon as possible”
served as baseline samples. Tubes were centrifuged for 10 min
at 1800g at 4°C, plasma was transferred to 1.00 mL cryotubes
and kept on ice until storage at −80 °C. Samples were stored
for 3–16 weeks until analysis.
Preparation of Stock Solutions, Calibrator, and Quality
Control Samples
Stock solutions (1.00 mg/mL) of dFdC and dFdU for standards
and quality controls (QCs) were prepared separately in ultra-
pure water, and preserved at −80°C.23 Prior to spiking to cal-
ibration standard solutions, aliquots were thawed and diluted
in human plasma to 100 :g/mL. Stock solutions for internal
standards (ISs) were prepared in ultra-pure water at concen-
trations of 1.50 and 2.00 mg/mL for dFdC* and dFdU*, respec-
tively. Prior to adding into spiked plasma samples, ISs were
diluted in cold methanol to 20.0 and 26.7 :g/mL for dFdC*
and dFdU*, respectively. A 10 mg/mL THU stock solution was
prepared in ultra-pure water and stored at −80°C.
Blood for preparation of calibrators was collected from vol-
unteers in the laboratory into 6 mL EDTA tubes prefilled with
300 :g THU, and centrifuged at 1800g for 10 min at 4°C. Plasma
was pooled and immediately spiked with solutions of dFdC and
dFdU, giving seven calibration standards in the ranges 0.125–
40.0 :g/mL for dFdC and 1.25–80.0 :g/mL for dFdU. QC sam-
ples were prepared from stock solutions separate from those
used for calibration standards. Concentrations of QC samples
are given in Table 1.
Sample Preparation
Plasma samples (60 :L) were mixed with ice-cold IS methanol
solution (90 :L) in 1.5 mL Eppendorf vials, vortexed for 30 s
and left on ice for 10 min for protein precipitation. Then, mix-
tures were vortexed again and centrifuged at 4°C for 5 min at
21,000g. Supernatant (100 :L) was transferred to new Eppen-
dorf vials and dried under nitrogen at 37°C for 30–60 min,
using TurboVap R© LV Concentration Workstation (Caliper
LifeSciences, PerkinElmer, Hopkinton, Massachusetts, USA).
The residue was dissolved in 100 :L ultra-pure water and
Table 1. QC Sample Concentrations and Assay Performance Data for dFdC and dFdU
Nominal Within Run Within Run Between Run Between Run
QC Concentrations Accuracy Precision Accuracy Precision
Compound Sample (:g/mL) (%) (CV%) (%) (CV%)
dFdC LLOQ 0.125 106 4.10 107 11.5
L 0.500 111 4.70 103 4.90
M1 10.0 94.5 1.30 84.5 6.50
M2 20.0 102 2.00 90.3 5.70
H 30.0 92.7 1.90 98.7 4.90
dFdU LLOQ 1.25 107 3.20 115 5.20
L 5.00 109 9.80 98.5 6.80
M1 20.0 96.6 1.80 82.1 5.80
M2 40.0 104 2.80 86.4 5.50
H 60.0 97.6 3.20 102 4.70
dFdC, 2′, 2′-difluoro-2′-deoxycytidine; dFdU, 2′, 2′-difluoro-2′-deoxyuridine; CV, coefficient of variation; LLOQ, lower limit of quantification; L, low; M1, medium
1; M2, medium 2; H, high; QC, quality control.
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Figure 1. Representative chromatograms of the analytes in a patient
sample, with dFdC and dFdU concentrations of 26.2 and 27.3 :g/mL,
respectively. dFdC, 2′, 2′-difluoro-2′-deoxycytidine; *dFdC, dFdC stable
13C, 15N2-isotope; dFdU, 2
′, 2′-difluoro-2′-deoxyuridine; *dFdU, dFdU
stable 13C, 15N2-isotope.
centrifuged for 5 min at 21,000g. Supernatant was transferred
to a 1.50 mL vial (Agilent) with a 250 :L insert. During LC–
MS/MS method validation, the same procedure had been ap-
plied using spiked plasma solutions.
LC–MS/MS Method
The HPLC system consisted of an Agilent 1200 series separa-
tion module (Agilent Technologies, Waldbronn, Germany) and
a BDS HYPERSIL C18, 3 :m, 100 × 2.1 mm2 column, coupled
with a 10 × 2.1 mm2 precolumn (Thermo Scientific, Matriks,
Oslo, Norway) maintained at 40°C during analysis. The injec-
tion volume was 10.0 :L. Mobile phase A was a 0.100% solu-
tion of formic acid. Mobile phase B was 100% acetonitrile. The
HPLC operated the first 5 min at isocratic conditions of 4.00%
mobile phase B, followed by a washing step with 100% B from
5.10 to 10.1 min and from 10.2 to 20.1 min with 4.00% mobile
phase B. Total run time was 20.3 min. An Agilent Technologies
6410 triple-quad mass spectrometer (Agilent Technologies Inc.,
Santa Clara, California) was operated at positive ion electro-
spray ionization and the MS was applied in MRM mode. Precur-
sor and product ion scan parameters (m/z) were 264.0 → 112.0
for dFdC, 267.1 → 115.1 for *dFdC, 265.1 → 112.9 for dFdU
and 268.1 → 116.1 for *dFdU. Representative chromatograms
of the analytes in a patient sample are shown in Figure 1,
with dFdC and dFdU concentrations of 26.2 and 27.3 :g/mL,
respectively. dFdC and dFdU eluted at 2.30 and 4.20 min,
respectively.
The method was validated over the ranges of 0.125–40.0
and 1.25–80.0 :g/mL for dFdC and dFdU, respectively. Lin-
ear correlation coefficients (R2) from seven calibrators ana-
lyzed in triplicate in freshly prepared plasma were 0.975 and
higher (data not shown). Recoveries were assessed using con-
trol plasma samples and water spiked with working solutions of
dFdC and dFdU to five QC-sample concentrations. Each spike
level was processed and analyzed in ten replicates. Recoveries
of analytes were calculated in relation to peaks in ultra-pure
water, using heights of corresponding peaks for comparison,
and expressed as mean of 10 replicates. Across all QC concen-
trations the recoveries [mean (SD)] were 102 (6.71)% and 103
(4.91)% for dFdC and dFdU, respectively. Precision and accu-
racy were determined by analyzing 10 replicates each of the five
QC samples, along with a front calibration curve. Within run
accuracy was calculated as a relative ratio (%) of the mean
concentration (N = 10) per analytical run and the nomi-
nal concentration. Between run accuracy was calculated as
a relative ratio (%) of the mean concentration of 10 analyti-
cal runs and the nominal concentration. Within and between
run precision were expressed as coefficient of variation (CV).
Table 1 summarizes assay performance data of the LC–MS/MS
method.
After three freeze–thaw cycles of QC samples, maximum de-
viations were 9.70% and 4.90% for dFdC and dFdU, respec-
tively. In five patient samples, the maximum deviations after
as much as five freeze–thaw cycles were 9.40% and 8.50% for
dFdC and dFdU, respectively. All patient samples were pro-
cessed within one freeze–thaw cycle. Autosampler stability of
QC and patient samples were tested up to 48 h. 80% of all con-
centrations deviated less than 2.00%, and the highest deviation
across all concentrations was 5.60%.
Data Processing and Statistics
Data were processed using Agilent MassHunter software, Mi-
crosoft Office Excel 2010 and IBM SPSS Statistics 21.0. Varia-
tions of data were expressed as SD of repeated measurements,
and as CV. Plasma concentrations from the preanalytical sta-
bility study were visualized in relation to the method precision
performance in differential plots based on the Bland-Altman
approach.24 The absolute differences between subsequent con-
centrations and the initial concentrations, *[dFdC] (Y-axis),
measured in each individual patient were plotted against the
respective initial concentrations (X-axis). Positive *[dFdC] val-
ues indicated that concentrations were higher than the baseline
concentrations, whereas negative values indicated lower con-
centrations. 95% confidence intervals (CIs), which indicated the
maximum expected analytical variation was outlined within
each differential plot. The construction of the CI was based
on the highest CV obtained during validation of non-LLOQ
QC samples. Analytes were considered to be stable if all con-
centrations were within the 95% CI of the expected analytical
variation.
RESULTS AND DISCUSSION
dFdC and dFdU in Blood Samples from Patients Treated with
Gemcitabine
Blood samples from seven PDAC patients were collected ap-
proximately 3 min before the end of 30-min gemcitabine infu-
sions, that is, at the expected dFdC maximum concentrations
(Cmax). Median delay from sampling until the first centrifuga-
tion was 7 min (range 6–17). Separated plasma samples were
stored at −80°C for 3–16 weeks until analysis, which was well
within the limits of the analyte stability demonstrated by Free-
man et al.,25 that is, at least eight and 21 months at −20°C and
−70°C, respectively, for both dFdC and dFdU.
In samples from all seven patients, dFdC and dFdU concen-
trations at baseline in heparin plasma were dFdC 27.7 :g/mL
(18.9–39.5) and 29.7 :g/mL (13.8–39.9), respectively, and did
not differ from those in EDTA plasma [dFdC 27.2 :g/mL
(18.9–36.6); dFdU 29.6 :g/mL (13.4–40.1)]. Mean relative hep-
arin/EDTA concentrations in all samples from each patient
were 101% (data not shown), indicating that the two an-
ticoagulants could be used interchangeably in this setting.
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Figure 2. Boxplot showing concentrations (%) relative to those at ini-
tial separation (100%, reference), of dFdC and dFdU in heparin plasma
from seven patients. dFdC, 2′, 2′-difluoro-2′-deoxycytidine; dFdU, 2′,
2′-difluoro-2′-deoxyuridine.
Concentrations of dFdC and dFdU were in accordance with
previous studies of gemcitabine pharmacokinetics following in-
fusions of 800–1000 mg/m2: in eight patients with advanced
breast cancer,26 six patients with pancreatic cancer17 and
five patients with other solid tumors.2 Plasma concentrations,
analyzed in triplicate, from one patient are presented in Sup-
plementary Table S1. The CVs of mean concentrations at each
individual time-point in this patient were 0.600%–5.70%, which
was in agreement with data from spiked samples (Table 1) and
demonstrated the validity of the LC–MS/MS method in clinical
samples.
We assessed the stability of dFdC and dFdU in whole blood
samples during storage for 0–24 h until separation of plasma.
First, we studied whether CDA activity was inhibited effec-
tively. We calculated dFdC/dFdU concentration ratios as a func-
tion of time. The mean change from the first (7 min) to the last
(24 h) sample in all patients was less than 4.50% (data not
shown). Hence, adding THU in a concentration of 50 :g/mL
blood prevented deamination effectively, which was in accor-
dance with data from Bowen et al.11 Second, we investigated
whether concentrations of dFdC and dFdU in plasma remained
unchanged following storage of whole blood at ice-cold temper-
ature, to indirectly address whether transmembrane transport
(Supplementary Fig. S1) was inhibited effectively. The dFdC
and dFdU concentrations in heparin plasma from all seven
patients, calculated as % from the concentrations obtained at
baseline (100%), are shown in Figure 2. There was no change
in the concentrations of dFdC and dFdU during the first 2 h
of storage. However, dFdC tended to decrease as a function
of further storage time. The mean dFdC concentrations after
240 min and 24 h were 94.0% (SD 2.00%) and 93.0% (SD 6.00%),
respectively, compared with the baseline concentrations (100%,
initial separation). To visualize the change in concentrations in
relation to the analytical imprecision, we constructed differen-
tial plots based on the Bland-Altman method24 and included
lines indicating the 95% CIs (Figs. 3a–3d) based on an analyti-
cal imprecision (CV) of 6.50%. This CV represented the highest
variation for dFdC in QC samples at concentrations ranging
from 0.500 to 30.0 :g/mL (Table 1), excluding LLOQ, which was
Figure 3. Differential plots of [dFdC] (X-axis, measured concentrations) versus *[dFdC] (Y-axis, difference from initial separation) in heparin
plasma from patients (n = 7). Gray lines indicate 95% CIs of [dFdC] based on an analytical CV of 6.50%. (a) Initial separation (at 7 min).
(b) Separation at 120 min. (c) Separation at 240 min. (d) Separation at 24 h. dFdC, 2′, 2′-difluoro-2′-deoxycytidine; dFdU, 2′, 2′-difluoro-2′-
deoxyuridine; CI, confidence intervals; CV, coefficient of variation.
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considered to be less relevant for comparison with samples ac-
quired at Cmax. Data from the supplementary Table S1 sup-
ported our choice of using the highest CV from non-LLOQ QC
samples when constructing the 95% CI in Figures 3a–3d. In
Figures 3a and 3b, dFdC concentrations up to 120 min were
within the 95% CI. After 240 min, all *[dFdC] were below
zero but within the 95% CI (Fig. 3c). Hence, analytical vari-
ation within the boundaries of the described method impreci-
sion could not be ruled out. After 24 h, two of the seven con-
centrations were outside the 95% CI, differing 13.0%–14.0%
from their respective baseline concentrations (Fig. 3d). There-
fore, based on the definition of stability used in our study, a
time interval of 24 h until separation of plasma was consid-
ered not to be acceptable to be included into a routine blood
sampling procedure. In the same samples, the corresponding
dFdU concentrations were 7.00%–11.0% lower than at base-
line (data not shown), which indicated that the decline in dFdC
after 24 h was not caused by incomplete CDA inhibition. In-
creased variation of concentrations in blood samples stored
over time could reflect analyte instability.27 Whether these de-
viations in the concentrations were caused by analytical vari-
ation exceeding the expected 95% CIs calculated from spiked
QC samples cannot be ruled out. This may underline the chal-
lenge of distinguishing preanalytical variations from analytical
variations in a newly established method, where for which per-
formance calculations are mainly based on data from spiked QC
samples.
General pharmacokinetic data for gemcitabine1,13 indicate
that a distributional steady state between plasma and blood
cells may not be achieved during a 30-min gemcitabine infu-
sion. Thus, our data on analyte stability over at least 4 h may
preferentially be explained by efficiently inhibited transmem-
branous transport due to low temperatures during storage of
blood. This notion is in accordance with findings in previous in
vitro studies of [3H]uridine-transport.20,21 Alternatively, dFdC
and dFdU were already evenly distributed between blood cells
and plasma at the time of the first sample separation. However,
as we did not analyze intracellular concentrations of dFdC and
dFdU, we could not calculate EPP ratios to further elucidate
these options.
Taken together, we demonstrated the validity of a newly
established and validated LC–MS/MS method for the quantifi-
cation of dFdC and dFdU, and showed that plasma concentra-
tions of these analytes in both heparin and EDTA blood sam-
ples spiked with THU to a final concentration of 50.0 :g/mL
blood and kept on ice during storage, were stable for at least
4 h until plasma was separated. This time interval allows
batch-centrifugation of samples acquired at different time-
points from different patients, and of samples collected consec-
utively from single patients for pharmacokinetic evaluations.
During this time interval, the risk of introducing a preanalyti-
cal bias due to variation in time until centrifugation seems to be
negligible.
CONCLUSIONS
Our study showed that storage of whole blood samples for up
to at least 4 h until centrifugation, provided that the samples
were spiked with THU and kept on ice, may not be an im-
portant factor of variance when comparing results within or
across studies of gemcitabine plasma pharmacokinetics. Our
findings encourage further use of the established preanalytical
procedures and the LC–MS/MS method, in future studies of
individualized treatment strategies with gemcitabine.
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a b s t r a c t
Quantification of endogenous nucleotides is of interest for investigation of numerous cellular biochem-
ical processes, such as energy metabolism and signal transduction, and may also be applied in cancer
and antiretroviral therapies in which nucleoside analogues are used. For these purposes we developed
and validated a sensitive and high accuracy ion-pair liquid chromatography tandem mass spectrometry
(IP LC–MS/MS) method for simultaneous quantification of eight endogenous nucleotides (ATP, CTP, GTP,
UTP, dATP, dCTP, dGTP, dTTP) and 2′,2′-difluoro-2′-deoxycytidine triphosphate (dFdCTP), an intracellular
metabolite of the nucleoside analogue gemcitabine. The assay was validated using 200 mL aliquots of
peripheral blood mononuclear cell (20 × 106 cells/ml, 4 × 106 cells) extracts, pretreated with activated
charcoal and spiked with unlabeled nucleotides, deoxynucleotides and dFdCTP. Analytes were extracted
by simple precipitation with cold 60% methanol containing isotope labeled internal standards and sep-
arated on a porous graphitic carbon column. For method validation, the concentration ranges were:
0.125–20.8 pmol injected for deoxynucleotides, 0.25–312.5 pmol injected for dFdCTP and 5–3200 pmol
injected for nucleotides. The highest coefficients of variation (CV) were 12.1% for within run assay and
11.4% for between run assay, both representing the precision at the lowest analyte concentrations. The
method was applied to monitor dFdCTP and changes in endogenous nucleotides in patients who were
receiving gemcitabine infusions.
© 2015 Elsevier B.V. All rights reserved.
Abbreviations: ACN, acetonitrile; AcOH, acetic acid; ATP, adenosine 5′-
triphosphate; BRA, between run accuracy; BRP, between run precision; Br-ATP, 8-
bromoadenosine 5′-triphosphate; CD, cytidinedeaminase; CE, collision energy; CTP,
cytidine 5′-triphosphate; CV, coefficient of variation; dATP, 2′-deoxyadenosine 5′-
triphosphate; dCK, deoxycytidine kinase; dCMP, deoxycytidine-5′-monophosphate;
dCTP, 2′-deoxycytidine 5′-triphosphate; DEA, diethylamine; dFdC, 2′ ,2′-difluoro-
2′-deoxycytidine, gemcitabine; dFdCTP, 2′ ,2′-difluoro-2′-deoxycytidine triphos-
phate, gemcitabine triphosphate; dFdU, 2′ ,2′-difluoro-2′-deoxyuridine; dGTP,
2′-deoxyguanosine 5′-triphosphate; DNA, deoxyribonucleic acid; dNTP, deoxyribo-
nucleoside triphosphate; FV, fragmentor voltage; GTP, guanosine 5′-triphosphate;
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graphitic carbon; QC, quality control; RR, ribonucleotide reductase; SPE, solid phase
1. Introduction
Nucleosides and nucleotides are involved in important cellular
processes, such as polymerase-mediated synthesis of nucleic acids,
cellular signal transduction, enzyme regulation and metabolism.
Alterations in the size or composition of the intracellular nucleotide
pool affect essential biologic functions including cellular growth
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and differentiation, DNA replication and repair, immunocompe-
tence and chromosome stability and can lead to spontaneous
or induced mutability [1]. As such, analysis of nucleotides and
deoxynucleotides may not only be of interest in genetic and molec-
ular biology research, but also in studies involving nucleoside
analogues used in anti-cancer, anti-viral and immunosuppress-
ive therapies [2]. To elucidate intracellular pharmacokinetics
of nucleoside analogues and their effect on the endogenous
nucleotide pool, it is necessary to possess a sensitive assay for
simultaneous quantification of both endogenous nucleotides and
intracellular metabolites of the nucleoside analogue of interest.
There are several challenges in quantification of nucleotides
in cellular matrices. Firstly, their concentrations vary among dif-
ferent cell types and are generally very low, in the range of
77–3532 pmol/106 cells for nucleoside triphosphates (NTPs) and
0.7–69 pmol/106 cells for deoxynucleoside triphosphates (dNTPs)
[3–7]. Secondly, they resemble each other in their chemical
structure which requires highly selective methods for their quan-
tification. Thirdly, nucleotides have poor retention when separated
by conventional reverse phase high performance liquid chromatog-
raphy (HPLC) due to their high hydrophilicity, and a majority
of assays developed for their quantification are based on anion-
exchange or ion-pair (IP) chromatography [8–15]. However, poor
lot to lot reproducibility and instability of ion-exchange columns, as
well as the use of high salt concentrations incompatible with mass
spectrometry (MS), limit the application of strong anion exchange
mechanism for this purpose [16,17]. High salt concentrations can
be avoided by weak anion exchange (WAX) chromatography which
utilizes the change of eluent pH for compound separation [12,18].
Ion-pair chromatography on reversed phase columns have high
efficiency and greater versatility than fixed-site ion exchanger
[19,20], but main disadvantages are low volatility of IP agents used
and the significant ion-suppression they can cause. Still, IP agents
are necessary to reduce peak tailing characteristic for NTPs, and
a compromise has been made by separation on porous graphitic
carbon (PGC) columns using low concentrations of these agents
[12,17]. An alternative to circumvent MS compatibility issues is
to dephosphorylate nucleotides to nucleosides prior to analysis,
but the method requires laborious and time-consuming sample
preparation [17]. Hydrophilic interaction chromatography (HILIC)
methods which utilize MS-compatible buffers have recently been
developed. This technique has generally yielded poor separation
and unsatisfactory peak shapes for di- and triphosphorylated ana-
lytes, and HILIC columns are not straightforward to optimize
[21–23].
We describe a sensitive IP LC–MS/MS method for separation and
quantification of 8 endogenous nucleotides (ATP, CTP, GTP, UTP,
dATP, dCTP, dGTP and dTTP) and 2′,2′-difluoro-2′-deoxycytidine
triphosphate (dFdCTP), the active metabolite of gemcitabine, in
peripheral blood mononuclear cells (PBMC). The method has been
validated for sensitive and accurate determination of all analytes
and innovative steps in preparation of standards are described.
2. Experimental
2.1. Chemicals and reagents
Adenosine 5′-triphosphate (ATP) disodium salt hydrate, cyti-
dine 5′-triphosphate (CTP) disodium salt hydrate, guanosine
5′-triphosphate (GTP) sodium salt hydrate, uridine 5′-triphosphate
(UTP) trisodium salt hydrate, 2′-deoxyadenosine 5′-triphosphate
(dATP) disodium salt, 2′-deoxycytidine 5′-triphosphate (dCTP)
disodium salt, 2′-deoxyguanosine 5′-triphosphate (dGTP) sodium
salt hydrate, thymidine 5′-triphosphate (dTTP) sodium salt
and 8-bromoadenosine 5′-triphosphate (Br-ATP) sodium
salt were purchased from Sigma–Aldrich (Oslo, Norway).
Gemcitabine triphosphate (dFdCTP) ditriethylamine was
manufactured by Toronto Research Chemicals (ON, Canada).





























in 5 mM Tris buffer were purchased from ISOTEC, Sigma–Aldrich
(Oslo, Norway). 30% ammonium hydroxide solution (NH4OH),
phosphate buffered saline (PBS) and IP reagents hexylamine (HA)
and diethylamine (DEA), were also purchased from Sigma–Aldrich
(Oslo, Norway). Ammonium acetate (NH4OAc) was purchased
from KeboLab (Bromma, Sweden), acetic acid (AcOH) from Merck
(Darmstadt, Germany) and tetrahydrouridine (THU) from Bio-
Vision (Milpitas, CA, USA). HPLC grade acetonitrile (ACN) and
methanol (MeOH) were provided by Fisher Scientific (Oslo,
Norway). The activated charcoal was manufactured by Merck
(Darmstadt, Germany) and purchased from VWR International
AS (Oslo, Norway). The water (analytical grade) was produced




The HPLC system was an Agilent 1200 series (Waldbronn,
Germany) with a binary pump, a degasser, a variable volume injec-
tor and a thermostated autosampler. Chromatographic separation
was conducted at 30 ◦C, on a Hypercarb column 100 mm × 2.1 mm,
5 mm (Thermo Fisher Scientific, Waltham, MA, USA) connected to
a guard column of the same type (10 mm × 2.1 mm, 5 mm). Mobile
phase A was 5 mM hexylamine (HA) and 0.5% diethylamine (DEA)
in water, with pH adjusted to 10 with acetic acid (AcOH). Mobile
phase B was 50:50 acetonitrile (ACN):water (v:v) [3]. The gradient
was as follows: 0–24% B for 15 min, 24% B for 20 min, 24–50% B for
10 min and 100% B for 9 min. The flow rate was 0.25 mL/min and
all peaks were eluted in 51 min. The injection volume was 5 mL and
effluent from the column was directed into the mass spectrometer
in the time interval between 20 and 51 min, otherwise to waste.
The column was reconditioned between subsequent analyses with
100% A for 14 min (flow rate 0.75 mL/min), resulting in a total run
time of 68 min.
2.2.2. Mass spectrometry
The MS was an Agilent 6410 Triple Quad LC–MS (Agilent Tech-
nologies Inc., Santa Clara, CA, USA). The acquisition settings were
optimized for NTPs, dNTPs, their stable isotopes, Br-ATP and dFd-
CTP. Depending on the analyte, the MS was operated in positive
or negative ion multiple reaction mode (MRM) with different
mass spectral settings, divided into six time segments (Table 1).
Source parameters were as follows: gas temperature 350 ◦C, gas
flow 13 L/min and nebulizer pressure 60 psi. Capillary voltage was
6000 V in negative mode and 4000 V in positive mode. MassHunter
software was used for LC–MS/MS system control, data acquisition
and data processing.
2.3. Sample preparation
2.3.1. Isolation of PBMC and preparation of cell supernatant
Isolation of PBMCs was performed with slight modifications
of the procedure described by Losa et al. [20]. Clinical samples
were collected from patients during treatment with gemcitabine
infusion in an experimental treatment protocol (ClinicalTrials.gov
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Mode Analyte MRM (m/z) FV (V) CE (eV) Dwell time (ms)
I
20–25
− CTP 481.8 → 158.9 135 28 120
UTP 482.9 → 158.9 140 28 160
UTP13C,15N 494.0 → 159.0 140 28 160
dCTP 465.9 → 158.8 135 24 400
dCTP13C,15N 478.0 → 159.0 135 24 400
II
25-32
+ dFdCTP 504.1 → 326.1 200 15 300
III
32–45.5
− dTTP 481.0→158.9 135 22 840
dTTP13C,15N 493.0 → 159.0 135 22 840
GTP 521.9 → 158.8 155 28 800
GTP13C,15N 537.0 → 159.0 155 28 800
IV
45.5–47.3
+ ATP 581.0 → 136.1 125 28 125
ATP13C,15N 596.2 → 146.1 125 28 125
dGTP 580.9 → 152.1 100 28 375
dGTP13C,15N 596.2 → 162.1 100 28 375
V
47.3–49
− dATP 489.9 → 158.9 130 28 500
dATP13C,15N 505.0 → 159.0 130 28 500
VI
49–51
+ Br-ATP 660.9 → 215.7 125 25 200
Identifier: NCT01674556), which included pharmacokinetic anal-
yses in plasma and nucleotide pool quantification in PBMC [16].
To prevent analyte metabolism ex vivo, PBMC isolation was per-
formed on ice and cells were lysed as quickly as possible. In
addition, all tubes (6 mL) had been prefilled with 300 mg (30 mL) of a
10 mg/mL aquatic solution of aquatic solution of tetrahydrouridine
(THU) to effectively inhibit the deamination of 2′,2′-difluoro-2′-
deoxycytidine (dFdC) via cytidine deaminase [24]. From each
patient who was available for sampling (n = 4) 10 mL blood was
collected into cold heparinized vacutainer tubes at six time-
points (before and 30, 60, 120, 180 and 240 min after initiating
gemcitabine infusion), diluted with cold 10 mL 0.01 M phosphate
buffered saline (PBS), transferred into cold 50 mL Lymphoprep
TubesTM (Axis Shield, Norway) prefilled with 10 ml Lymphoprep
medium, and centrifuged for 25 min at 1000×g at 4 ◦C. The layer
of PBMCs above the Lymphoprep medium was gently harvested,
washed twice in ice-cold PBS, dissolved in 500 mL 60% MeOH solu-
tion, vortexed vigorously and frozen in liquid N2 to lyse the cells
effectively. In cell samples prepared from buffy coats the final
sample volume was adjusted to achieve a standardized concentra-
tion of 20 × 106 cells/mL MeOH. Samples were kept at −80 ◦C until
analyses. Special attention was given to avoid contamination by
other blood cells, as this has been shown to introduce variations in
matrix effects and cause ion suppression [25]. Before the final cen-
trifugation, 100–300 mL of the cell suspension was removed, and
cells were counted on an ADVIA 2120 (Siemens Medical, Erlangen,
Germany) to be able to relate the measured nucleotide concen-
trations to the cell number in each sample. Prior to analyses, cell
lysates were vortexed and centrifuged at 21,000×g at 4 ◦C for 5 min,
and precipitates were discarded.
PBMCs for stock solutions used in the validation procedure
were isolated from 50 mL buffy coats in blood acquired from blood
donors. To prepare nucleotide-free matrix, PBMC cell lysate was
treated with activated charcoal prior to spiking with the predefined
concentrations of analytes. This method known as “matrix strip-
ping”, was successfully used in our previous analytical methods for
preparation of folate free matrix [26–28]. The charcoal suspension
(40 mg per mL cell supernatant) was mixed for 5 min and cen-
trifuged at 21,000×g for 5 min. The supernatant was collected and
stored at −80 ◦C until analysis.
2.3.2. Preparation of standards
Stock solutions containing all NTPs, dNTPs and dFdCTP were
prepared in charcoal treated cell supernatant to the following
concentrations: 8 mM ATP, 0.4 mM CTP, 0.8 mM GTP, 2 mM UTP,
0.026 mM dATP, 0.014 mM dCTP, 0.01 mM dGTP, 0.052 mM dTTP
and 1.42 mM dFdCTP. Calibration (C) and quality control (QC) solu-
tions were prepared individually by spiking carbon treated cell
supernatant with stock solution to yield spiked concentrations in
the ranges: 10–320 mM for ATP, 0.5–16 mM for CTP, 1–32 mM for
GTP, 2.5–80 mM for UTP, 0.03–1.10 mM for dATP, 0.01–0.56 mM
for dCTP, 0.01–0.40 mM for dGTP, 0.06–2.10 mM for dTTP and
0.02–31.25 mM for dFdCTP. To recalculate the amount of analytes
as pmol per 106 PBMCs, the concentration values given in mM
should be multiplied by 50. One ml aliquots of stock, calibra-
tion and quality control solutions were stored at −80 ◦C. ISs stock
solution was prepared in water by diluting 100 mM commercially
available solutions of isotope labeled NTPs and dNTPs to the follow-
ing concentrations: 200 mM ATP13C,15N, 20 mM GTP13C,15N, 50 mM
UTP13C,15N, 0.65 mM dATP13C,15N, 0.35 mM dCTP13C,15N, 0.25 mM
dGTP13C,15N and 1.3 mM dTTP13C,15N. Working IS solution was pre-
pared by diluting stock solution to 1:100 in MeOH and 1 mL aliquots
were stored at −80 ◦C.A 0.17 mM stock solution of Br-ATP, which
is used as the IS for dFdCTP, was prepared in mobile phase A and
1 mL aliquots were stored at −80 ◦C.
2.3.3. Nucleotide extraction
As SPE is time consuming and may cause less accuracy
[3,17,29,30], we decided to investigate whether this step could
be excluded. Both procedures, without SPE and with SPE, were
performed for comparison. Without SPE: calibration solutions, QC
solutions, Br-ATP stock solution, internal standards working solu-
tions and carbon treated cell supernatants were thawed at room
temperature. 200 mL calibration and QC solution, 80 mL internal
standard working solution and 10 mL of Br-ATP solution were vig-
orously vortexed and evaporated to dryness under nitrogen gas
flow using TurboVap® LV Concentration Workstation (Caliper Life-
Sciences, PerkinElmer, MA, USA) at 37 ◦C. Dried residues were
resuspended in 100 mL mobile phase A, vortexed, centrifuged at
21,000×g for 5 min, transferred to a 1.5 mL vial (Agilent technolo-
gies) with a 250 mL insert and placed in an autosampler (4 ◦C) until
analysis. With SPE: 200 mL calibration and QC solution, 80 mL inter-
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Table 2
Assay performance data for ATP, CTP, GTP, UTP, dATP, dCTP, dGTP, dTTP and dFdCTP















ATP 20 101.99 2.40 103.12 4.73
72 107.84 1.98 101.86 3.45
288 105.98 5.99 96.54 3.71
CTP 1 102.71 5.45 101.39 5.46
3.6 106.03 2.21 99.13 4.77
14.4 105.52 7.31 94.06 4.23
GTP 2 104.56 3.26 104.42 6.14
7.2 103.73 2.03 98.01 4.48
28.8 106.91 6.80 96.07 4.57
UTP 5 106.43 2.18 106.41 4.67
18 102.53 2.31 96.51 4.91
72 105.71 7.34 97.52 3.52
dATP 0.065 101.52 9.08 90.72 11.35
0.234 104.33 3.88 101.44 4.24
0.936 105.27 6.05 96.80 4.12
dCTP 0.035 103.54 10.59 105.05 8.43
0.126 104.67 2.96 99.29 4.98
0.504 105.20 6.73 93.58 4.75
dGTP 0.025 105.04 3.12 103.40 5.75
0.09 103.06 2.65 99.13 3.76
0.504 105.04 6.78 97.09 2.86
dTTP 0.117 102.34 6.44 105.65 4.47
0.468 99.30 8.31 94.26 6.10
1.80 98.01 2.30 105.65 4.00
dFdCTP 0.05 105.70 12.08 100.47 11.44
1.125 101.08 5.25 86.96 11.35
28.125 103.70 3.95 96.86 3.87
nal standard working solution, 10 mL of Br-ATP solution and 60%
MeOH solution were added to a final sample volume of 2 mL. SPE
was performed using weak anion exchange columns OASIS®WAX
60 mg, 60 mm (Waters, Milford, USA), as described by Cohen et al.
[3]. WAX columns were first conditioned with 2 mL MeOH, washed
with 2 mL NH4OAc (50 mM, pH 4.5 adjusted with AcOH), loaded
with 2 mL samples and washed again with 2 mL NH4OAc. Analytes
were eluted in separate tubes by applying 2 mL MeOH:H2O:NH4OH
(80:15:5 v/v) mixture on the WAX columns. Eluates were evapo-
rated to dryness, reconstituted in 100 mL mobile phase A, vortexed,
centrifuged at 21,000×g for 5 min, transferred to a 1.5 mL vial (Agi-
lent technologies) with 250 mL insert and placed in autosampler
(4 ◦C) until analyzed.
2.4. Method validation
The method was validated by carrying out tests of linearity,
within- and between run precision and recovery, lower limit of
quantitation (LLOQ) and stability. To evaluate the matrix effects
in charcoal treated cell supernatant and in an original matrix, both
were spiked with stable isotopes (ISs), dFdCTP and Br-ATP to known
concentrations. Three concentration levels as those given in the
Table 2 for QC samples were evaluated. The matrix effect in these
two matrices was considered similar if the corresponding peak
areas in charcoal treated and untreated cell supernatant did not
deviate more than 25% [31]. The linearity curves were obtained
by analyzing PBMC lysate containing dFdCTP and eight NTPs and
dNTPs at six concentration levels in the ranges given in Section
2.3.2. All calibration curves were constructed from data obtained
in triplicate. Calibration curves for each analyte were obtained as
plots of relative intensities (ratios of analyte and corresponding IS
peak areas) versus relative concentrations (ratios of analyte and
IS concentrations) by linear regression using a weighting factor of
the reciprocal of the relative concentration (1/x). The within run
precision (WRP) and within run accuracy (WRA) were determined
by measuring ten replicates of QC samples at three concentration
levels (20, 72 and 288 mM for ATP; 1.0, 3.6 and 14.4 mM for CTP;
2.0, 7.2 and 28.8 mM for GTP; 5, 18 and 72 mM for UTP; 0.07, 0.23
and 0.94 mM for dATP; 0.04, 0.13 and 0.50 for dCTP; 0.03, 0.09 and
0.36 mM for dGTP; 0.13, 0.478 and 1.80 mM for dTTP; and 0.05, 1.13
and 28.13 mM for dFdCTP). For between run precision (BRP) and
between run accuracy (BRA), ten replicates of QC samples at the
same three concentrations were analyzed during a 2-week period.
WRP and BRP were reported as coefficients of variation (CVs), which
represented the ratio of standard deviations and mean values of
10 within run or between run samples, multiplied by 100. WRA
and BRA were expressed as ratios of mean values and nominal
concentrations in per cent. Recovery data at low, medium and
high concentrations were calculated as ratios of peak areas of each
analyte from chromatograms obtained by the methods described
in Section 2.3.3 (with and without SPE steps) and peak areas of
corresponding analytes at the same concentrations in 60% MeOH
solution. Data were obtained from six replicates at each concen-
tration and all results are presented in per cents. Stability of NTPs
and dNTPs was assessed in stock and working solutions stored at
−80 ◦C for 3 months, in samples after two freeze and thaw cycles
and in processed samples at autosampler temperature (4 ◦C) after
48 h. Analytes were considered stable if the determined concen-
trations did not deviate more than +15 % from the concentration
determined at time zero.
2.5. Quantification of gemcitabine (dFdC) and its metabolite
dFdU in plasma
Plasma supernatant from Lymphoprep tubes (Section 2.3.1)
was collected and prepared for analysis on an in-house developed
LC–MS/MS method for quantification of dFdC and 2′,2′-difluoro-
2′-deoxyuridine (dFdU) (manuscript submitted). Samples (60 mL)
were mixed with ice cold methanol solution (90 mL), containing sta-
ble 13C,15N2-isotopes of dFdC and dFdU, and left on ice for protein
precipitation. After centrifugation (21,000×g, 5 min, 4 ◦C), 100 mL
supernatant was transferred to a new Eppendorf vial, dried under
nitrogen flow, reconstituted in 100 mL ultra-pure water, trans-
ferred to a vial (Agilent) and placed in the autosampler (4 ◦C).
Separation of sample components was performed on a BDS HYPER-
SIL C18, 3 mm, 100 × 2.1 mm column, coupled with a 10 × 2.1 mm
precolumn (Thermo Scientific, Matriks, Oslo) maintained at 40 ◦C
during analysis. Mobile phase A was a 0.1% solution of formic acid.
Mobile phase B was 100% acetonitrile. The HPLC system was set up
to operate the first 5 min at a flow rate of 0.2 mL/min at isocratic
conditions of 4% mobile phase B, followed by a washing step with
100% B from 5.1 to 10.1 min at a flow rate of 0.3 mL/min. From 10.2
to 20.1 min the flow rate with 4% mobile phase B was 0.3 mL/min,
and at 20.2 min it was returned to 0.2 mL/min. The total run time
was 20.3 min. The injection volume was 10 mL. The capillary volt-
age was 6000 V, gas temperature was 350 ◦C and the flow rate was
set to 13 L/min.
3. Results and discussion
We present a method for simultaneous quantification of 8
endogenous NTPs and dNTPs and the active metabolite of gemc-
itabine, dFdCTP. One of the main goals in developing this method
was to simplify the sample preparation procedure and, if possi-
ble, to avoid SPE. PBMC supernatant naturally contained all NTPs
and dNTPs, and using unlabeled standards to prepare solutions
with known concentration of analytes was not possible. Isotope
labeled standards could be used as analytes, but this would limit
the choice of internal standard and lead to higher deviations in
recovery results [3]. Hence, it was of importance to find conditions
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Fig. 1. Multiple reaction mode (MRM) ion chromatograms of NTPs, dNTPs and dFdCTP of a spiked cell supernatant at concentrations corresponding to LLOQ. Concentration
of Br-ATP, used as IS for dFdCTP, was 17 mM.
under which endogenous nucleotides could be effectively removed.
In our previous analytical methods, the activated charcoal treat-
ment was successfully used for preparing folate-free serum [26,27],
and we adjusted the same procedure to prepare nucleotide-free cell
supernatant. Incubation of cell supernatant with activated char-
coal (40 mg/mL, 5 min) effectively removed the traces of isotope
labeled nucleotides at concentrations which were higher than those
expected for endogenous nucleotides. Peak areas of endogenous
NTPs decreased to less than 1% of corresponding peak areas before
the treatment, while peaks of dNTP could not even be detected (data
not shown). This innovative approach influenced other important
aspects of the method. Firstly, we prepared calibration solutions by
spiking carbon treated cell matrix to known concentrations of unla-
beled analytes and used 13C,15N isotopes of compounds as their
internal standards. This is one of the most important advantages
of our method, because internal standards had identic separa-
tion, ionization and fragmentation patterns which resulted in high
precision and accuracy, particularly at low concentrations [32].
Exceptions were made for dFdCTP, where Br-ATP was used as an
internal standard instead of very expensive stable isotope labeled
dFdCTP. In the case of CTP, 13C,15N isotope of UTP was chosen as
internal standard because stable isotope labeled CTP and UTP had
the same transitions and we did not achieve baseline separation
between them. Secondly, the choice of internal standards simpli-
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fied the nucleotide extraction step. Interferences originating from
cellular matrix which influence recovery of analytes and internal
standards were greatly reduced, and additional steps for “cleaning”
of the matrix, for example by time-consuming SPE, was unnec-
essary. Finally, dGTP, ATP and dFdCTP were analyzed in positive
mode, while all the other NTPs and dNTPs had more efficient ioniza-
tion in negative mode. By using isotope labeled internal standards
for each analyte (except for dFdCTP and CTP) it was possible to
quantify all compounds by chromatographic separation in defined
time segments (Table 1), where the mass spectrometer was oper-
ated in either negative or positive mode. Using Br-ATP as IS for all
analytes, as described by Cohen et al. [3], would have required a
LC–MS/MS instrument which is able to switch between negative
and positive mode rapidly. As the Agilent 6410A instrument does
not have this ability, we would have had to run each sample in pos-
itive and negative mode separately and the run-time would have
been doubled.
3.1. Chromatography
PGC chromatography has abilities to retain polar and ionic
compounds. However, it is necessary to introduce low concentra-
tion of ion pair agents (DEA) to reduce peak tailing, characteristic
for triphosphates. Variations in retention times between analyti-
cal runs required an additional preconditioning step (see Section
2.2.1) [17,33–35]. The analytes and their corresponding ISs had
the following retention times: 18.6 min for CTP, 19.3 for dCTP and
dCTP*, 19.5 for UTP and UTP*, 24.6 min for dFdCTP, 35.8 min for
dTTP and dTTP*, 42.7 min for GTP and GTP*, 45.7 min for dGTP and
dGTP*, 46.0 min for ATP and ATP*, 47.2 for dATP and dATP* and
50 min for BrATP, where the asterisk (*) represents isotope labeled
compounds. MRM ion chromatograms of all analytes at LLOQ con-
centrations are presented in Fig. 1.
3.2. Mass spectrometry
Negative ionization mode is the most common ionization mode
described for the analysis of triphosphorylated nucleotides, charac-
terized by loss of a pyrophosphate group [16,36,37]. In the present
method dFdCTP, ATP, dGTP and BrATP were analyzed in positive
mode. ATP and dGTP have the same molecular weight and mass
transition during analysis (m/z 506 → 159.09), but in the presence
of an ion pair agent the fragmentation pathway is modified. DEA
adducts of ATP and dGTP have different transitions, with the daugh-
ter ion from adenine at m/z = 136 and from guanine at m/z = 152.
Hence, detection of positive ions and the addition of DEA in the
mobile phase in this case enabled simultaneous determination of
ATP and dGTP [3,16]. dFdCTP was found to give a better signal in
positive than in negative mode and BrATP was used as internal
standard for its quantification. As our instrument does not have
the ability to switch rapidly between negative and positive ioniza-
tion modes, careful determination of time segments (Table 1) and
standardization of retention times was required.
3.3. Validation
To validate the activated charcoal treatment the peak areas of ISs
and dFdCTP at three concentrations in charcoal treated and origi-
nal cell supernatant were compared. The corresponding results did
not deviate more than 15.12% for high, 21.24% for medium and
24.81% for low concentrations, and the matrix effect in original
and surrogate – charcoal treated cell supernatant was confirmed
as similar.
A concentration–response calibration curve for each analyte
was determined in triplicate for six concentration levels over the
defined ranges. The method exhibited excellent linearity with cor-
relation coefficients ranging from 0.9991 to 0.9998.
The LLOQs, estimated as the minimum analyte concentration
providing signal to noise ratio of at least 10 measured in peak-to-
peak mode, were 10.17 mM for ATP, 0.52 mM for CTP, 1.13 mM for
GTP and 2.89 mM for UTP, 0.033 mM for dATP, 0.018 mM for dCTP,
0.013 mM for dGTP, 0.062 mM for dTTP and 0.062 mM for dFdCTP.
To recalculate the amount of analytes as pmol injected, the con-
centration values given in mM should be multiplied by 10. The
between-run precision of the assay was less than 11.15% for all
compounds and the accuracy was in the range of 82.7–119.8%. The
LLOQs for NTPs were tested to the concentrations that are suffi-
cient for application of the method and the values could be set
Fig. 2. Concentrations of NTPs (nmol/106 cells) and dNTPs (pmol/106 cells) extracted from PBMCs from pancreatic cancer patient before and 240 min after initiating a 30-min
gemcitabine infusion.
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Fig. 3. (a) Concentrations of dFdCTP in PBMCs (pmol/106 cells) obtained from a pancreatic cancer patient acquired at different time points after initiating a 30-min gemcitabine
infusion. Results were obtained by the described method, during the same analytical run and from the same samples in which all NTPs and dNTPs were determined (Fig. 2).
(b) Concentrations of dFdC and dFdU (mg/mL) versus time, determined in plasma from the same blood samples using another analytical method (shortly described in Section
2.5).
Table 3
Recovery data for all NTPs and dNTPs at three concentration levels (QClow, QCmed
and QChigh) and their ISs, calculated for two sample preparation methods, one
including protein precipitation with 60% MeOH, evaporation and resuspension in
mobile phase A (Without SPE) and the method including additional solid phase
extraction (With SPE) step.
Compound Recovery (With SPE) (%) Recovery (Without SPE) (%)
QClow QCmed QChigh QClow QCmed QChigh
ATP 99.5 99.7 100.9 71.7 79.0 81.6
CTP 104.0 105.7 106.1 68.3 70.6 73.4
GTP 95.9 95.5 104.7 66.8 70.7 72.4
UTP 101.9 110.6 102.5 67.6 70.6 73.7
dATP 95.1 98.4 115.6 59.2 69.2 69.6
dCTP 107.8 108.1 107.4 59.9 69.9 75.5
dGTP 94.2 96.0 95.1 65.8 70.7 88.6
dTTP 102.1 90.7 121.8 73.8 80.3 67.0
dFdCTP 111.1 112.0 118.2 59.2 66.7 77.3
ATP* 100.1 97.0 101.6 74.5 75.4 91.9
GTP* 98.1 93.5 108.4 67.0 66.7 74.1
UTP* 101.5 106.2 106.5 66.5 65.7 73.8
dATP* 95.1 98.4 115.6 59.2 69.2 69.6
dCTP* 104.5 101.7 109.4 64.5 66.2 75.9
dGTP* 99.1 94.6 93.6 68.1 66.9 89.2
dTTP* 97.9 70.5 121.9 71.0 70.2 72.8
BrATP 101.78 95.53 107.63 73.8 72.82 77.41
lower. These values suggest that our assay is more sensitive than
previously published methods [3,36,37], even though the sample
preparation was simplified.
The assay within- and between run precision and accuracy data
are summarized in Table 2 for all analytes at three concentra-
tions levels. The within run accuracy ranged from 98.01 to 107.84%,
while the between run accuracy ranged from 86.96 to 106.41%. The
standard relative deviation was not higher than 12.08% for within
run precision and 11.44% for between run precision.
The extraction recovery data were calculated for two types of
extraction, described in Section 2.3.3. The first one was a simple
protein precipitation with 60% MeOH, evaporation of the super-
natant and resuspension in mobile phase A (“without SPE”). The
second approach included precipitation, solid phase extraction on
a WAX column, evaporation and resuspension (“with SPE”). Recov-
ery data for all analytes at three concentrations and IS are presented
in Table 3. When calculating recovery according to peak areas, the
“without SPE” procedure resulted in recoveries ranging from 59.2%
to 91.9%. In the “with SPE” procedure the recoveries ranged from
94.2% to 121.8%. Lower recovery for the first method was expected
and can be explained by a higher ion suppression originating from
a more complex matrix. However, as the analytes and their 13C,15N
isotopes are affected equally by the cell matrix, the quantification
of each NTP and dNTP could be determined more accurately than
in the method reported by Cohen et al. [3]. This fast, sensitive and
relatively simple method for nucleotide extraction may be a bet-
ter choice than one including SPE, which is time consuming, more
expensive and includes more experimental steps that could lead to
higher inaccuracy.
Stability of NTPs and dNTPs in stock and working solutions, pre-
pared in cellular lysis extract remained stable for at least 3 months
at −80 ◦C, as has been reported also earlier [3]. Short term stability
at room temperature and long term stability in original matrix at
freezer (−80 ◦C) were not assessed because the described sample
preparation requires immediate handling of the samples, includ-
ing adding of MeOH and freezing in liquid nitrogen, in order to
reduce the potential of introducing a preanalytical bias, such as ana-
lyte metabolism ex vivo. Samples (in 60% MeOH) remained stable
between two freeze–thaw cycles, as the concentration of the ana-
lytes did not deviate more than 15%. Stability of NTPs and dNTPs in
processed samples (in reconstitution solution) maintained during
48 h at 4 ◦C was acceptable since responses did not deviate more
than 12.3% from initial values.
3.4. Application of the method
Nucleotides were extracted from PBMCs isolated from blood
drawn at different time points (0–240 min) after initiating a 30-
min infusion of gemcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC)
given to pancreatic cancer patients. All NTPs and dNTPs, as well
as dFdCTP were quantified using the described method, and their
concentrations (given in mM) were recalculated in relation to the
number of PBMCs in each analyzed sample. In Fig. 2, concentrations
of NTPs and dNTPs given in pmol/106 cells before and 240 min after
gemcitabine infusion are presented. In samples acquired before
treatment (t = 0 min) all nucleotides except ATP and GTP were
within expected ranges according to literature values [38]. We
speculate that the high amounts of ATP and GTP in untreated cells
may be due to variations of intrinsic NTP pools dependent on cell
types or to the method of cell culturing [39]. In our study PBMCs
were isolated from venous blood samples in patients treated with
gemcitabine infusions, while most published data are based on
measurements in solid tumor and in cultured leukemia cells lines
incubated with the drug. Four hours after initiating a gemcitabine
infusion, all NTPs and dNTPs increased significantly (Fig. 2), which
is in agreement with results from studies with cell cultures [38,40].
Concentrations versus time of intracellular dFdCTP in PBMCs
from samples of one patient are given in Fig. 3(a). Gemcitabine
and its main metabolite, dFdU were quantified in plasma samples
acquired simultaneously and a concentration versus time profile
is presented in Fig. 3(b). As has been shown in previous studies,
dFdC in plasma peaked at the end of a 30-min after infusion, while
dFdU peaked after another 30 min and was eliminated slowly [41].
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However, the concentration plateau of dFdCTP was not reached
within the first 4 h after infusion. An explanation for this finding
is not readily apparent as different nucleoside membrane trans-
porter genotypes and different infusion rates (8–50 mg/m2/min)
affect the rate and extent of dFdCTP accumulation [42], and these
factors were not assessed in our preliminary study. We suggest the
presented LC–MS/MS method to be a useful tool in future studies of
the nucleotide pool and of intracellular gemcitabine pharmacology.
4. Conclusion
A sensitive and accurate ion-pair LC–MS/MS method on a porous
graphitic column was developed and validated for simultaneous
quantification of 8 endogenous nucleotides and the most impor-
tant active metabolite of gemcitabine, dFdCTP, in PBMCs. During
validation of the method, cell supernatant was treated with a cti-
vated charcoal to remove traces of endogenous NTPs and dNTPs,
so that unlabeled compounds could be used as spike solutions and
13C,15N isotopes as internal standards. This method is applicable in
cellular biology and pharmacological studies, and may be further
evaluated for the investigation of the nucleotide pool and of intra-
cellular gemcitabine pharmacokinetics and pharmacodynamics in
blood cells acquired from patients treated with this drug.
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Background: The primary aim of our study was to evaluate the safety and potential toxicity of gemcitabine com-
bined with microbubbles under sonication in inoperable pancreatic cancer patients. The secondary aim was to
evaluate a novel image-guided microbubble-based therapy, based on commercially available technology, to-
wards improving chemotherapeutic efficacy, preserving patient performance status, and prolonging survival.
Methods: Ten patients were enrolled and treated in this Phase I clinical trial. Gemcitabine was infused intrave-
nously over 30 min. Subsequently, patients were treated using a commercial clinical ultrasound scanner for
31.5 min. SonoVue®was injected intravenously (0.5 ml followed by 5 ml saline every 3.5 min) during the ultra-
sound treatment with the aim of inducing sonoporation, thus enhancing therapeutic efficacy.
Results: The combined therapeutic regimen did not induce any additional toxicity or increased frequency of side
effects when compared to gemcitabine chemotherapy alone (historical controls). Combination treated patients
(n = 10) tolerated an increased number of gemcitabine cycles compared with historical controls (n = 63 pa-
tients; average of 8.3 ± 6.0 cycles, versus 13.8 ± 5.6 cycles, p = 0.008, unpaired t-test). In five patients, the
maximum tumour diameter was decreased from the first to last treatment. The median survival in our patients
(n = 10) was also increased from 8.9 months to 17.6 months (p = 0.011).
Conclusions: It is possible to combine ultrasound, microbubbles, and chemotherapy in a clinical setting using
commercially available equipment with no additional toxicities. This combined treatmentmay improve the clin-
ical efficacy of gemcitabine, prolong the quality of life, and extend survival in patients with pancreatic ductal
adenocarcinoma.










A diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries one
of the most dismal prognoses in all of medicine. Currently the 4th most
lethal cancer in the western world, it has an average 5-year survival of
approximately 5% and is predictedwithin the decade to become the sec-
ond greatest cause of cancer death [1]. Surgery provides the only possi-
bility for cure, however N85% of newly diagnosed pancreatic tumours
are considered unresectable due to locally advanced disease with en-
casement of large blood vessels or metastasis. Furthermore, the preva-
lence of extreme desmoplasia generally renders the disease resistant
to chemo-radiative approaches [2]. Untreated, locally advanced PDAC
patients have a median survival of 6–10 months and 3–5 months for
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patients with metastatic disease [3–5] highlighting the immediate and
dire need for novel therapeutic interventions.
Gemcitabine has been the standard chemotherapeutic used in
recent years and the most effective single agent. Compared to 5-
fluorouracil, gemcitabine extends the survival by approximately one
month whilst also improving clinical symptoms [6]. Recently,
FOLFIRINOX (bolus and infusion of 5-fluorouracil, leucovorin,
irinotecan, and oxaliplatin) emerged as a new chemotherapeutic option
for patients with metastatic pancreatic cancer and an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0–1. For this cohort
of patients FOLFIRINOX is now the reference treatment. However,
owing to the demonstrable toxicities and side effects of this therapy,
gemcitabine is still the standard of care in patients with poor perfor-
mance status or contraindication to FOLFIRINOX [7]. Furthermore, the
combination of nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
and gemcitabine provides another new therapeutic option resulting
with improved median survival of 1.8 months, compared to
gemcitabine alone [8]. Despite these novel interventions, the reported
increases in survival areminimal andwe continue ourwait for a therapy
that will impact survival, provide a bridge to reductive surgery and ulti-
mately cure PDAC.
Diagnostic ultrasound (US) imaging has been used in the clinic for N
50 years [9,10], with detection of pancreatic lesions dating back to the
late 1960s [11]. Over the past 30 years, the use of ultrasound to detect
PDAC has significantly increased [11–13]. Contrast-enhanced ultra-
sound uses stabilised gas microbubbles (MBs) to enhance the signal-
to-noise ratio of the vasculature and allows clinicians to better visualise
tissue perfusion. Twenty years ago, researchers discover that upon ap-
plication of ultrasound these microbubbles volumetrically oscillate. If
these oscillating microbubbles were in the vicinity of cells, small pores
could be formed increasing the uptake of macromolecules significantly
[14–16]. Henceforth, the use of ultrasound and microbubbles to invoke
biomechanical effects that increase the permeability of the vascular bar-
rier and/or the extravasation of drug in a specific location is now com-
monly known as “sonoporation”.
Numerous researchers have shown in vitro and in vivo that
sonoporation is a viable technique to improve drug delivery and im-
prove therapeutic efficacy in various cell lines derived from pharyngeal
[17], glioma [18], prostate [19,20], melanoma [21], and pancreatic can-
cer [22]. Sonoporation has also been used to open the blood brain barri-
er [23,24]. In general, sonoporation research is split into two camps: A)
high-intensity, i.e., using inertial cavitation [9,25–27] and/or taking ad-
vantage of the thermal effects [28,29], and B) low-intensity, i.e., using
stable cavitation [30,31] and non-thermal effects [32–34].
The use of high-intensity ultrasound without MB has previously
been evaluated clinically and shown considerable success for pain ther-
apy [35,36], ablation of breast fibroadenomas [37], opening the blood-
brain barrier [38] and treatment of pancreatic adenocarcinoma [39].
Nevertheless, to our knowledge, there has been no clinical trial evaluat-
ing the efficacy of low-intensity ultrasound in combination with
microbubbles to improve the chemotherapeutic efficacy in patients
with PDAC.
We have previously demonstrated in vitro and preclinically in an
orthotopic model of PDAC, enhanced treatment effects of gemcitabine
with concurrent exposure to SonoVue® MB and US at low acoustic in-
tensities [40]. Based on these preclinical results we initiated an open
label phase I, single centre, safety evaluation study in PDAC patients
by combining an ultrasound contrast agent and gemcitabine under son-
ication at clinical diagnostic conditions.
The primary objective of this study was to evaluate the safety and
potential toxicity of gemcitabine combined with ultrasound contrast
agent under ultrasound treatment in inoperable pancreatic cancer pa-
tients. The secondary objective was to evaluate a novel image-guided
microbubble-based therapy, based on commercially available technolo-
gy, towards improving chemotherapeutic efficacy, preserving patient
performance status and prolonging survival.
2. Material and methods
2.1. Subjects
Over a 23-month period (January 2012–November 2013), we re-
cruited ten consecutive voluntary patients with inoperable pancreatic
cancer (ICD-10 C25.0–3) at Haukeland University Hospital. All had his-
tologically verified, locally advanced (non-resectable Stage III) or meta-
static (Stage IV) pancreatic adenocarcinoma. Needle biopsies were
obtained either from the primary tumour or from a metastatic lesion.
The tissuewas processed in the diagnostic pathology laboratory accord-
ing to standard routines (formalin-fixation, paraffin-embedment, stain-
ing with hematoxylin and eosin). The histology was evaluated by a
senior pathologist with special competence in gastrointestinal patholo-
gy. Patients were ambulatory with an Eastern Cooperative Oncology
Group (ECOG) performance status 0–1 (Table 1). Patients had to meet
the standard criteria at our hospital for treatment with gemcitabine
and no known intolerance to gemcitabine or SonoVue® (Bracco Imag-
ing Scandinavia AB, Oslo, Norway) ultrasound contrast agent [45].
Historical data from PDAC patients undergoing equal gemcitabine
treatment following the same inclusion and exclusion criteria, between
2009 and 2011 atHaukelandUniversityHospital, were used for compar-
ison of treatment tolerance, safety, and overall survival. The only differ-
ence in treatment between the historical control group and our treated
group was the addition of ultrasound and microbubbles following che-
motherapeutic infusion. Gemcitabine was considered the standard of
care for the treatment time period of the control patients and through-
out this clinical study.
2.2. Chemotherapeutic and microbubble dosage
Two experienced oncologists, not participating in the study,were re-
sponsible for the chemotherapeutic treatment. The only divergence
from normal administration practice was relocation to the research
unit. We used the standard recommended treatment protocol of
Table 1
Clinico-pathological characteristics of all pancreatic cancer patients. There was no statisti-
cally significant difference between the sonoporation treated cohort and historical control







Start of treatment End of treatment Start of treatment






23.7 (±4.3) 23.9 (±5.1) 22.9 (±3.05)
ECOG performance
status (%)
0 50 10 71




Locally advanced 70 NA 55
Metastatic 30 45
Blood chemistry
B-hemoglobin (g/dL) 13.4 (±1.5) 11.9 (±0.9) 12.6 (±1.5)
ALAT (U/L) 45.2 (±21.8) 59.7 (±42.9) 71.2 (±59.6)
LD (mg/dL) 151.4 (±27.6) 209.6 (±46.0) 177.7 (±49.4)
Bilirubin (μmol/L) 14.5 (±8.46) 7.3 (±4.0) 37.3 (±66.0)
CA 125 (U/mL) 54.1 (±39.6) 62 (±60.1) 90.0 (±100.5)
CA19-9 (U/mL)a 248.5 (±380.8) 117.1 (±202.9) NA
Comments:
Obligatory lab values for chemotherapy inclusion: B-Hemoglobin N10, Neutrophils
(polymorphoneuclear leukocytes) N3.5, Platelets N150, Bilirubin N75.
a One sonoporation treatedpatient exhibited abnormally highCA19-9 values at 4608U/
mL hence not included in average CA19-9 values.
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gemcitabine hydrochloride (Gemzar®, Eli Lilly & Co., Indianapolis, USA)
[45]. Specifically, an initial phase of intravenous gemcitabine infusion
was administered at a frequency of one cycle per week for seven
weeks followed by a one-week pause. Subsequent cycles of infusions
were given once weekly for 3 consecutive weeks out of every 4 weeks.
Treatment pauses or any dose adjustments were administered accord-
ing to standard guidelines [43,45]. Chemotherapy was continued as
long as the treatment was beneficial [46]. The patients were monitored
according to the requirements for Phase I studies [47].
Maximum plasma concentration of gemcitabine is achieved after
30min atwhich point sonoporationwith Sonovue®was initiated to en-
sure maximal possible tumour exposures [48]. Clinically approved
SonoVue® ultrasound contrast agent was used as the microbubble for
sonoporation [49]. Ethical approval limited treatment to the use of a sin-
gle vial of microbubbles, paralleling traditional imaging protocols. Due
to the acoustic emission limitations of the clinical diagnostic scanner
(c.f., Section 2.4) we chose to maximise the treatment time to achieve
the longest active sonoporation time (i.e., time when ultrasound
waves and microbubbles were present). The expected in-vivo life time
of microbubbles was 4–5 min, hence we chose to inject boluses every
3.5 min to ensure microbubbles were present continuously throughout
the whole treatment. Previous experience [50] showed that we were
able to detect microbubble using non-linear ultrasound imaging using
0.5 ml boluses [51]. Due to these requirements, microbubble dosage re-
sults in 0.5 ml of SonoVue® followed by 5-ml saline every 3.5 min, im-
mediately after the end of the intravenous infusion of gemcitabine [43].
A complete vial was used in 31.5 min. The total dose of contrast agent
used throughout each treatment was within standard clinical practice
[52].
2.3. Ultrasound scanner configuration
In our previous studies we determined that sonoporation had a sig-
nificant therapeutic effect when using long pulse durations, specifically
40 μs pulses every 100 μs (i.e., a duty cycle of 40%) [41,44]. This resulted
in minimal acoustic energy deposition within FDA and IEC guidelines
and maximum therapeutic efficacy [53,54]. In this clinical study, an
unmodified clinical diagnostic ultrasound scanner (LOGIQ 9, GE
Healthcare, Waukesha, WI) in combination with a 4C curvilinear
probe (GE Healthcare) was used to apply the therapeutic ultrasound.
Unfortunately, it is not possible to generate such long duty cycles with
an unmodified clinical diagnostic machine, due to technical limitations.
In addition, such long duty cycles would severely degrade the image
resolution. Hence, we attempted to maximise the ultrasonic duty cycle
emitted by the clinical machine, whilst keeping linear waves, to avoid
bubble destruction and energy deposition at higher harmonics.
In order to determine the ideal settings, the machine was
characterised and calibrated in a bespoke, automated, 3-axis ultrasound
characterisation chamberfilledwithfiltered, degassed, deionisedwater.
To waterproof the probe prior to submersion, the transmission surface
was covered in AQUASONIC® ultrasound transmission gel (Parker Lab-
oratories, Fairfield, NJ), and subsequently covered using a latex ultra-
sound probe cover (Sheathing Technologies, Inc., Morgan Hill, CA).
The probe was locked in place and a range of acoustic emission condi-
tions were evaluated with the aim of reaching the longest duty cycle
with linear waves (i.e., minimum amount of harmonics) at a de-rated
MI of 0.2. The ultrasound emission conditions were characterised fol-
lowing FDA and IEC ultrasound guidelines [53,54]. To achieve the max-
imum pulse repetition rate the packet size was maximized. Whilst this
reduced the frame rate substantially, it resulted in increasing the pulse
repetition significantly higher than possible with a frame rate increase
alone. Knowing that each patient would have a different tumour
depth and size, various focal and image depths were calibrated to en-
sure all patients were treated with identical conditions. The ultrasound
scanner configuration was programmed to maximise the duty cycle,
with short broadband linear pulse in order excite asmanymicrobubbles
as possible for the longest period possible. These acoustic emission con-
ditionswere considered optimal in relation to the limitations of the clin-
ical ultrasound system emission configuration conditions. The device
optimized acoustic conditions resulted in a derated MI of 0.2
(0.27 MPa peak-negative pressure), a 0.3% duty cycle with a center
emission frequency of 1.9MHz, and a spatial-peak temporal-average in-
tensity of 0.25 mW/(cm) [2]. Specifically, the beamformed ultrasound
bursts consisted of 4 cycles (2.1 μs) every 21 ms, i.e., a transmission
duty cycle of 1%. Following the completion of the 12 ultrasound packet
transmissions, therewas a transmission pause allowing for echo capture
and image reconstruction resulting in an overall duty cycle of 0.3%. The
center frequency of 1.9MHzwas ideal as it was close to the natural res-
onance of the SonoVue®microbubbles [55]. At an MI of 0.2, only stable
cavitation was expected to be induced throughout treatment. These
acoustic emission conditions resulted in a 1-cm thick treatment slice
based on a −3 dB contour [43].
To make sure that treatment only occurred at the target, i.e., the
tumour, the image plane and non-linear contrast region of interest
(ROI) was limited to the tumour area +1 cm surrounding area. We
avoided treating any liver or bowel area. The acoustic focal depth
was placed at the centre of the tumour. The expected treatment
height, based on a −3 dB contour was 3 cm above and below the
acoustic focus depth.
This image-guided therapy model is based on the expectation that
treatment only occurswhere the ultrasound andmicrobubbles are pres-
ent, i.e., what is being imaged.
The ultrasound probe was re-calibrated every six months to
ensure acoustic consistency. The exact acoustic conditions and the
ultrasound field map are thoroughly described in our previous pub-
lication [43].
2.4. Transabdominal ultrasound
Routine abdominal US imaging [56] was performed during the
last 10 min (T = 20 min) of chemotherapeutic delivery using the
same LOGIQ 9 clinical diagnostic ultrasound scanner as for treat-
ment. The ultrasound probe was attached to a ball-head mount
allowing for initial free-hand scanning. Once in the optimal position
for treating the tumour, with the largest diameter targeted, the ball-
head mount was locked and the ultrasound probe was kept in this
position till completion of the treatment [43] (c.f., Fig. 1). The opti-
mal treatment position of the 4C clinical diagnostic ultrasound
probe to ensure a clear acoustic path to the tumour without any ob-
structions such as stomach and bowel air varied per patient. This was
achieved by following established diagnostic protocols for imaging
the pancreas [56,57]. In general, the probe was positioned in the epi-
gastric region with the acoustic propagation path pointing towards
the pancreatic tumour. The azimuth and elevation of the probe was
adjusted to avoid any air pockets and liver tissue. The patients
were allowed to lie in their most comfortable position prior to locat-
ing the tumour and locking the transducer in place. The patients
were consulted if any discomfort was felt, and pressure adjustments
were made if necessary. The large vasculature near the primary tu-
mour was visualized using non-linear contrast mode in order to val-
idate that microbubbles were being sonicated near the target
tumour. Patient breathing allowed for passive scanning of the tu-
mour, as with each breath the tumour would move through the
acoustic field. The amount of passive scanning varied per patient
breathing volume. Breathing based passive scanning ranged be-
tween 1 and 3 cm at the tumour level.
The total duration of combined ultrasound and microbubble treat-
ment was 31.5 min. Fig. 1 shows the experimental setup used to com-
bine chemotherapy, ultrasound, and microbubbles. Panel A shows the
time course of each treatment cycle whilst Panel B shows a photograph
of the ultrasound positioned to treat the tumour.
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2.5. Pharmacokinetic evaluations
Analytical methods for pharmacokinetic (PK) evaluations were de-
veloped in parallel to the clinical study [58]. Whole blood samples
were collected sequentially into prechilled heparinized tubes at the fol-
lowing time-points: T = 0, 30, 60, 120, 180 and 240 min. Tubes were
spiked with the cytidine deaminase inhibitor tetrahydrouridine to pre-
vent deamination of gemcitabine to dFdU [58]. Plasma andmononucle-
ar cells were separated from whole blood as described previously.
Concentrations of gemcitabine and dFdU were measured in plasma
using in-house LC-MS/MS methods [58].
2.6. Monitoring
All patients underwent dual-phase computed tomography (CT) im-
aging ≤3 weeks before study inclusion. Routine abdominal CT was per-
formed every 8th week where maximum tumour diameter was
quantified by independent radiologists. Tumour size and development
was characterised according to the Response Evaluation Criteria in
Solid Tumours (RECIST). Positron emission tomography (PET) imaging
with F-18-fluoro-deoxyglucose (FDG)was performed prior to the treat-
ment to determine if metastases were present.
Assessment of clinical state during the treatment also included an
evaluation of the clinical benefit response and if surgical resection
could be performed [46,59]. ECOG performance status was used as a
proxy to monitor the effectiveness of the combined treatment. The
ECOG scale describes patients' level of functioning in terms of their
ability to care for themselves, daily activity, and physical ability [46].
An ECOG grade of 0 indicates a patient who is fully active and able to
carry on all pre-disease performance without restriction. An ECOG
grade of 1 indicates that a patient is restricted in physical strenuous ac-
tivity but ambulatory and able to carry out work of a light or sedentary
nature, e.g., light housework, officework. An ECOGgrade of 2 indicates a
patient is ambulatory and capable of all self-care but unable to carry out
any work activities. The patient is up and about N50% of waking hours.
An ECOG grade of 3 indicates a patient capable of limited self-care and
confided to bed or chair N50% of waking hours. Hence, the longer a pa-
tient stayed below an ECOG grade of 3, themore effective the treatment
was considered indicating an extended period of well-being. When a
patient reaches an ECOG grade of 3, they are no-longer able to undergo
gemcitabine chemotherapy.
Select patients also underwent diagnostic contrast-enhanced ultra-
sound following established clinical procedures [60]. Blood analysis
was performed to evaluate if there was any acute toxicity.
2.7. Statistical analysis
The results are expressed asmean values± SD, unless otherwise in-
dicated. Continuous data was analysed using t-tests, or Mann-Whitney
tests if data were not normally distributed. Gehan-Breslow-Wilcoxon
test and Log-rank (Mantel-Cox) test were used to compare survival.
Variance is expressed through 95% confidence intervals. p b 0.05 was
considered statistical significant. Patients removed from the study due
to improvement were considered as intention to treat in the survival
statistical analysis.
Fig. 1. (A) Treatment procedure flow chart with timings of chemotherapeutics, ultrasound exposure, and microbubble infusion. Using the current protocol, the treatment duration was
61.5 min. The first 30 min were reserved for chemotherapeutic infusion and the last 31.5 min were reserved for ultrasound and microbubble treatment. Abdominal imaging was
performed for the last 10 min of infusion. Every 3.5 min, 0.5 ml of SonoVue® microbubbles were injected. (B) Photograph of patient with PDAC undergoing treatment using a clinically
available diagnostic scanner. The ultrasound probe was locked in position using a mechanical arm targeted at the primary tumour for the full 31.5 min of ultrasound and microbubble
treatment.
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3. Results
3.1. Tumour targeting
The established guidelines for imaging the pancreas [56,57] allowed
us to target the primary PDAC tumour, independent of tumour depth
and size. Fig. 2 shows four representative ultrasound images of the
PDAC tumours from our treated patient cohort captured prior to
switching the diagnostic ultrasound scanner settings to “treatment
mode”. In these images tumour depths ranges from 3.1 cm to 8.9 cm in-
dicating that shallow or deep tumour did not inhibit tumour visualisa-
tion or targeting.
3.2. Toxicity evaluation
The direct parameters used to evaluate the toxicity of our treatment
were clinical parameters including vital signs, ECG and blood chemistry.
Overall, all data indicated that gemcitabine in combination with US did
not induce any unexpected deviation or additional toxicities than che-
motherapy alone.
One patientwas hospitalised for a serious adverse event (SAE) unre-
lated to protocol therapy. Four SAEs occurred during protocol therapy.
Two patients had symptoms indicating biliary obstruction and necessi-
tated hospitalisation and rescheduling of the treatment. One was treat-
ed for pneumonia and one had fever due to cholangitis. The most
frequent possibly treatment-related toxicities i.e., adverse events (AE)
were abdominal pain (n=9), nausea (n=7), fever (n=6), neutrope-
nia (n=6), and fatigue (n=6) as described in Fig. 3. These eventswere
registered as possibly related to protocol therapy. Since all the reported
toxicities are expected side effects of gemcitabine, they were evaluated
as gemcitabine related. All other AE were probably related to progres-
sion of underlying disease. There were no treatment-related deaths.
3.3. Blood biochemistry
No additional toxicity was observed. Blood values changed as ex-
pected. CA 19-9 and CA 125 levels decreased in 5 out of 8 patients mea-
sured, and 7 of the 10 patients, respectively.
When evaluating the levels of cancer marker CA 125 we observed a
decline following combined treatment. A total of four out of ten patients
went from elevated to normal counts and only a single patient went
from normal to elevated counts. Whilst fewer measurements were
made in the CA 19-9 counts a similar trend was also observed where
three patientswent fromelevated counts to normal counts,five patients
showed a decrease, two patients showed an increase, and only a single
patient went from normal to elevated counts. No correlation between
tumour size change and cancer marker count was observed (Supple-
mental Fig. 1).
Bilirubin, LD, ALAT and other liver parameters were in line with the
expected variation under gemcitabine treatment. Thesewere all consid-
ered to be normal blood biochemistry changes as expected from chemo-
therapy and disease course.
3.4. Clinical benefit and response assessment
The followingmethodswere applied to evaluate the responses in the
ten patients: RECIST, tumour size, ECOG grade and treatment cycles
[59,61].
Fig. 2. Representative ultrasound images showing the PDAC tumour in four of the ultrasound andmicrobubble treated patients. Tumour height andwidth are indicated by the yellow and
green dotted lines. The ultrasound transducer was positioned to ensure no obstructions of the acoustical beam path to the tumour. This resulted in a unique ultrasound probe position per
patient and treatment. Distance 1 and 2 indicate the tumour width and height respectively. Value D indicated the tumour centroid depth.
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The patients considered to be positive clinical responders were reg-
ularly evaluated by the Dept. of Oncology for FOLFIRINOX treatment or
consolidative radiation therapy and surgery. After 12 treatment cycles,
one patient was down-staged from 8.6 cm to 4.2 cm in tumour size
and thereby became available for potentially curative therapy. She
was removed from the clinical trial and underwent radiation therapy
and subsequent pancreatectomy. Five patients exhibited partial re-
sponses as evidenced by reduction in tumour diameter. As a result,
they were offered either consolidative radiation therapy or FOLFIRINOX
treatment.
Fig. 4 shows the effect of our combined treatment on the tumour
size. The green lines indicate the patient tumour size recession or stabi-
lization from the start to the end of the treatment, whereas the red lines
indicate tumour size increase. When the line ends, this indicates that
the patient was removed from the clinical trial.
An average of 13.8 ± 5.6 and median 12.5 (range 5–26) treatment
cycles of protocol therapy were delivered per patient. In comparison,
our historical control group treated with the same chemotherapeutic
protocol of gemcitabine alone received an average of 8.3 ± 6.0 andme-
dian 7 (range 1–28) treatment cycles (p=0.008). Fig. 5A shows awhis-
ker plot depicting the number and range of treatment cycles.
Fig. 5B shows the survival curve of the combined treatment group
compared to the historical control group. The number of treatment cy-
cles and days of survival in our patient group are summarised in
Table 2. Both Gehan-Breslow-Wilcoxon test and Log-rank (Mantel-
Cox) test showed that the survival was significantly different with
p = 0.0043 and p = 0.011, respectively.
3.5. Gemcitabine pharmacokinetics
Concentration profiles of gemcitabine and dFdU in plasma samples
were in accordance with previous studies of gemcitabine-infusions of
800–1000 mg/m2 administered to breast, lung, pancreatic and patients
with various other solid tumours [48,62]. This demonstrates that the
combination regimen did not seem to alter the systemic pharmacoki-
netics of gemcitabine. A representative concentration profile from one
of the patients is shown in Supplemental Fig. 2.
4. Discussion
To our knowledge, this is the first human trial evaluating the use of
low intensity ultrasound and microbubbles to treat cancer. All previous
studies have only been performed in vitro or pre-clinically. Clinical stud-
ies using ultrasound for therapy have been focused on high-intensity ul-
trasound without microbubbles, or for pain treatment. Hence the effect
of low intensity sonoporation therapy for PDAC in humans is unknown
[44,63–65].
In our previous study [43], we presented the experimental protocol
focusing on the technical aspects of implementing low-intensity
sonoporation using a clinical diagnostic ultrasound scanner. We also
presented pilot results of five patients briefly discussing the number of
cycles and tumour sizes. In the currentworkwe present the final results
and clinical data of all 10 patients, including a comparison of overall sur-
vival. In addition,we provide a toxicity report regarding the safety of the
study following 138 treatment cycles.
The primary aim of this Phase I study was to evaluate the safety and
potential toxicity, when combing microbubbles, ultrasound, and a che-
motherapeutic agent in patients with PDAC. Hence, in this clinical trial
we only evaluated a total of ten patients, as required by the NMA. Over-
all, all data clearly indicated that this combination did not induce any
additional toxicities.
4.1. Cancer markers
These results indicate that chemotherapy in combination with
microbubbles andultrasoundmayhave a positive impact on tumour de-
velopment. It iswell known that there are correlations between CA 19-9
decline and both overall survival and time to treatment failure in pa-
tients treated with gemcitabine alone [66]. The limited number of pa-
tients in our Phase-I-trial does not allow us to make any further
conclusions.
Fig. 3. Percentage of patients with PDAC treated with sonoporation that experienced a given adverse event. This graph shows all the adverse events experienced by all patients regardless
of severity grade, or direct correlation to the treatment. All adverse events were already associated with gemcitabine treatment alone, indicating that addition of ultrasound and
microbubbles did not induce or increase the frequency of new adverse events.
Fig. 4. Maximum tumour size as function of time for all ten patients with inoperable
pancreatic adenocarcinoma. Green lines indicate tumour size recession or stabilization.
Red/orange or grey lines indicate tumour size increase. Colour gradient indicates linear
regression fit of tumour growth gradient (lighter = shallower). Five out of ten patients
(50%) showed tumour size reduction during treatment. A reduction in tumour size may
allow for surgical resection; the only current curative option. The star (*) indicates
which patients showed tumour size reduction and were evaluated for consolidative
radiation therapy or FOLFIRINOX treatment.
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4.2. Adverse events
In our present work, we present all adverse events experienced
by the patients independent of grade and severity (Fig. 3). This also
includes adverse events due to the actual malignancy, or personal
experiences. Other clinical studies typically only register adverse
events that can be directly correlated to the treatment itself, with oc-
currences above 10% and grades ≥3 [45]. As adverse events are rarely
registered clinically, we were unable to directly compare with our
historical group. To aid comparison we have compared to values
available in literature (c.f., Supplemental Fig. 3). In this Figure, we
observe a 40% difference of abdominal pain. The primary symptoms
of pancreatic cancer are abdominal pain and weight loss [67], as a re-
sult this symptom is rarely recorded. Nine out of our ten patients ex-
hibited abdominal pain prior to treatment, hence we do not attribute
this adverse event as treatment related. In contrast, in studies where
weight loss was recorded, it was observed in nearly all patients. In
our treated patient cohort, only 20% (2 patients) exhibited weight
loss. Throughout this study all AE had already been previously asso-
ciated with gemcitabine chemotherapy alone. This strongly suggests
that there is no additional toxicity when combining ultrasound and
microbubbles with gemcitabine chemotherapy.
4.3. Overall survival and well being
When the patients' health deteriorates, and their ECOG status rises
above 2, they are no longer able to undergo therapy. Hence, number
of treatment cycles indirectly represents the physical well-being of the
patients. Our clinical trial group was able to undergo 66% more cycles
than the historical control group. It is important to note that the analysis
of treatment cycles is biased against the sonoporation group as four out
of ten patients were removed from the study due to reduction of the tu-
mour size. If these patients had continued treatment, the number of
treatment cycles would be higher. This suggests that chemotherapy in
combination with ultrasound and microbubbles may prolong the phys-
ical health and ambulatory status of patients with pancreatic cancer.
Due to the study design, our data may not be directly comparable to
the historical control cohort; hence these results should be interpreted
with caution.
When evaluating survival, our results showed a mean survival of
21.4 months andmedian survival of 17.6 months. This was significantly
longer than our historical control group (8.9 months) and literature
values (6.7months) [5].Whilst these results should be interpreted care-
fully, we argue that chemotherapy in combination with ultrasound and
microbubbles probably increases survival in patients with pancreatic
cancer.
4.4. Other chemotherapeutic options
Whilst gemcitabine is no longer considered at the forefront of che-
motherapeutic treatment for PDAC, it was the first choice treatment
when this clinical trial was initiated [68]. Other drugs and drug-combi-
nations such as FOLFIRINOX and Gemcitabine+ nab-Paclitaxel are now
considered state-of-the-art [7,8]. As this trial was initiated using
Gemcitabine we could not modify the protocol when other drugs and
drug combinations reached the forefront of PDAC chemotherapeutic
treatment. Gemcitabine is still commonly usedworldwide for the treat-
ment of PDAC, hence this protocolmay allow for easier implementation.
When we compare median survivals of these patient groups from
literature we see that FOLFIRINOX results in median survival of 11.7
months while gemcitabine + nab-Paclitaxel give a median survival of
12.2 months [69]. The observed median survival in our study far
surpassed both these values using a less effective drug (Graphical Ab-
stract). As sonoporation is not limited to any specific drug, inducing
sonoporation with a more effective chemotherapeutic may further im-
prove the therapeutic efficacy. In the case of combined chemotherapeu-
tics, sonoporation could either be induced during or after infusion of all
drugs, or at a time point where all chemotherapeutics are in the
bloodstream.
4.5. Tumour perfusion
PDAC is well known to be a hypovascular tumour [70], meaning it
has less perfusion than the tissue surrounding it. This is falsely correlat-
ed to no perfusion.Nevertheless, in the clinicalfield it iswell known that
PDAC still exhibits perfusion. An example of such hypovascular perfu-
sion can be seen the Supplemental video 1 and Fig. 6. Fig. 6 shows a B-
Mode image, contrast-enhanced image, and a perfusion curve of the
aorta, healthy pancreatic tissue and the primary PDAC tumour.
Microbubbles can be clearly distinguished in the primary PDAC tumour
when comparing the primary PDAC tumour area in Fig. 6 A vs. B. The
perfusion curve Fig. 6C, depicts non-linear contrast echo amplitude as
Fig. 5. (A) Whisker plot comparing the number of treatment cycles undergone in patients with pancreatic adenocarcinoma. Patients treated with sonoporation showed a statistically
significant increase in number of treatment cycles (p = 0.008, unpaired t-test) indicating inhibited tumour progression and extended period of well-being (B) Survival plot comparing
patients treated with ultrasound, microbubbles, and gemcitabine vs gemcitabine alone. The survival curve indicated that the combined treatment group had near twice as high median
survival compared to treatment with gemcitabine alone; from a median of 8.9 months to 17.6 months (p = 0.011, Log Rank test).
Table 2
Number of cycles and days survival as of diagnosis for patients with pancreatic cancer
treated with ultrasound, microbubbles, and gemcitabine. The number of treatment cycles
ranged from 5 to 26 cycles whereas survival ranged from 207 to over 1333 days.














a Patients removed from the study due to improvement.
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a function of time for three regions of interest (ROI). The results validate
that microbubbles enter the PDAC tumour. At T= 0, i.e., the time of in-
jection, no microbubbles are present (i.e, −68 dB is the base line). At
around 25 s the aorta is the first ROI to reachmaximumperfusion, as ex-
pected. The pancreas reachesmaximumperfusion at around27 s,whilst
the PDAC tumour reachesmaximumperfusion at around 32 s. The aorta
shows the highest nonlinear echo amplitude, followed by the pancreatic
tissue. The PDAC has the lowest nonlinear echo amplitude whilst still
being 26 dB higher than the baseline, but only 5–10 dB lower than the
pancreas. This indicates the tumour has lower perfusion than the sur-
rounding tissue, yet is sufficiently perfused to allow microbubbles to
enter.
It is important to note that our historical control group treated with
gemcitabine alone has amedian survival of 8.9months, which is slightly
higher than that previously reported in literature (6.7 months) [3,5,71]
indicating that our historical control group was not negatively biased.
4.6. Potential mechanisms of sonoporation in vivo
In vitro, sonoporation is typically evaluated on a cell monolayer
allowing direct contact between the target cell line and microbubbles.
In vivo, the microbubbles flow through the vasculature and capillaries
allowing direct contact only with endothelial cells, resulting in
enhanced uptake only by these cells or, in some cases, in deeper cell
layers [72,73]. We believe that the therapeutic efficacy observed in
this Phase I clinical trial cannot only be attributed to the potential in-
crease of gemcitabine uptake in the endothelial cell walls. The interac-
tion between the vascular barrier and microbubbles may result in
increased fenestration size allowing deeper drug penetration [74]. It is
also known that ultrasound in combination with microbubbles can in-
crease intracellular stress signalling [75]. This increased stress, in combi-
nation with the chemotherapeutic may result in enhanced drug
sensitivity. Nevertheless, further work needs to be performed, pre-clin-
ically and clinically to ascertain the true mechanisms behind the im-
proved therapeutic efficacy.
4.7. Limitations
Whilst all these results show great promise, we cannot make global
assertions on the efficacy of ultrasound-enhanced chemotherapy based
on this study. To further understand and validate these results it is par-
amount to perform mechanistic experimental studies and examine a
larger patient cohort in a prospective randomized controlled Phase II
trial.
The tumour size reduction was measured using the maximum tu-
mour diameter. Whilst this method gives a representative overview of
Fig. 6. Contrast-enhanced ultrasound of the PDAC tumour in Patient 7. Panel A: B-mode image. Panel B: Contrast-Enhanced image using SonoVue®microbubbles. Pancreatic tissue, the
PDAC tumour and aorta have been labeled. Microbubbles can be clearly distinguished in the PDAC tumour when comparing to the B-Mode image. Panel C: Perfusion curve depicting
non-linear echo amplitude as a function of time for the three regions of interest: Aorta (yellow), pancreatic tissue (red) and PDAC tumour (cyan). The PDAC tumour exhibits a longer
time-to-peak and lower perfusion than both the aorta and pancreas, yet is still adequately perfused for microbubbles to enter. Panels A and B are freeze frames of late phase perfusion,
57 s after microbubbles injection (c.f.,white arrows in Panel C).
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tumour progression it does not take into account the 3D structural
change of the tumour. In our opinion, future work should address the
treatment effect on the tumour volume and not only the maximal
diameter.
The primary limitations of this study are that only a single 2D slice of
the tumour was treated. Using a 3D ultrasound probewith further opti-
mized acoustic conditions and modifying the microbubble type and
concentration may improve the therapeutic efficacy [44].
The ultrasound emission conditions used here were severely limited
by the clinical diagnostic scanner. In previous studies, longer duty cycles
have shown to have a better therapeutic effect than short duty cycles
[76]. Future work should aim to determine the ultrasound conditions
that induce the highest therapeutic effect and to allow implementation
of such conditions in the clinic.
There is currently no consensus on what is considered an ideal
microbubble dose. At high dosages, the microbubbles may interact
more with each other than the cells due to secondary Bjerknes forces
[42], whereas at low concentrations, there may not be enough
microbubbles to interact with the cells. Future work should evaluate
and optimise the microbubble type and dosage.
In thefield of sonoporation, it is typically assumed that the enhanced
effect is due to the increase in local drug concentrations. In ourwork,we
did not evaluate if the local drug concentrationwas increased and if this
could be the reason for the enhanced effect. Future work should evalu-
ate if there is an increase in local drug concentration, or if the improved
therapeutic efficacy is due to increase or decrease in perfusion, or other
intracellular responses.
5. Conclusion
In conclusion, our study indicated that chemotherapy in combina-
tion with ultrasound and microbubbles seems to be safe. No additional
toxicity was observed when compared to chemotherapy alone. In our
patient cohort, sonoporation has the additional benefit of improving
the number of treatment cycles the patients were able to undergo and
correspondingly extending the period of well-being. Significantly in-
creased survival was also observed compared to a historical cohort of
patients. Acknowledging the small treatment group with sub-optimal
treatment conditions in this study, a larger study with improved acous-
tic conditions and microbubble delivery is essential to improve our un-
derstanding and validating our results. Nevertheless, in our opinion
these novel results show great promise for ultrasound andmicrobubble
enhanced therapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2016.10.007.
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Cytidine deaminase (CDA) is a determinant of in vivo gemcitabine elimination kinetics and 
cellular toxicity. The impact of CDA activity in pancreatic ductal adenocarcinoma (PDAC) cell 
lines has not been elucidated. We hypothesized that CDA regulates gemcitabine flux through 
its inactivation and activation pathways in PDAC cell lines. 
Three PDAC cell lines (BxPC-3, MIA PaCa-2 and PANC-1) were incubated with 10 or 100 
µM gemcitabine for 60 minutes or 24 hours, with or without tetrahydrouridine (THU), a CDA 
inhibitor. Extracellular inactive gemcitabine metabolite (dFdU) and intracellular active 
metabolite (dFdCTP) were quantified with liquid chromatography tandem mass spectrometry. 
Cellular expression of CDA was assessed with real-time PCR and Western blot. 
Gemcitabine conversion to dFdU was extensive in BxPC-3 and low in MIA PaCa-2 and 
PANC-1, in accordance with their respective CDA expression levels. CDA inhibition was 
associated with low or undetectable dFdU in all three cell lines. After 24 hours gemcitabine 
incubation, dFdCTP was highest in MIA PaCa-2 and lowest in BxPC-3. CDA inhibition 
resulted in a profound dFdCTP increase in BxPC-3, but not in MIA PaCa-2 or PANC-1. 
dFdCTP concentrations were not higher after exposure to 100 vs. 10 µM gemcitabine when 
CDA-activities were low (MIA PaCa-2 and PANC-1) or inhibited (BxPC-3).  
The results suggest a regulatory role of CDA for gemcitabine activation in PDAC cells, but 





The importance of cytidine deaminase (CDA) for cellular gemcitabine toxicity, linking a lower 
activity to higher toxicity, is well described. An underlying assumption is that CDA, by 
inactivating gemcitabine, limits the amount available for the intracellular activation pathway. 
Our study is the first to illustrate this regulatory role of CDA in pancreatic ductal 
adenocarcinoma cell lines by quantifying intracellular and extracellular gemcitabine 








Gemcitabine (2’,2’-difluoro-2’-deoxycytidine, dFdC) is a nucleoside analogue used either 
alone or in combination with other cytostatic agents for treatment of inoperable pancreatic 
ductal adenocarcinoma (PDAC), and several other human cancers (Norwegian Medicines 
Agency, 2018). Following intracellular uptake, mainly by transmembrane equilibrative (hENT) 
and concentrative nucleoside transporter proteins (Wong et al., 2009), gemcitabine 
undergoes a stepwise phosphorylation process. Deoxycytidine kinase (dCK) catalyses the 
initial phosphorylation to gemcitabine monophosphate (dFdCMP), and is considered to be 
the rate limiting step in the activation pathway (Wong et al., 2009). The main active 
metabolite is gemcitabine triphosphate (dFdCTP), which inhibits DNA-replication. In tumor 
specimens from PDAC patients, high expression of hENT1 and dCK have been shown to 
favour the outcome of gemcitabine treatment (Marechal et al., 2012).  
Cytidine deaminase (CDA) catalyses the inactivation of gemcitabine to 2’,2’-difluoro-2’-
deoxyuridine (dFdU) (Gusella et al., 2011; Simon et al., 2015; Cohen et al., 2018). CDA 
expression and activity in peripheral blood (Bowen et al., 2009) have been attributed both to 
lack of effect and increased toxicity of gemcitabine (Sugiyama et al., 2007; Ciccolini et al., 
2010; Gusella et al., 2011). In PDAC tumor tissue, it has been found that CDA mRNA 
expression is higher compared to healthy tissues (Mameri et al., 2017). Bacteria and cells 
such as macrophages in the tumor microenvironment that express CDA might contribute to 
gemcitabine resistance (Vande Voorde et al., 2014; Weizman et al., 2014; Geller et al., 2017; 
Hessmann et al., 2018). However, the impact of intracellular CDA on gemcitabine 
metabolism in cancer cells is less studied (Morita et al., 2003; Vande Voorde et al., 2014). 
Mameri and co-workers (Mameri et al., 2017) restored the expression of CDA in two a priori 
CDA-deficient cancer cell lines, and showed that survival of these cells was higher than that 
of their CDA-deficient counterparts following in vitro incubation with gemcitabine. Indeed, 
similar results have also been achieved by others, indicating a reciprocal relationship 
between intracellular CDA activity and cellular gemcitabine sensitivity (Morita et al., 2003; 


Giovannetti et al., 2007; Yoshida et al., 2010; Peters et al., 2019). Thus, intracellular 
conversion of gemcitabine to dFdU is likely to be a mechanism contributing to gemcitabine 
resistance in this setting (Bardenheuer et al., 2005; Giovannetti et al., 2007; Ohmine et al., 
2012; Vande Voorde et al., 2014; Mameri et al., 2017; Tibaldi et al., 2018).  
In this study, we hypothesized that CDA plays a regulatory role in intracellular gemcitabine 
activation in PDAC cells. To test the hypothesis we assessed intracellular and extracellular 
concentrations of gemcitabine and metabolites after exposure to gemcitabine with and 
without the use of the CDA inhibitor tetrahydrouridine (THU). We also determined basal 
mRNA and protein expression profiles of CDA and other main proteins involved in the 





Materials and Methods 
Chemicals, Reagents and Consumables 
Unless otherwise stated, chemicals and reagents were purchased from Merck KGaA 
(Darmstadt, Germany) and were of analytical grade. Horse serum and sodium pyruvate were 
bought from Thermo Fisher Scientific (Oslo, Norway), culture flasks and cryotubes from VWR 
(Oslo, Norway), centrifuge tubes from Sarstedt (Oslo, Norway), and tetrahydrouridine (THU) 
from AH diagnostics (Oslo, Norway). All other reagents and equipment used for Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) methods have been described 
previously (Bjanes et al., 2015; Kamceva et al., 2015).  
 
Cell culture 
Three human PDAC cell lines, BxPC-3, MIA PaCa-2 and PANC-1, generously provided by 
Prof. Anders Molven (University of Bergen), were cultured in 75 cm2 flasks in a humidified 
atmosphere with 5 % CO2 at 37 °C, and sub-cultured twice weekly. BxPC-3 cells were 
cultured in Roswell Park Memorial Institute 1640 medium (RPMI). MIA PaCa-2 and PANC-1 
were cultured in Dulbecco’s Modified Eagles Medium D5671 (DMEM). All media were 
supplemented with 10 % fetal bovine serum (FBS), 4 mM sodium pyruvate and 2 mM L-
glutamine. The medium used for MIA PaCa-2 was additionally supplied with horse serum 
(2.5 %), as recommended by the manufacturer. No antibiotics were used. Mycoplasma tests 
performed on a regular basis were negative. 


Gemcitabine incubation  
Cell-free media (RPMI, DMEM, and DMEM with horse serum) were spiked with 10 or 100 µM 
gemcitabine. Resulting spiked medium samples were aliquoted and stored in 1.5 mL 
Eppendorf tubes at 4 °C, room temperature (RT) and 37 °C for up to seven days, and 
subsequently stored at -80°C until the entire batch was analysed concurrently. The 
concentration ratios of dFdU over the sum of gemcitabine and dFdU in each sample, 
dFdU/(gemcitabine+dFdU) (%), was used as an indicator of CDA activity.
PDAC cell lines (0.25 – 0.4 x 106 cells per well in 2 mL culture medium) were seeded in six-
well plates 48 hours prior to gemcitabine incubation. Culture media was removed and 
replaced with freshly prepared drug-supplemented media at initiation of the experiments. The 
cells were incubated in quadruplicate for a) 24 hours with 10 or 100 µM gemcitabine, with or 
without 200 µM THU  or b) 60 minutes with 10 or 100 µM gemcitabine with or without 200 µM 
THU. The two different durations of gemcitabine incubation were chosen based on a) that 24 
hours is within a typical range applied in in vitro cytotoxicity experiments (Giovannetti et al., 
2007; Yoshida et al., 2010; Mameri et al., 2017) and b) that 60 minutes in vitro incubation 
reflects a comparable exposure to in vivo gemcitabine treatment (Gusella et al., 2011). . 
Following gemcitabine incubation, media was collected, transferred to cryotubes and stored 
at -80 °C until quantification of extracellular gemcitabine and dFdU. Wells were rinsed twice 
with PBS, and cells were subsequently trypsinized for five to eight minutes, harvested and 
gently re-suspended in cold culture medium. Manual cell counting was performed on a 
representative sample of the suspension. Cell suspensions were centrifuged for five minutes. 
Supernatant was discarded and the cell pellets were dissolved in cold 60 % methanol, 
transferred to cryotubes, vortexed for 20 seconds and snap frozen on liquid nitrogen. All 




Gemcitabine and -metabolite quantification 
Quantification of gemcitabine and its metabolites was performed using an Agilent 1200 
series HPLC-system (Agilent Technologies, Waldbronn, Germany) for chromatographic 
separation and an Agilent 6410 triple-quad mass spectrometer for mass detection. 
Gemcitabine and dFdU in culture media samples were quantified as described previously 
(Bjanes et al., 2015), optimized with lower limits of quantitation of 0.1 µM for both 
gemcitabine and dFdU. Gemcitabine triphosphate (dFdCTP) was analysed in cell lysates 
with a modified version of our previously published method (Kamceva et al., 2015). 
Modification consisted in shorter analysis time and with the mass spectrometer operating in 
positive ionization mode, since we were only interested in quantification of dFdCTP and not 
in the endogenous nucleosides that eluted later. dCTP was used as internal standard due to 
its similar structure and retention time with dFdCTP. Concentrations above the lower limit of 
quantitation of 0.05 µM were normalized to the cell count in each sample and expressed as 
pmol per 106 cells (abbreviated to pmol/106 throughout the manuscript). 
 
mRNA and protein expression 
Extraction of mRNA was performed on cell pellets from each cell line, in quadruplicate, using 
the Qiagen column extraction kit. Two µg of mRNA was used for reverse transcription with 
M-MLV reverse transcriptase (InVitrogen). cDNA was diluted, and relative gene expression 
determined by PCR in a final volume of 6.67 µL with Takyon NoRox SYBR MasterMix blue 
dTTP (Eurogentec). Triplicate runs were performed on a Lightcycler (LC480, Roche Life 
Science). Relative quantification was performed by the CT method using 28S mRNA 
expression as a housekeeping gene and mean CT values as reference. Primers used for 
each gene are given in Supplemental table 1A.  
Total proteins were extracted using cold buffer (20 mM Tris-HCl pH 6.8, 1 mM MgCl2, 2 mM 
EGTA, 0.5% NP40 and phosphatase inhibitor cocktails) with 60 minutes incubation on ice, 


followed by centrifugation (15 minutes, 12 000 g, 4°C). Proteins were separated by SDS-
PAGE and transferred onto PVDF membranes using the iBlot® system (Life Technologies). 
Membranes were incubated with specific antibodies, as shown in Supplemental table 1B. 
Protein expression was visualized using the Odyssey infrared system (LI-COR Biosciences). 
Protein bands were quantified using the Odyssey system, subtracting background noise from 
a similarly sized area just below the band, and presented as ratio of the expression of 
proteins of interest versus beta-actin expression. 
 
Data processing and statistics 
Quantitative data were analysed with SPSS Statistics 24.0 (IBM Inc., Armon, NY, USA) and 
GraphPad Prism 8 (San Diego, CA, USA) for Windows. Results were expressed as means ± 
standard deviations (SD) or as concentration ratios between analytes (%). A two-sided 
student’s t-test was used to compare results in individual cell lines under different 
experimental conditions. One-way analysis of variance (ANOVA) with Bonferroni post hoc 







CDA activity in cell-free culture media  
We investigated whether cell-free culture media had any CDA activity, which would be of 
importance in the subsequent interpretation of data from cell lines incubated with 
gemcitabine. We found CDA activity only in DMEM supplemented with horse serum, used for 
culturing MIA PaCa-2 cells. Within the maximum duration of our cell experiments (24 hours), 
the highest dFdU/(gemcitabine+dFdU) ratio at both gemcitabine concentrations was 6.3 % at 
37 °C (Supplemental Figure 1). No CDA activity was found in either RPMI or DMEM media 
without horse serum.  
 
Accumulation of inactive gemcitabine metabolite in culture media 
To quantify inactivation of gemcitabine in PDAC cells, we measured extracellular dFdU 
concentrations after incubation with 10 and 100 µM gemcitabine for 60 minutes or 24 hours, 
with or without inhibition of CDA. After 24 hours incubation of BxPC-3, MIA PaCa-2 and 
PANC-1 with 100 µM gemcitabine, mean dFdU concentrations were 86.3, 23.5 and 7.3 µM, 
respectively (Figure 1A). After 60 minutes incubation with 100 µM gemcitabine, the 
corresponding dFdU concentrations were 17.7, 3.7 and 0.2 µM (Supplemental Figure 2A). 
The percentage conversion of gemcitabine to dFdU was similar when cells had been 
incubated with 10 µM gemcitabine, both after 60 minutes and 24 hours. After co-incubation 
with gemcitabine and THU, dFdU was low or undetectable in medium from all three cell lines 
both after 60 minutes and 24 hours.  
 
Intracellular accumulation of active gemcitabine metabolite 
After 24 hours incubation of BxPC-3, MIA PaCa-2 and PANC-1 with 10 µM gemcitabine, 
mean dFdCTP concentrations were 210, 1466 and 955 pmol/106, respectively (Figure 1B). 


After 24 hours incubation with 100 µM gemcitabine, dFdCTP concentrations in BxPC-3 were 
significantly higher (851 pmol/106; p<0.001) than with 10 µM gemcitabine incubation. In MIA 
PaCa-2, dFdCTP concentrations were not significantly different between the two gemcitabine 
concentrations (p = 0.12), whereas in PANC-1 they were significantly lower at 100 µM 
gemcitabine (662 pmol/106; p<0.05). CDA-inhibition resulted in significantly higher dFdCTP 
concentrations in BxPC-3, with mean concentrations of 1370 (p<0.01) and 1368 pmol/106 
(p<0.05) at 10 and 100 µM gemcitabine, respectively. In MIA PaCa-2 or PANC-1, dFdCTP 
concentrations were not significantly different with vs without CDA-inhibition.  
After 60 minutes incubation with 10 µM gemcitabine, mean dFdCTP concentrations were 92, 
80 and 110 pmol/106 in BxPC-3, MIA PaCa-2 and PANC-1, respectively. 60 minutes 
incubation with 100 µM gemcitabine did not result in significantly higher dFdCTP 
concentrations in any of the three cell line. Also, CDA-inhibition had no effect on dFdCTP 
concentrations at both gemcitabine concentrations under these experimental conditions 
(Supplemental Figure 2B).  
 
Basal mRNA and protein expression  
We assessed basal mRNA and protein expression of selected transporters and enzymes 
involved in gemcitabine uptake, metabolism and activity, in gemcitabine-untreated cell lines. 
Relative expression of mRNA and proteins are given in Figure 2A and Figure 2B, 
respectively. Original Western blots can be seen in Supplemental Figure 3. CDA showed 
highest mRNA and protein expression in BxPC-3. Lower CDA mRNA expression (Figure 2A) 
and zero protein expression (Figure 2B) was detected in both MIA PaCa-2 and PANC-1. The 
majority of the other transporters and enzymes revealed highest mRNA and protein 






Our overall finding was that intracellular cytidine deaminase plays a regulatory role for 
gemcitabine activation in PDAC cells, hence confirming our hypothesis. 
 
Gemcitabine inactivation 
Almost all gemcitabine added to the culture medium was converted to dFdU during 24 hours 
gemcitabine incubation of BxPC-3, highlighting the extensive CDA activity in this cell line. A 
comparable extent of gemcitabine conversion was reported by Bowen and co-workers 
(Bowen et al., 2009) in ex vivo whole blood from healthy volunteers; 50 % after five hours 
incubation and close to 100 % after 24 hours. In accordance with other publications 
(Funamizu et al., 2012a; Funamizu et al., 2012b), we also found that CDA displayed the 
highest mRNA (Figure 2A) and protein expression (Figure 2B) in BxPC-3, compared to MIA 
PaCa-2 and PANC-1. 
Based on the pre-experimental stability assessments in cell-free culture media, all dFdU in 
BxPC-3 experiments was a result of cellular uptake, intracellular conversion and subsequent 
efflux into the culture medium. In MIA PaCa-2 and PANC-1, respectively, the extent of 
gemcitabine conversion to dFdU was 20–30% and <10 % of BxPC-3 (Figure 1A). This 
indicated that CDA-activities were lower in MIA PaCa-2 and PANC-1. Gemcitabine was also 
to some extent converted to dFdU in the medium used for culturing MIA PaCa-2 
(Supplemental Figure 1). However, the conversion in cell-free medium only accounted for 20-
30 % of the total amount found after 24 hours gemcitabine incubation of MIA PaCa-2 cells 
(Figure 1A). The finding of no detectable CDA protein expression (Figure 2B) in MIA PaCa-2 
and PANC-1 did not fit with the appearance of dFdU following 24 hours gemcitabine 
incubation. These inconsistencies could preferably be explained by lack of sensitivity in the 
protein expression assay (Supplemental Figure 3), since both cell lines expressed CDA 
mRNA (Figure 2A). Moreover, it has been suggested that transcriptional, posttranscriptional 


(Mameri et al., 2017) and posttranslational (Frese et al., 2012) modulations could blur the 
relationship between mRNA and protein expression and the observed CDA phenotype.  
In all cell lines, a long-lasting and strong inhibition of gemcitabine inactivation was achieved 
with 200 µM THU even at the highest gemcitabine concentrations, and at both incubation 
durations. This is in line with previous studies in human blood performed by our own group 
(Bjanes et al., 2015) and other researchers (Bowen et al., 2009). dFdU could otherwise be 
assumed to be derived from the deamination of dFdCMP (Wong et al., 2009), but THU is not 
known to inhibit gemcitabine inactivating enzymes other than CDA (Heinemann and Plunkett, 
1989). The fact that co-incubation of the cell lines with THU inhibited the formation of dFdU 
effectively underscores that direct gemcitabine deamination through CDA was the main 
source of dFdU in our experiments. 
 
Gemcitabine activation 
Without CDA-inhibition, BxPC-3 accumulated significantly less dFdCTP over 24 hours 
compared to the two other cell lines (Figure 1B). A probable explanation, in line with previous 
theories (Riva et al., 1992; Bardenheuer et al., 2005), was that the supply into the activation 
pathway was limited due to extensive conversion of gemcitabine to dFdU (Figure 1A). This 
notion was supported by the observation that dFdCTP concentrations in BxPC-3 were 
significantly higher when gemcitabine exposure was increased, either by increasing 
gemcitabine concentrations from 10 to 100 µM (Figure 1B, dashed line), or by inhibiting CDA 
(Figure 1B, solid line). No increase in dFdCTP concentrations was seen with increasing 
gemcitabine concentrations in MIA PaCa-2 or PANC-1, although baseline CDA-activities 
were low. The same was true in BxPC-3 when CDA was inhibited. These findings were 
consistent with saturation kinetics of dCK, as previously described by other authors 
(Grunewald et al., 1991; Wong et al., 2009).  


Despite the distinct effects after 24 hours incubation in BxPC-3, CDA inhibition had no effect 
on dFdCTP concentrations in any of the three cell lines when incubated for 60 minutes 
(Supplemental Figure 2B). These findings could preferably be explained by sufficient 
concentrations of gemcitabine still available for the activation pathway in all three cell lines, 
but with dCK operating close to its saturation limit. This view is supported by the fact that the 
mean percentage gemcitabine remaining in the medium after 60 minutes vs. 24 hours 
incubation without THU, was 77 vs. <5% in BxPC-3, 92 vs. 66% in MIA PaCa-2 and >98 vs. 
80% in PANC-1.  
 
Overall perspective 
Studies have highlighted the importance of CDA with respect to in vivo gemcitabine systemic 
pharmacokinetics (Sugiyama et al., 2007; Ciccolini et al., 2010; Gusella et al., 2011), and in 
vitro drug sensitivity (Yoshida et al., 2010; Funamizu et al., 2012b; Vande Voorde et al., 
2014; Mameri et al., 2017), but the quantitative aspects of intracellular gemcitabine 
metabolism in PDAC cells has previously not been examined. We found that concentrations 
of both dFdU and dFdCTP after incubation with gemcitabine varied considerably between the 
PDAC cell lines, depending on CDA-activity. As all three cell lines in this study are frequently 
used in in vitro PDAC studies (Funamizu et al., 2010; Paproski et al., 2010; Funamizu et al., 
2012a; Mariglia et al., 2018), the observed metabolic variability may be important to take into 
account when interpreting results from gemcitabine incubation experiments. Moreover, the 
quantitative contribution of intracellular CDA in gemcitabine metabolism provides a 
mechanistic explanation by which manipulating CDA-activity modifies cellular gemcitabine 
sensitivity, as demonstrated by Mameri and co-workers (Mameri et al., 2017) and 
Bardenheuer and co-workers (Bardenheuer et al., 2005). 
By incubating the cell lines with gemcitabine with and without THU, we demonstrated that an 
extensive CDA-mediated gemcitabine conversion to dFdU in BxPC-3 was associated with 
less accumulation of the active metabolite dFdCTP. This was evident after 24 hours 


incubation, but not after 60 minutes, indicating that a balanced substrate supply to dCK was 
an important factor for the accumulation of dFdCTP. In MIA PaCa-2 and PANC-1 no such 
effect of CDA-inhibition on the gemcitabine activation pathway was seen, which was 
consistent with their a priori low CDA activities. This supports the idea that CDA activity may 
be a predictor for gemcitabine toxicity by regulating intracellular gemcitabine metabolism 
(Bardenheuer et al., 2005; Tibaldi et al., 2018). The observation that MIA PaCa-2 cells 
produced both more dFdU and dFdCTP than PANC-1 cells following 24 hours gemcitabine 
incubation, could be explained by the higher expression of 5’-nucleotidases in PANC-1 
(Figure 2B), in particular cN-IIIA. Indeed, this enzyme has been suggested to 
dephosphorylate dFdCMP and thus oppose the accumulation of dFdCTP (Li et al., 2008; 
Aksoy et al., 2009). To decipher the exact mechanisms of these differences and the 
involvement of each of the other proteins shown in Figure 2A-B, it would be necessary to 
develop additional tools (protein-deficient cells, specific inhibitors etc.) that are outside the 
scope of this work. 
Direct quantification of gemcitabine and its metabolites (Figure 1A-B), combined with CDA-
inhibition, provided insight into differential CDA-activities that could not be revealed by 
expression-analyses alone (Figure 2A-B). In a recent commentary by Peters and co-workers 
(Peters et al., 2019), phenotyping with cytidine or gemcitabine was also recommended over 
genotyping for pre-treatment assessment of in vivo CDA-activity in patients. Hodge and co-
workers (Hodge et al., 2011a; Hodge et al., 2011b) also demonstrated the value of applying 
different drug concentrations and duration of incubations, combined with enzyme-inhibition, 
when studying cellular regulation of gemcitabine transport (Hodge et al., 2011b) and 
metabolic (Hodge et al., 2011a) pathways.  
In our experiments, we measured the free dFdCTP concentrations, and did not have a 
measure of the total intracellular amount comprising both free and DNA-bound gemcitabine 
that might correlate better with cytotoxicity (Gandhi et al., 1991). The ratio between free and 
total dFdCTP is expected to change over time during and after gemcitabine incubation, and 


cell lines might also behave differently based on intracellular enzyme expressions, illustrated 
by our own results in Figure 2A and Figure 2B. Based on in silico simulations, Battaglia and 
co-workers suggested that the rate of DNA-incorporation in general is a slow process 
compared to the production rate of dFdCTP (Battaglia and Parker, 2011). Hence, 
quantification of free dFdCTP could therefore be a better measure of cellular uptake and 
metabolism of gemcitabine following 60 minutes incubation, compared to 24 hours 
incubation. Incubation for 60 minutes with 10 – 100 µM gemcitabine in vitro might also more 
accurately represent the in vivo drug exposure during and after clinically applied 30-minutes 
gemcitabine infusions of 1000 mg/m2, with a comparable concentration-time-product (AUC) 
of 41 ± 12 µM*h (Gusella et al., 2011). We calculated that 60 minutes or 24 hours in vitro 
incubation with 10 µM gemcitabine render AUCs of 10 or 240 µM*h, respectively. 
In general, data from in vitro experiments should be interpreted with caution in terms of in 
vivo relevance. However, our findings that increased gemcitabine exposure does not 
necessarily lead to an increase in the intracellular active metabolite concentrations are in line 
with observations from in vivo studies, as illustrated by Hessmann and co-workers 
(Hessmann et al., 2018). 
 
Conclusion 
Our findings reveal quantitative aspects of gemcitabine intracellular metabolism in PDAC cell 
lines. The data support the notion that high CDA-activity limits intracellular dFdCTP 
accumulation. However, low CDA activity may not necessarily result in increased dFdCTP 
accumulation. Both CDA activity and the cellular ability to synthesize active metabolites 
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Figure 1. Concentrations of gemcitabine metabolites following 24 hours incubation with 10 or 
100 µM gemcitabine ± 200 µM tetrahydrouridine (THU), a cytidine deaminase inhibitor. A 
and B show extracellular dFdU* (µM) and intracellular dFdCTP (pmol/106), respectively. 
Insert in Figure 1A: Data from 10 µM gemcitabine incubations in greater detail, with a 
differently scaled Y-axis. Data are displayed as means (n = 4 – 8). Error bars excluded from 
view for clarity. Original data (means and standard deviations) are shown in Supplemental 
Table 2. *dFdCTP concentrations in PANC-1 incubated with 10 µM gemcitabine with or 





Figure 2A. Relative mRNA expression of selected proteins involved in the transport and 
metabolism of gemcitabine in BxPC-3, MIA PaCa-2 and PANC-1. Cytidine deaminase 
highlighted (red rectangle). Data are displayed as means of 4 independent samples studied 
in triplicate, and error bars are standard deviations. 
SLC28A1*: Concentrative nucleoside transporter 1 (hCNT1); SLC29A1: Equlibrative nucleoside transporter 1 
(hENT1); SLC29A2: Equlibrative nucleoside transporter 2 (hENT2); dCK: deoxycytidine kinase; CMPK1: 
uridine/cytosine monophosphate kinase; NME2: nucleoside diphosphate kinase (NdPK); CDA: Cytidine 
deaminase; dCTD: deoxycytidine monophosphate deaminase; NT5C: cytosolic 5’(3’)-deoxyribonucleotidase 
(cdN); NT5C2: cytosolic 5’-nucleotidase II (cN-II); NT5C3: cytosolic 5’-nucleotidase III A (cN-IIIA); NT5M: 
mitochondrial 5’(3’)-deoxyribonucleotidase (mdN); RRM1: Large subunit of ribonucleotide reductase; RRM2: 
Small subunit of ribonucleotide reductase; DCTPP1: deoxycytidine triphosphate pyrophosphatase 1; CTPS1*: 
cytidine triphosphate synthase 1; POLA1: deoxyribonucleic acid polymerase alpha 




Figure 2B. Relative protein expression of selected proteins involved in the transport* and 
metabolism of gemcitabine in BxPC-3, MIA PaCa-2 and PANC-1. Cytidine deaminase 
highlighted (red rectangle). Data are displayed as means of 3 independent samples, and 
error bars are standard deviations. Raw data are available in Supplemental Figure 3. 
dCK: deoxycytidine kinase; CDA: Cytidine deaminase; cN-II: cytosolic 5’-nucleotidase II (NT5C2); cN-IIIA: 
cytosolic 5’-nucleotidase III A (NT5C3); RRM1: Large subunit of ribonucleotide reductase; RRM2: Small subunit of 
ribonucleotide reductase 











Forward primer (5’-3’) Reverse primer (5’-3’) 
   
RPS28 CGATCCATCATCCGCAATG AGCCAAGCTCAGCGCAAC 
SLC28A1 TCTGTGGATTTGCCAATTTCAG CGGAGCACTATCTGGGAGAAGT 
SLC29A1 GCTGGGTCTGACCGTCGTAT CGTTACAGGGTGCATGATGG 
SLC29A2 ATGAGAACGGGATTCCCAGTAG GCTCTGATTCCGGCTCCTT 
DCK AAACCTGAACGATGGTCTTTTACC CTTTGAGCTTGCCATTCAGAGA 
CMPK1 GGGCATATTCTTTGCTTCCA TGCATTTCAAGGTTCCACTG 
NME2 ATGCAGTGCGGCCTGGTGGG GACCCAGTCATGAGCACAAGAC 
CDA GAGCTGCAATCGTGTCTGG CAGAGCAGCGGGAAACAG 
DCTD GTCGCCTTGTTCCCTTGTAA TCTTGCTGCACTTCGGTATG 
NT5C GGACACGCAGGTCTTCATCTG GCGGTACTTCTCACCCACACA 
NT5C2 ACCTGCTGTATTACCCTTTCAGCTA GCTCCACCGTTGATTCATGA 
NT5C3A AATCGGCGATGTACTAGAG CATCTGCCATTCTTAAGTCTC 
NT5M CATCAGCATTTGGGAGTCAA CGACACAATCTGCTCCAGAA 
DCTPP1 AAATGGACATCAACCGGCGA AGTCACAGGGAATGTCCGCA 
CTPS1 GTGGCGAAATACACCGAGTT TCCTCGAACACCAAATCCTC 
POLA1 AGCTTGACCTGATTGCTGTC ATGACGGGACAAAGACAAGG 
RRM1 GCAGCTGAGAGAGGTGCTTT CAGGATCCACACATCAGACA 
RRM2 GAGTTCCTCACTGAGGCC TTAGAAGTCAGCATCCAAG 
   
   
RPS28; Ribosomal protein S 28; SLC28A1*: Concentrative nucleoside transporter 1 (hCNT1); SLC29A1: 
Equlibrative nucleoside transporter 1 (hENT1); SLC29A2: Equlibrative nucleoside transporter 2 (hENT2); 
dCK: deoxycytidine kinase; CMPK1: uridine/cytosine monophosphate kinase; NME2: nucleoside 
diphosphate kinase (NdPK); CDA: Cytidine deaminase; dCTD: deoxycytidine monophosphate deaminase; 
NT5C: cytosolic 5’(3’)-deoxyribonucleotidase (cdN); NT5C2: cytosolic 5’-nucleotidase II (cN-II); NT5C3: 
cytosolic 5’-nucleotidase III A (cN-IIIA); NT5M: mitochondrial 5’(3’)-deoxyribonucleotidase (mdN); RRM1: 
Large subunit of ribonucleotide reductase; RRM2: Small subunit of ribonucleotide reductase; DCTPP1: 
deoxycytidine triphosphate pyrophosphatase 1; CTPS1*: cytidine triphosphate synthase 1; POLA1: 





















      
CDA -/ab56053 1/500 Primary Rabbit Abcam 
cN-II 3C1/H00022978-M02 1/500 Primary Mouse Abnova 
cN-IIIA -/ARP32185 1/1000 Primary Rabbit Aviva Systems Biology 
dCK -/ab96599 1/2000 Primary Rabbit Abcam 
RRM1 -/sc11733 1/1000 Primary Goat Santa Cruz Biotechnology 
RRM2 -/sc10846 1/1000 Primary Goat Santa Cruz Biotechnology 
Beta-actin AC-15/A5441 1/5000 Primary Mouse Sigma 
      
Anti-murine -/926-32210 1/5000 Secondary Goat LI-COR Bioscience 
Anti-rabbit -/926-68171 1/5000 Secondary Goat LI-COR Bioscience 
Anti-goat -/926-32214 1/5000 Secondary Donkey LI-COR Bioscience 
   
 
CDA: Cytidine deaminase; cN-II: cytosolic 5’-nucleotidase II (NT5C2); cN-IIIA: cytosolic 5’-nucleotidase III A 
(NT5C3); dCK: deoxycytidine kinase; RRM1: Large subunit of ribonucleotide reductase; RRM2: Small subunit 
of ribonucleotide reductase 







Supplemental table 2. Extracellular dFdU and intracellular dFdCTP concentrations 
following 24 hours gemcitabine (10 or 100 µM) incubation with or without 200 µM 
tetrahydrouridine. Data displayed in Figure 1A and 1B.  
Cell line 









      
  10 µM  10.5* 1.1  209.6 29.5 
  10 µM + THU  0.6* 0.05  1370.0 182.4 
  100 µM  86.3 4.1  850.5 127.1 
  100 µM + THU  1.5 0.02  1368.5 200.5 
 
MIA PaCa-2       
  10 µM  3.4* 0.8  1465.5 247.6 
  10 µM + THU  n.d. n.d.  1420.4 95.7 
  100 µM  23.5* 7.1  1242.2* 197.0 
  100 µM + THU  0.8 0.2  1187.7* 203.6 
 
PANC-1       
  10 µM  1.1 0.0  954.7 224.7 
  10 µM + THU  0.2 0.0  950.9 66.8 
  100 µM  7.3 0.7  662.5 77.2 
  100 µM + THU  0.2 0.05  600.7 77.4 
       
n = 4-8 per observation; * experiments with n=8 
 







Supplemental Figure 1. Stability of 10 µM gemcitabine (dFdC) in Dulbecco’s modified 
Eagles medium with horse serum at 4 °C, room temperature (RT) and 37 °C. dFdU 
concentrations relative to the sum of dFdC and dFdU concentrations 
([dFdU]/([dFdC]+[dFdU]), %), was used as a measure of CDA-activity. No CDA activity was 





Supplemental Figure 2. Concentrations gemcitabine metabolites following 60 minutes 
incubation with 10 or 100 µM gemcitabine ± 200 µM tetrahydrouridine (THU), a cytidine 
deaminase inhibitor. A and B show extracellular dFdU* (µM) and intracellular dFdCTP 
(pmol/106), respectively. Data are displayed as means (n = 4 – 8). Error bars excluded from 
view for clarity. 
* Solid lines aligned along the X-axis are poorly visible. They represent extracellular dFdU which was low or 






Supplemental Figure 3. Western blots of protein expression of selected proteins involved in 
the transport* and metabolism of gemcitabine in BxPC-3, MIA PaCa-2 and PANC-1. 
Brackets indicate the individual analytical runs, with each beta-actin control included. 
CDA: Cytidine deaminase; cN-II: cytosolic 5’-nucleotidase II (NT5C2); cN-IIIA: cytosolic 5’-nucleotidase IIIA 
(NT5C3); dCK: deoxycytidine kinase; RRM1: Large subunit of ribonucleotide reductase; RRM2: Small subunit of 
ribonucleotide reductase 
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• Treatment of pancreatic ductal adenocarcinoma (PDAC) is hampered by poor drug 
delivery 
 
• We demonstrated that diagnostic intensity ultrasound and microbubbles 
(sonoporation) induced a moderate increase in gemcitabine uptake in PDAC cell lines 
 
• Membrane transport proteins and gemcitabine metabolizing enzymes modified the 






Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer deaths worldwide. 
Poor drug delivery to tumours is thought to limit chemotherapeutic treatment efficacy. 
Sonoporation combines ultrasound (US) and microbubbles to increase the permeability of 
cell membranes. 
Methods: We assessed gemcitabine uptake combined with sonoporation in vitro in three 
PDAC cell lines (BxPC-3, MIA PaCa-2 and PANC-1). Cells were cultured in hypoxic 
bioreactors, and gemcitabine incubation and sonoporation was conducted in cells with 
operational and inhibited nucleoside membrane transporters. Intracellular active metabolite 
(dFdCTP), extracellular gemcitabine and inactive metabolite (dFdU) concentrations were 
measured with liquid chromatography tandem mass spectrometry. 
Results & Discussion: Sonoporation with increasing US intensities resulted in decreasing 
extracellular gemcitabine concentrations in all three cell lines with inhibited membrane 
transporters. In cells with inhibited membrane transporters, without sonoporation, dFdCTP 
concentrations were reduced down to 10% of baseline. Sonoporation partially restored 
gemcitabine uptake in these cells, as indicated by a moderate increase in dFdCTP 
concentrations (up to 37% of baseline) in MIA PaCa-2 and PANC-1. In BxPC-3, gemcitabine 
was effectively inactivated to dFdU, which might represent a protective mechanism against 
dFdCTP accumulation in these cells. Intracellular dFdCTP concentrations did not change 
significantly following sonoporation in any of the cell lines with operational membrane 
transporters, indicating that the gemcitabine activation pathway may have been saturated 
with the drug. 
Conclusion: Sonoporation allowed a moderate increase in gemcitabine transmembrane 
uptake in all three cell lines, but pre-existing nucleoside transporters were the major 
determinants of gemcitabine uptake and retention.  
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death 
worldwide [1, 2]. Late stage diagnosis precludes surgical excision in the majority of patients 
[3], and poor drug delivery into the tumour tissue may limit chemotherapeutic efficacy in 
patients with advanced disease [4-6].  
Gemcitabine monotherapy is one of the three main chemotherapeutic drug regimens being 
used in the palliative setting of PDAC patients worldwide [7]. Following cellular uptake, 
primarily via the equilibrative nucleoside transporter 1 (hENT1), gemcitabine is either 
inactivated by cytidine deaminase (CDA) to 2’,2’-difluoro-2’-deoxyuridine (dFdU) and 
effluxed, or phosphorylated through a series of nucleoside kinases to active metabolites. 
Deoxycytidine kinase (dCK), catalysing the initial phosphorylation of gemcitabine to 
gemcitabine monophosphate (dFdCMP), is a rate limiting step in the activation pathway [8]. 
The main active gemcitabine triphosphate (dFdCTP) metabolite exerts its activity by 
inhibiting DNA replication [8]. Expression of hENT1 [9, 10], CDA [11] and dCK [10] in tumour 
tissue have been associated with gemcitabine efficacy.  
Paproski and co-workers showed that in vitro inhibition of hENT1 with dilazep reduced 
average gemcitabine uptake 24-fold and sensitivity 13-fold in both PDAC and non-PDAC cell 
lines. Restoration of nucleoside membrane transport by transfection with an active 
nucleoside influx pump re-established gemcitabine uptake and sensitivity [12]. This illustrated 
that hENT1 is of particular interest in studies of gemcitabine transport across cell 
membranes. Macrophages [13, 14], fibroblasts [2] and bacteria [15, 16] in the tumour 
microenvironment may also modulate gemcitabine efficacy. Moreover, limited drug delivery 
to PDAC tumours has been postulated to confer treatment failure [9]. 
The combination of microbubbles and ultrasound (US) may facilitate the formation of 
transient pores in biological membranes through a process commonly referred to as 
sonoporation, and thereby potentially allow increased tissue drug delivery and cellular uptake 
[17]. In a phase 1 clinical trial, ten PDAC patients were treated with gemcitabine followed by 
repeated intravenous boluses of SonoVue® microbubbles and US focused at their primary 
tumours. The sonoporation treated patients experienced more tumour shrinkage, tolerated 
an increased number of treatment cycles, and survived longer than a historical control group 
treated with gemcitabine alone [18]. Similar results were achieved in a preclinical trial in mice 
with orthotopic PDAC xenografts [19]. It was postulated that the observed effects might partly 
be explained by increased gemcitabine delivery to PDAC tumour cells.  
This hypothesis was not supported by Mariglia and co-workers [20], who found no increase 
in intracellular uptake and retention of a radiolabelled nucleoside analogue similar to 
gemcitabine, following in vitro sonoporation of a suspension of the PDAC cell line BxPC-3. 
The authors proposed that direct effects of sonoporation, rather than an increase of cellular 
gemcitabine delivery, could potentially explain an additive cytotoxicity which was observed at 
increasing US intensities, employing a frequency of 0.5 MHz and mechanical indices (MI) of 
0.31 – 0.50 – 0.75, ISPPA 1.61 – 4.32 – 9.36 W/cm2 and ISPTA 0.052 – 0.14 – 0.30 W/cm2 [20].  
Differences between cell lines regarding activities in hENT1 and enzymes involved in drug-
metabolism, such as CDA, have not been taken into account in previous sonoporation 
studies of gemcitabine [18-20]. We therefore assessed in vitro uptake and metabolism of 
gemcitabine in three adherent PDAC cell lines, with and without inhibited hENTs and CDA, 
following incubation with therapeutically relevant drug concentrations, commercially available 
microbubbles and US intensities within a clinically translatable range. We hypothesized that 
the effect of sonoporation could depend on the activities of hENTs or gemcitabine 
metabolizing enzymes.  
Materials and Methods 
Chemicals and reagents 
Chemicals and reagents were purchased from Merck KGaA (Darmstadt, Germany) unless 
otherwise stated, and were of analytical grade. Culture flasks and cryotubes were purchased 
from VWR (Oslo, Norway), centrifuge tubes from Sarstedt (Oslo, Norway) and Petaka® G3 
LOT (Celartia, Columbus, OH, USA) hypoxic cell culture bioreactors (hereafter entitled 
“Petakas”) from Tebu-Bio (Denmark). Horse serum and sodium pyruvate were obtained from 
Thermo Fisher Scientific (Oslo, Norway) and tetrahydrouridine (THU) from AH diagnostics 
(Oslo, Norway). Reagents and equipment used for liquid chromatography tandem mass 
spectrometric methods (LC-MS/MS) are described elsewhere [21, 22].  
 
Cell culture 
The PDAC cell lines, BxPC-3, MIA PaCa-2 and PANC-1, were kindly provided by Prof. 
Anders Molven (University of Bergen, Norway). BxPC-3 were cultured in Roswell Park 
Memorial Institute 1640 medium  (RPMI) and MIA PaCa-2 and PANC-1 in Dulbecco’s 
Modified Eagles Medium (DMEM) in a humidified atmosphere with 5 % CO2 at 37 °C. Media 
were complemented with 4 mM sodium pyruvate, 2 mM L-glutamine and 10 % fetal bovine 
serum (FBS). Horse serum (2.5 %) was added to the medium used for MIA PaCa-2. No 
antibiotics were used. Mycoplasma-tests performed on a regular basis were negative. 
Two or three days before experiments with gemcitabine, cells were harvested using 0.05 % 
trypsin-EDTA, counted and reseeded into Petakas (Figure 1A) at a density of 2.0 – 4.0 x 106 
cells per 25 mL medium.  Petakas were kept in a horizontal position for 24 hours to ensure 
even cell distribution over the surface, and then flipped to a vertical position with the air vent 
at the top, until the day of the experiments. At the day of experiments, the cell confluency 
was between 70 – 80 %. A priori evaluation of cell growth had been performed for each cell 
line at four different seeding densities, and surface area coverage was quantified using 
MIPAR™ image analysis software [23] (Supplemental Figure 1).   
 
Gemcitabine incubation and sonoporation 
Three main series of sonoporation experiments were performed in all three cell lines: 1) 60 
minutes incubation with 10 µM gemcitabine, 2) 20 minutes pre-incubation with 100 µM 
dilazep followed by 60 minutes incubation with 10 µM gemcitabine and 3) 60 minutes co-
incubation with 10 µM gemcitabine and 200 µM tetrahydrouridine (THU), an inhibitor of 
cytidine deaminase (CDA).  
In all experiments, we used one microbubble concentration and selected US intensities 
based on a priori optimization, using the cell-impermeable dye calcein as “model drug” 
(Supplemental Figure 2). Sonazoid® was prepared using the venting needle method. A total 
of 2 mL of saline (B.Braun AG, Melsungen, Germany) was slowly added to the vented vial 
and gently agitated for 30 seconds. Eighty µL Sonazoid® stock solution with 1.20 x 109 
microbubbles per mL was added to 1 mL of the prepared gemcitabine solution, and injected 
into the Petakas. Air pockets were removed and the entire Petaka was exposed to US 
immediately thereafter. The Petakas (Figure 1A) were placed in the water bath of a custom-
made US treatment system, with the cell monolayer on the upper surface to maximize cell-
microbubble contact. The US treatment system (Figure 1B) was based on a previous design 
[24] and consisted of 128, 9×6 mm PZ26 elements firing upwards in groups of 16 elements at 
a time as a plane-wave into the Petaka. The US transducers were driven by a custom Open 
Ultrasound system (Lecoeur Electronique, Chuelles, France). The acoustic field had been 
calibrated in the fully assembled US chamber in three axes using a 200-µm needle 
hydrophone (Precision acoustics Ltd, Dorset, United Kingdom). The Petaka was placed at 
the acoustic focus. Ultrasound was applied for a total of 5 minutes at a frequency of 2.0 MHz. 
Two acoustic intensity levels were applied: Medium (MI 0.2, 80 cycles, duty cycle (DC) 1.8 
%, ISPPA 3 W/cm2 and ISPTA 50 mW/cm2) and High (MI 0.378, 160 cycles, DC 3.6 %, ISPPA 10 
W/cm2 and ISPTA 358 mW/cm2), in addition to Control (no US). After treatment, Petakas were 
returned to the incubator until completion of 60 minutes gemcitabine incubation time. Due to 
experimental time and resource constraints, a maximum of nine Petakas were used in each 
batch (see schematic timeline in Figure 1C).  
At the end of experiments, 1 mL of medium was collected, transferred to cryotubes and kept 
at -80°C until quantification of extracellular gemcitabine and dFdU. The adherent cells were 
rinsed with phosphate buffered saline (PBS) and trypsinized for five to eight minutes and re-
suspended in cold culture medium. Cells were counted and centrifuged at 1250 RPM for five 
minutes. Supernatants were discarded and cell pellets were either diluted and reseeded in 
24-well plates for postexposure cell growth assays, or dissolved in cold 60 % methanol, 
transferred to cryovials, vortexed for 20 seconds, snap-frozen in liquid nitrogen and stored at 
-80 °C until quantification of intracellular dFdCTP. 
 
Quantification of gemcitabine and its metabolites 
Quantification of gemcitabine and its metabolites was performed using an Agilent 1200 
series HPLC-system (Agilent Technologies, Waldbronn, Germany) for chromatographic 
separation and an Agilent 6410 triple-quad mass spectrometer for mass detection. 
Concentrations of gemcitabine and dFdU in culture media samples were measured 
according to our previously published method [21], with optimized lower limits of quantitation 
(LLOQ) of 0.1 µM for both analytes. Gemcitabine triphosphate (dFdCTP) was quantified in 
cell lysates with a slightly modified version of our previously published method [22]. 
Modification consisted of shorter analysis time and with the mass spectrometer operating in 
positive ionization mode, since we only quantified dFdCTP and not the endogenous 
nucleosides that eluted later. dCTP was used as internal standard due to its similar structure 
and retention time with dFdCTP. Concentrations above the LLOQ of 0.05 µM were 
normalized to the cell count in each sample and expressed as pmol per 106 cells 
(abbreviated to pmol/106 throughout the manuscript). 
 
Cell growth after incubation with gemcitabine ± sonoporation 
Cell viability following exposure to 1) 60 min 10 µM gemcitabine alone, 2) sonoporation 
(High) alone, 3) 60 min 10 µM gemcitabine combined with sonoporation (High), and 4) 
Control (drug-free media, i.e. untreated cells), was assessed by monitoring cell growth for up 
to ten days. Each of the four experimental conditions was repeated once. BxPC-3 
suspensions were diluted to 2500 cells/mL, MIA PaCa-2 and PANC-1 to 1000 cells/mL, and 
reseeded in triplicate into 24-well plates. Five daily snapshots from each well were captured 
using a Zeiss Vert.A1 microscope, Axiocam 105 colour camera and the Zeiss ZEN Pro 2012 
blue edition software. Images (n=3600 in total) were analysed using MIPAR™ image 
analysis software [23]. Cell growth over time was expressed as percentage surface area 
coverage. Triplicate measurements from the repeated experiments (n=2) were combined into 
one graph for each cell line. 
 
Statistical analyses 
Quantitative data were processed using Microsoft Office Excel (2016) and GraphPad Prism 8 
(San Diego, CA, USA). Variations of repeated measurements were expressed as 
mean±standard deviations (SD). Two-sided independent student’s t-tests were used to 
compare means between measurements within each cell line. A one-tailed Pearson’s 
correlation was used to describe linear relationships between US intensities and gemcitabine 
and – metabolite concentrations within each cell line. One-tailed was based on the 
assumption that increasing US intensities would have a one-directional effect on gemcitabine 
and - metabolite concentrations. Pearson’s was based on the assumption that the measures 
of US intensities, MI and ISPTA, represented continuous variables to be examined for a linear 
relationship to gemcitabine and - and metabolite concentrations. A p-value less than 0.05 
was considered significant.   
Results 
Sonoporation and cellular gemcitabine uptake 
Cell lines were incubated with gemcitabine and Sonazoid® microbubbles, and treated with 
US at medium and high intensities, and without US (control). Data from cells with operational 
membrane transporters are displayed in Figure 2A–I, with inhibited membrane transporters in 
Figure 2J–R, and from cells with inhibited cytidine deaminase in Figure 3. 
 
Sonoporation of cells with operational membrane transporters 
In BxPC-3, after 60 minutes incubation with 10 µM gemcitabine and with application of the 
highest US intensity, mean±SD extracellular gemcitabine concentrations were reduced from 
9.0±0.4 µM (Control) to 8.2±0.4 µM (p=0.025) (Figure 2G). Extracellular dFdU (Figure 2D) 
and intracellular dFdCTP (Figure 2A) showed a trend towards higher concentrations, from 
1.0±0.3 µM and 91.3±13.1 pmol/106 (Control) to 1.5±0.4 µM and 107.0±12.7 pmol/106 (High), 
respectively, but the observed changes were statistically not significant (p=0.07 and p=0.14 
for dFdU and dFdCTP, respectively). A significant correlation was however observed 
between gemcitabine concentrations and MI (p=0.017, r2=0.997), and dFdU concentrations 
and MI (p=0.035, r2=0.988) in BxPC-3.  
In addition, a significant correlation was observed between dFdCTP concentrations and MI 
(p=0.005, r2=1.000) in MIA PaCa-2 (Figure 2B). In PANC-1, no correlations between 
concentrations of gemcitabine or -metabolites and US intensities were observed. 
 
Inhibition of membrane transporters 
Cells were incubated for 60 minutes with 10 µM gemcitabine, with or without 20 minutes pre-
incubation with 100 µM dilazep [12]. Without US (Control), in BxPC-3, extracellular dFdU 
concentrations in BxPC-3 were reduced from 1.0 µM without dilazep (Figure 2D) to 0.1 µM 
with dilazep (Figure 2M). In MIA PaCa-2 and PANC-1, dFdU concentrations were already 
low at baseline, and no further reductions could be quantified. In all three cell lines, 
intracellular dFdCTP concentrations were significantly reduced by dilazep: from 91.3 (Figure 
2A) to 11.4 pmol/106 (Figure 2J) in BxPC-3, from 12.9 (Figure 2B) to 2.9 pmol/106 (Figure 
2K) in MIA PaCa-2 and from 31.2 (Figure 2C) to 5.5 pmol/106 (Figure 2L) in PANC-1. 
 
Sonoporation of cells with inhibited membrane transporters 
Extracellular gemcitabine 
In all three cell lines, following preincubation with dilazep, small but significant decreases in 
extracellular gemcitabine concentrations from approximately 9.5 µM without US to below 9.0 
µM with increasing US intensity were noted (Figure 2P–R). Inverse correlations between 
gemcitabine concentrations and MI were observed for MIA PaCa-2 (p=0.006, r2=1.00) 
(Figure 4Q) and PANC-1 (p=0.006, r2=1.00) (Figure 4R).  
 
Extracellular dFdU 
In BxPC-3, extracellular dFdU concentrations increased from 0.1±0.04 (Control) to 0.2±0.03 
µM at medium US intensity (p=0.03) and further to 0.4±0.09 µM at high intensity (p=0.001) 
(Figure 2M). This trend showed a correlation with the ISPTA (p=0.02, r2=0.995). No changes in 
dFdU concentrations were seen in MIA PaCa-2 (Figure 2N) or PANC-1 (Figure 2O).  
 
Intracellular dFdCTP 
Intracellular dFdCTP concentrations increased from 2.9±0.2 (Control) to 4.8±0.6 pmol/106 at 
high US intensity (p=0.005) in MIA PaCa-2 (Figure 2K) and from 5.5±2.6 to 11.7±2.4 
pmol/106 (p=0.036) in PANC-1 (Figure 2L). In BxPC-3, an apparent small increase from 
11.4±0.9 (Control) to 12.8±2.5 pmol/106 at high US intensity was statistically not significant 
(p=0.367) (Figure 2J).  However, linear correlations between dFdCTP concentrations and MI 
were observed in BxPC-3 and MIA PaCa-2 (p=0.0006, r2=1.00 and p=0.0249, r2=0.994, 
respectively), whereas in PANC-1 a correlation was seen between dFdCTP and ISPTA 
(p=0.0063, r2=1.00). 
 
Sonoporation of cells with inhibited cytidine deaminase 
Sixty minutes co-incubation with 10 µM gemcitabine and 200 µM THU resulted in dFdU 
concentrations <0.1 µM in all three cell lines (Figure 3D–F). Without US, no significant 
differences in extracellular gemcitabine (Figure 3G–I) or intracellular dFdCTP (Figure 3A–C) 
concentrations were seen with or without THU added. There was also no significant change 
in dFdCTP concentrations in any of the three cell lines co-incubated with gemcitabine and 
THU when US intensity was increased.  
 
Cell growth after exposure to gemcitabine and/or sonoporation 
Growth of the cell lines was followed for ten days after exposure to 10 µM gemcitabine, 
sonoporation (High), or both, and compared to untreated cells (Figure 4). In MIA PaCa-2 and 
PANC-1, no differences between treatment groups were seen. In BxPC-3, cells that had 
been incubated with gemcitabine, either alone or combined with sonoporation, showed a 
slower initial growth compared to untreated cells.  When fitting the growth curves of BxPC-3 
to a 4-point logistic curve, the groups treated with gemcitabine had significantly different 
points of inflection compared to untreated cells and those with sonoporation alone 
(p<0.0001), but the growth rate (Hill slope) was the same for all groups (p=0.942). 
Discussion 
To our knowledge, this is to date the most comprehensive in vitro study of gemcitabine 
cellular uptake combined with sonoporation, using diagnostic intensity US and microbubbles. 
Our data demonstrate that gemcitabine uptake and metabolite accumulation following 
sonoporation depend on the activities of membrane transporters and metabolizing enzymes 
within the cells.  
 
Extracellular gemcitabine concentrations 
In BxPC-3 with operational membrane transporters (Figure 2G), and in all three cell lines 
when membrane transporters had been inhibited prior to gemcitabine incubation (Figure 2P, 
Q and R), extracellular gemcitabine concentrations decreased with increasing US intensities. 
Decreasing gemcitabine concentrations indicated that sonoporation enhanced 
transmembrane gemcitabine transport, since cellular uptake was the only possible route of 
drug removal from the media in our experimental system.  
 
Significance of membrane transporters 
Our results indicated that sonoporation contributed only to a small proportion of cellular 
gemcitabine uptake compared to pre-existing nucleoside membrane transporters (hENT). 
When hENTs had been inhibited, dFdCTP concentrations were reduced to approximately 
10–20 % (Figure 2J-L) of those in cells with operational membrane transporters (Figure 2A-
C). This substantiated the idea of hENTs being the main determinants of gemcitabine uptake 
and ultimately of cellular accumulation of dFdCTP, which also is in accordance with previous 
studies [12, 25]. Sonoporation partially restored the supply of gemcitabine in transport- 
inhibited MIA PaCa-2 and PANC-1, reflected by increases in dFdCTP concentrations up to 
4.8 and 11.7 pmol/106, respectively (Figure 2K and L). In both cell lines, these concentrations 
were 37.5 % of those achieved in cells with operational membrane transporters incubated 
with gemcitabine, but without sonoporation (Figure 2B and C). In BxPC-3, however, where 
CDA is highly expressed [26], the increased gemcitabine uptake resulted in an increase in 
the inactive metabolite (dFdU) (Figure 2M) and no significant change in dFdCTP 
concentrations was noted (Figure 2J). Although there were no significant differences 
between the mean dFdCTP concentrations, the correlations may suggest that higher US 
intensities are warranted [27] in order to increase dFdCTP in cells with deficient membrane 
transporters. 
  
Gemcitabine concentrations and enzyme saturation 
When CDA was inhibited (Figure 3), conversion of gemcitabine to dFdU was abolished in all 
three cell lines. In BxPC-3, in which a priori CDA-activity was extensive, we had speculated 
whether the inhibition would allow more gemcitabine to be metabolized to dFdCTP. However, 
no increase in dFdCTP was noted, neither in BxPC-3, nor in the other cell lines. This might 
indicate that the activation pathway was already sufficiently supplied with gemcitabine, which 
is in line with dCK being a rate-limiting step in this pathway [28-30]. Indeed, the experiments 
with CDA inhibition were only performed in cells with operational membrane transporters 
which would allow continuous gemcitabine uptake from the medium, and therefore with 
limited additional effect of sonoporation. Whether a more pronounced effect of sonoporation 
could have been unmasked if cells were incubated with gemcitabine concentrations lower 
than 10 µM, further below a potential saturation of dCK [28-30], remains to be investigated.  
 
Duration of incubation 
Previous findings suggest that the sonoporation effect has a duration of up to and exceeding 
one hour [31-33], supports our choice of the drug incubation time of 60 minutes in our 
experiments. Also, shorter incubation times could have been relevant in order to detect more 
subtle changes in sonoporation-induced cellular gemcitabine uptake. It is likely that a major 
proportion of gemcitabine transport across a permeabilized membrane would occur within 
seconds-to-minutes after initiation of drug incubation [34, 35]. Theoretically, if transport of 
gemcitabine through sonoporation-induced pores during this short time-scale were 
dominating, and hENT-mediated transport reached diffusion equilibrium later, early 
differences between cells with vs. without sonoporation would remain undetected. Drug-
incubation and handling of Petakas was quite laborious and time consuming so that 
seconds-to-minutes experiments could not be performed. Also, since our final outcome 
measure was intracellular dFdCTP concentrations, a combined marker of cellular drug 
uptake and subsequent phosphorylation, 60 minutes gemcitabine incubation time was 
considered to be rational [35]. 
 
Cellular responses to sonoporation and gemcitabine 
Growth curves over a 10-day period after exposure (Figure 4) indicated that BxPC-3 was 
more sensitive to gemcitabine than the other two cell lines. This agrees with the higher 
concentrations of dFdCTP in this cell line, compared to the other two cell lines (Figure 2A-C). 
Sonoporation, however, had no effect on cell growth over a 10-day period in any of the cell 
lines. We had shown in cells with operational membrane transporters, that sonoporation did 
not increase intracellular dFdCTP concentrations. This is in line with our observation that cell 
growth was not inhibited under these experimental conditions. However, cellular effects 
following a single 60-minutes treatment with gemcitabine and sonoporation with diagnostic 
intensity US might be more subtle than what can be observed with a growth assay. Mariglia 
and co-workers [20] used the MTT-assay 48 hours after sonoporation, and observed 
decreasing cell viability with increasing US intensities in suspended BxPC-3 cells. Definity® 
microbubbles used by Mariglia and co-workers are smaller and stiffer than the Sonazoid® 
microbubbles used in our study, but they also used higher MIs that are known to induce 
inertial cavitation. Furthermore, the Definity® microbubbles were driven at 0.5 MHz which is 
more than 20 times lower than their fundamental resonance frequency [36]. This suggests 
that the microbubble behaviour may be significantly different between our study and the 
study by Mariglia and co-workers, making it difficult to directly compare them. 
 
Implications, strengths and limitations 
The majority of in vitro research on US and microbubble assisted drug delivery has been 
performed using fluorescence labelled dyes that have no routes of spontaneous cellular entry 
[27, 31, 37]. As such, they are ideal model drugs for mechanistic studies and for optimization 
of sonoporation settings. Methods for semiquantitative measurements of these compounds, 
such as flow cytometry, are readily available. However, cell impermeable compounds are 
unlikely to represent all relevant properties of therapeutically active drugs. Cellular drug 
uptake occurs via transmembrane transport proteins or via diffusion through the lipid bilayer, 
and might be counterbalanced by passive or active efflux [38-42]. As we have demonstrated, 
sonoporation-induced cellular uptake of gemcitabine was lower that the uptake mediated via 
nucleoside membrane transporters. This would not have been recognized by using cell 
impermeable model drugs alone. Their widespread application and the use of percentage 
“positive” cells in most studies, rather than quantitation of cellular drug concentrations, might 
even have contributed to exaggerated conclusions in terms of quantitative significance of 
sonoporation induced drug uptake.  
Studying sonoporation and gemcitabine-uptake in PDAC cells cultured in hypoxic Petakas is 
of particular interest. It has been demonstrated that cellular responses to sonoporation 
depend on the condition of the cells [43, 44], which may be relevant for PDAC tumours when 
nutrient and oxygen supplies are limited [45]. Zhang and co-workers [46] showed that 
hypoxia induced perturbations in endogenous nucleotide pools, and they suggested that the 
efficacy and toxicity of nucleoside analogues such as gemcitabine would be modified 
accordingly. Moreover, US assisted drug delivery is not only a product of membrane pore 
formations; it has also been shown to interfere with the intracellular cytoskeleton [37], that 
might theoretically regulate membrane transport proteins [47]. Most authors studying 
sonoporation, including Mariglia and co-workers [20], have reported results from cancer cell 
lines in suspension. In Petakas, the PDAC cells were treated while adherent. This may 
represent a more relevant condition compared to suspended cells in which the cytoskeleton 
might already have been rearranged prior to sonoporation [48].  
 
Experiments were performed on plastic surfaces that do not mimic neither mechanical nor 
acoustic characteristics of tissue, which may increase acoustic aberration [49]. Furthermore, 
the static in vitro environment does not mimic the blood flow seen in vivo. A dynamic blood 
flow would drastically reduce the contact between bubbles and cells [50] and also affect how 
the cells grow [31]. The protein concentration in cell culture media are also low compared to 
blood, meaning the bubbles may have an increased stability as the proteins reduce the 
hydrophobicity of the lipids [51]. In vivo, the bubbles would not be directly in contact with the 
PDAC cells but initially with endothelial cells [50], hence the effect on the PDAC cells may be 
lower than in vitro. In addition, the pancreatic cancer microenvironment includes other cell 
types such as fibroblasts [2], macrophages [13, 14], and is typically displaying a 
desmoplastic reaction. Cells and surrounding tissue may be affected differently both by 
gemcitabine and sonoporation, and as a result the treatment outcome could theoretically also 
be influenced through effects on these cells/tissues. 
 
  
Conclusions and future perspectives 
Sonoporation with diagnostic intensity US and Sonazoid microbubbles allowed a moderate 
increase in gemcitabine transmembrane uptake in all three cell lines, but pre-existing 
nucleoside transporters were the major determinants of gemcitabine uptake and retention. 
Cell growth after a single 60 minutes treatment with sonoporation combined with gemcitabine 
was well preserved, which may reflect a general treatment resistance in these cell lines. 
Moreover, the data underscore that specific PDAC cell lines may respond differently to 
sonoporation due to different intracellular gemcitabine metabolism.   
Future studies should include cells of multiple different origins, since a single response on a 
given cell line or drug may not represent a universally valid effect. Furthermore, sonoporation 
should be evaluated by using therapeutic drugs in more complex PDAC models that include 
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Figure 1.  A) Petaka® G3 LOT hypoxic bioreactors, B) custom-made ultrasound 
treatment chamber and C) timeline of sonoporation experiments.  
In each batch of experiments, up to nine Petakas (A) were sequentially incubated. (C). 1 mL 
culture medium with the appropriate gemcitabine concentrations and Sonazoid® 
microbubbles were injected through the injection port. Immediately following injection, the 
Petakas were transferred to the ultrasound treatment chamber (B), sonicated for five minutes 
(indicated by blue in the timelines) and returned to the incubator. Culture media and 
trypsinized cells were aspirated through the injection port after incubation with gemcitabine 





Figure 2.Gemcitabine uptake and metabolism following sonoporation of PDAC cell 
lines with operational (panels A-I) and inhibited (panels J-R) membrane transporters. 
Extracellular concentrations of gemcitabine (dFdC, panels G, H, I and P, Q, R), extracellular 
inactive metabolite (dFdU, panels D, E, F and M, N, O) and intracellular active metabolite 
(dFdCTP, panels A, B, C and J, K, L) in BxPC-3 (orange), MIA PaCa-2 (purple) and PANC-1 
(green).  Results displayed as mean±SD with 3 – 4 observations per datapoint.  *p<0.05, 
**p<0.01 (Unpaired students t-tests). Notice the different scales on the Y-axes of extracellular 
dFdU and intracellular dFdCTP concentrations in experiments with operational vs. inhibited 
membrane transporters. 
“Operational membrane transporters” (panels A – I): 60 minutes incubation with 10 µM 
gemcitabine, 3.84x106 ppmL Sonazoid® microbubbles and 5 minutes ultrasound (US) at two 
acoustic intensities (Medium, High) and no US (Control). 
“Inhibited membrane transporters” (panels J – R): 20 minutes pre-incubation with 100 µM 
dilazep followed by 60 minutes incubation with 10 µM gemcitabine, 3.84x106 ppmL 





Figure 3. Gemcitabine uptake and metabolism following sonoporation of PDAC cell 
lines with inhibited cytidine deaminase. 
Extracellular gemcitabine (dFdC, panels G, H, I), extracellular inactive gemcitabine 
metabolite (dFdU, panels D, E, F), and intracellular active gemcitabine metabolite (dFdCTP, 
panels A, B, C), in BxPC-3 (orange), MIA PaCa-2 (purple) and PANC-1 (green) cell lines 
following 60 minutes co-incubation with 10 µM gemcitabine ± 200 µM tetrahydrouridine, 
3.84x106 ppmL Sonazoid® microbubbles and 5 minutes ultrasound (US at two acoustic 
intensities (Medium, High) and no US (Control) in Petakas. 60 minutes incubation with 10 µM 
gemcitabine without US included as control (leftmost data point in all panels). 
Results displayed as mean±SD with 3 – 4 observations per data point. 
 
Figure 4. Growth of cell lines up to ten days after exposure to 10 µM gemcitabine over 
60 minutes, sonoporation (High, 5 minutes) or both, compared to untreated cells 
(Control).  
Each experiment was repeated once (n = 2). Cell growth was monitored after re-seeding the 
cells in 24 well-plates, and daily images were captured. Images were analyzed with MIPAR™ 
image analysis software, and cell growth over time was expressed as surface area coverage. 
All data from repeated experiments (n = 2) were combined and displayed as mean±SD 
  
 
Supplemental Figure 1. Growth curves of BxPC-3, MIA PaCa-2 and PANC-1 seeded in 
Petakas at densities from 1.0 – 4.0 x 106 cells in 25 mL medium. 60 daily snapshots were 
captured across the surface of the Petakas. Images were analysed with MIPAR™ image 
analysis software and growth was expressed as surface area coverage (%) over time. 
  
 
Supplemental Figure 2. Example of sonoporation-induced uptake of cell-impermeable 
calcein at High* ultrasound intensity and increasing concentrations of Sonazoid® 
microbubbles in all three cell lines. Increase in % positive cells was considered to be an 
indicator of increasing efficacy of cell membrane permeabilization. 
*2.0 MHz, MI 0.378, 160 cycles, DC 3.6 %, ISPPA 10 W/cm
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